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Post-translation modifications, particularly phosphorylation, are the main mechanisms by
which signaling cascades regulate downstream transcription factors to execute changes in gene
expression. We have focused on understanding the roles of phosphorylation in regulating the
two transcription factors, YAN and Eyes absent (EYA).
We have been interested in determining the mechanisms of downregulating the
Drosophila protein YAN, a transcriptional repressor of the ETS family of transcription factors
that antagonizes receptor tyrosine kinase (RTK)/RAS/MAPK signaling. Under conditions of
minimal RTK induction YAN outcompetes Pointed (PNT), an ETS transcriptional activator, for
access to the DNA, resulting in transcriptional repression, thereby preventing inappropriate
differentiation or proliferation. Upon RAS/MAPK stimulation, MAPK-mediated
phosphorylation of YAN results in abrogation of YAN repressor activity, allowing PNT to
activate transcription of formerly repressed genes. We show (Chapter 2) that MAE, which has
been previously implicated in mediating the MAPK phosphorylation of YAN and PNT, plays a
separate role in mediating the CRM1 dependent nuclear export of YAN, an essential step in the
downregulation of YAN. In addition, MAE has been implicated in an inhibitory feedback loop
that attenuates PNT activation. Further work (Chapter 3 and Appendix III) has shown that
overexpression of MAE in S2 cells and the presumptive embryonic central nervous system
inhibits nuclear export of YAN. However, overexpression in the eye does not exhibit YAN
being aberrantly retained in the nuclei, but instead it results in an array of phenotypes that can be
rescued by overexpression of PNT. Thus MAE appears to play a role in downregulation of PNT
in vivo. Interesting, we find that mae transcription is regulated by YAN and PNT, adding further
complexity to the signaling cascade. Whereby the regulator, MAE, becomes the regulated.
In addition to studying the mechanisms underlying the function and regulation of YAN,
YAN has been used as a tool to identify other nuclear components downstream of RTK
signaling. Through a genetic interaction screen eyes absent (eya) mutants were identified as
enhancers of the rough eye phenotype of constitutively active YAN. EYA is a transcriptional
coactivator in the Retinal Determination (RD) Network, which encompasses a signaling cascade
of transcriptional regulators best known for their necessity during Drosophila eye development.
Loss of function mutants exhibit an eyeless phenotype, while overexpression either alone or in
conjunction with other RD members results in ectopic eye tissue. While one outcome of this
signaling cascade is eye formation, null mutations within this network exhibit lethality,
suggesting further roles during development. Homology between the EYA Domain, one of the
evolutionarily conserved domains of EYA, and haloacid dehalogenases suggested that EYA, in
addition to acting as a transcriptional coactivator, could be functioning as a phosphatase. We
have shown that EYA is a protein tyrosine phosphatase (Chapter 4). Phosphatase activity is
necessary for EYA function, as phosphatase mutants cannot rescue eya mutant phenotypes or
induce ectopic eyes at a comparable level to wild-type EYA. We also show that EYA is tyrosine
phosphorylated and serves as a substrate for itself. Continuing efforts to understand the roles of
tyrosine phosphorylation in regulating EYA have revealed that EYA is likely to by tyrosine
phosphorylated within the ED, and Y719 may be a site of phosphorylation (Chapter 5). Thus
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EYA possesses two functions, as a transcriptional coactivator and as a protein tyrosine
phosphatase, that are potentially regulated by tyrosine phosphorylation.
Phosphorylation of YAN has been shown to play a key role in its downregulation, while
the effects of tyrosine phosphorylation on EYA remain to be determined. It is important to note
that phosphorylation, in the case of YAN and likely in the case of EYA as well, is only one step
in a complex sequence of events required for the proper developmental outcome to occur. It is
especially intriguing that EYA, a known transcriptional regulator, possesses phosphatase
activity, and can regulate its own phosphorylation. Thus we have a case in which an enzyme
responsible for altering post-translational modifications, likely as a downstream effector of
signaling events, also mediates the transcriptional response.
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Chapter 1
I. Post-translational modifications influence transcription factor activity:
A view from the ETS superfamily
II. Dual function transcriptional regulators
Tina Tootle
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Abstract
As transcription factors are the nuclear effectors of signaling cascades, mechanisms must
exist to specifically regulate their activities in response to signaling events. Regulation can occur
at the DNA, RNA, or protein level. Many transcription factors are present in cells and tissues
before they are needed, allowing quick response to extracellular stimuli. In these cases the
activity of the transcription factor is regulated at the protein level. A wide variety of post-
translational modifications are known to play critical roles in regulating transcription factors, and
are capable of altering the localization, stability, interactions, other post-translational
modifications, and activity of a protein. The combinations of modifications that can occur on an
individual protein yield immense regulatory possibilities. Aside from analyses of the effects of
serine/threonine (S/T) phosphorylation, studies on post-translational modifications of
transcription factors are only in the beginning stages.
The current paradigm that an enzyme activated in response to upstream signaling will
localize to the nucleus and modify specific transcription factors is an over-simplification.
Intriguingly, there appears to be an emerging theme in which the transcription factor itself
possesses a second, enzymatic function. This creates an entirely new set of regulatory
mechanisms that emanate locally from the transcriptional complexes themselves. Thus
transcription factors are not passive on/off switches controlled by signaling pathways, but are
active players in determining the activity, output, and regulation of transcriptional complexes.
Here I will review the various post-translational modifications that are mediated by such dual
function transcription factors and other signaling regulated enzymes, and provide specific
examples of how such modifications regulate the activities of ETS transcription factors. Then I
11
will review the enzymatic functions of the transcriptional regulators EYA, DBP1, ERK5, p300,
and TAFII250.
Post-translational modifications influence transcription factor activity: A view from the
ETS superfamily
ETS transcription factors have a wide range of roles throughout development including
regulation of cell proliferation, differentiation, migration, apoptosis, and mesenchymal-epithelial
interactions (Maroulakou and Bowe 2000). The majority of ETS transcription factors function as
transcriptional activators, while some possess repressive activities (Mavrothalassitis and
Ghysdael 2000), and others are capable of acting as both activators and repressors in a context
dependent manner (Sharrocks 2001; Rohrbaugh et al. 2002; Wei et al. 2003; Yang et al. 2003).
The founding ETS transcription factor was identified as the oncogene transduced by the
avian retrovirus E26, and thus ETS stands for E wenty-six (Karim et al. 1990; Laudet et al.
1999; Sharrocks 2001). There are approximately thirty ETS transcription factors in mammals,
and multiple phylogenic analyses suggest these fall into eleven to thirteen groups (Laudet et al.
1999; Lim et al. 1999; Sharrocks 2001). There are eight ETS transcription factors in Drosophila
(Hsu and Schulz 2000), providing a unique representation of the major mammalian groups.
Thus, the functional redundancy that complicates the analysis of ETS transcription factors in
mammals is not present in Drosophila.
An approximately eighty-five amino acid domain termed the ETS DNA binding domain
or ETS domain characterizes ETS transcription factors. The ETS domain belongs to the
superfamily of winged helix-turn-helix (HTH) DNA binding proteins. Structural analysis of
various ETS transcription factors indicates that the DNA binding domain is made up of three a
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helices and four (I sheets. The third t helix contacts the major groove of the DNA where it
interacts with the central GGAA/T motif, while additional contacts are made by the loop
between strands 3 and 4 (the "wing") and the loop between cc helices 2 and 3 (Donaldson et al.
1996; Kodandapani et al. 1996; Sharrocks et al. 1997; Werner et al. 1997; Batchelor et al. 1998;
Mo et al. 1998; Mo et al. 2000; Sharrocks 2001).
The core recognition sequence for ETS transcription factors, referred to as the ETS
binding site (EBS), is GGAA/T. Sequences flanking this core EBS are variable and contribute to
the specificity of individual ETS transcription factors (Bosselut et al. 1993; Shore et al. 1996;
Sharrocks et al. 1997; Pio et al. 1999; Mo et al. 2000; Lelievre et al. 2001).
One-third of ETS transcription factors also contain a conserved amino-terminal domain
called a pointed domain (PD). PDs belong to the Sterile Alpha Motif (SAM) family, and are
involved in both homo and hetero-typic protein-protein interactions (Stapleton et al. 1999).
Functions associated with PDs of ETS transcription factors include homooligomerization in the
case of human TEL (Kim et al. 2001) and its Drosophila homolog YAN (J. Bowie, personal
communication), heterodimerization, as exemplified by TEL - FLI-1 interactions (Kwiatkowski
et al. 1.998), and transrepression, documented for both TEL (Lopez et al. 1999) and YAN (Tootle
et al. 2003a). PDs can also be the site of regulation by extracellular signaling pathways via
MAPK mediated phosphorylation, as is the case for PNT-P2, ETS-1, ETS-2 and YAN (see
below) (Lelievre et al. 2001).
Some ETS transcription factors also contain inhibitory domains that flank their ETS
domain, and thus regulate their DNA binding affinity (Hagman and Grosschedl 1992; Jonsen et
al. 1996; Skalicky et al. 1996; Cowley and Graves 2000; Greenall et al. 2001; Lelievre et al.
2001; Garvie et al. 2002; Wang et al. 2002). In the absence of DNA, the amino-terminal
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inhibitory domain binds to the ETS domain and the carboxy-terminal inhibitory domain,
blocking DNA binding. The inhibitory domains can be positively or negatively regulated by
phosphorylation, as is the case for ETS-1 (see below), and positively or negatively regulated by
protein-protein interactions (Lelievre et al. 2001; Sharrocks 2001).
ETS transcription factors exhibit overlapping expression patterns, and as they bind to
similar or even identical DNA binding sites, their specificity must be regulated by other means.
One common mechanism of regulating the specificity of ETS transcription factors is by their
interactions with other transcriptional regulators (Lelievre et al. 2001; Sharrocks 2001). ETS
transcription factors interact with other DNA binding transcription factors, such as AP-1
(JUN/FOS) (Bergelson and Daniel 1994; Wu et al. 1994), NFKB (Gri et al. 1998), and PAX
family members (Plaza et al. 1994; Fitzsimmons et al. 1996), and the resulting complex then
recognizes juxtaposed binding sites for the two transcription factors, increasing their respective
DNA binding affinities and adding to their specificity (Li et al. 2000; Lelievre et al. 2001;
Sharrocks 2001). In addition, interactions with non-DNA binding transcription factors and co-
activators (Janknecht and Nordheim 1996; Yang et al. 1998a; Yamamoto et al. 1999; Yamamoto
el: al. 2002; Goel and Janknecht 2004) or co-repressors (Chakrabarti and Nucifora 1999; Guidez
et al. 2000; Yang et al. 2001; Suzuki et al. 2003) can also contribute to DNA binding specificity,
by altering the conformation of the ETS transcription factor (Lelievre et al. 2001; Sharrocks
2001).
ETS transcription factors are the nuclear targets of many extracellular signaling events.
Thus, the other common mechanism of altering the specificity of ETS transcription factors is
regulation by signaling cascades, often resulting in phosphorylation of ETS transcription factors.
Phosphorylation can regulate the subcellular localization, protein-protein interactions, the DNA
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binding ability, and the transcriptional activity of ETS transcription factors (see below for
specific examples).
The specificity and thus the activity of ETS transcription factors are also affected by post-
translational modifications besides phosphorylation. Below, I summarize what is known about
the various post-translational modifications, phosphorylation, ubiquitination, sumoylation,
acetylation, methylation, and glycosylation, and their affects on ETS transcription factors.
Phosphorylation
Phosphorylation is by far the best-studied post-translational modification, and many ETS
transcription factors are regulated by phosphorylation. I will discuss general information on
phosphorylation, discuss mitogen activated protein kinase (MAPK)-mediated serine/threonine
(S/T) phosphorylation, overview the ETS transcription factors that are S/T phosphorylated, and
provide specific examples of how phosphorylation regulates YAN and PNT-P2, ETS-1, and
TEL. Lastly I will discuss tyrosine (Y) phosphorylation, a modification that has not been studied
intensively in the context of nuclear transcription factors, but in light of work on EYA (Chapters
4 and 5), will likely prove relevant to this context.
General information about phosphorylation
Phosphorylation occurs by addition of a phosphate group to the hydroxyl group of
serine (S), threonine (T), or tyrosine (Y) residues. The negative charge introduced by
phosphorylation can affect the activity of the modified protein by inducing allosteric
conformational changes, in addition to inducing repulsive and attractive forces (Holmberg et al.
2002). Thus single and multi-site phosphorylation can affect both protein-protein interactions
and induce global changes in protein structure.
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Two broad families of kinases mediate the phosphorylation of transcriptional regulators,
S/T protein kinases, and Y kinases. Both types of kinases can be either receptor or membrane
bound, or nonmembrane. In the majority of cases, transcription factors are modified by
nonmembrane kinases. Like most post-translational modifications, phosphorylation is reversible.
The enzymes responsible for dephosphorylation are phosphatases, which can be S/T, Y, or dual
specificity phosphatases.
Phosphorylation and dephosphorylation can affect transcription factor function in a
multitude of ways, including altering protein-protein interactions (either homo- or hetero- typic),
subcellular localization, protein stability, DNA binding ability, and regulating transcriptional
activity both positively and negatively (Whitmarsh and Davis 2000; Holmberg et al. 2002). Due
to the large number of kinases, multiple signaling pathways can converge to regulate a particular
transcription factor by differential phosphorylation at different or even the same residues
(Holmberg et al. 2002). Thus multiple sites of phosphorylation add further potential for signal
integration.
MAPK mediated S/T phosphorylation
While phosphorylation can occur at either S/T or Y residues, S/T phosphorylation as a
means of regulating transcription factors appears more widespread and is better characterized.
Mitogen activated protein kinase (MAPK) mediated S/T phosphorylation of transcription factors
is a common mechanism by which extracellular signals regulate gene expression. There are
three families of MAPKs: ERK, JNK, and p38 (Karin and Hunter 1995). Various receptors
transduce the extracellular signals by utilizing both RAS dependent and independent means to
activate a specific MAPK kinase kinase (MAPKKK), such as RAF, which in turn phosphorylates
a MAPK kinase (MAPKK or MEK). MEKs, which are dual specific kinases, phosphorylate
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MAPKs at both S/T and Y residues (Marshall 1994; Karin and Hunter 1995; Keyse 2000).
Unphosphorylated MAPKs are tethered in the cytoplasm by MEKs, and phosphorylation of
MAPKs result in release from this complex and subsequent nuclear localization, where MAPKs
phosphorylate transcriptional regulators (Davis 1993; Marshall 1994; Karin and Hunter 1995;
Keyse 2000; Kolch 2000). MAPKs thus provide the link between extracellular signaling and the
corresponding changes in gene expression. It is thought that MAPKs are tethered in the nucleus
by a protein whose expression is induced by the activated MAPK. This anchoring protein may
be a phosphatase, retaining inactive MAPK in the nucleus to prevent reactivation by MEKs
(Kolch 2000).
All MAPKs phosphorylate the same consensus sequence, with the strict consensus being
P-X-S/T-P and the weak consensus being S/T-P (Davis 1993; Holland and Cooper 1999).
However, each MAPK has different substrate specificities. ERK MAPKs are known to dock on
the sequence LAQRRX 4 s5L (Gavin and Nebreda 1999; Smith et al. 1999), while JNK docks on
the sequence KX2!+X4LXL, where + is R or K (Adler et al. 1992; Hibi et al. 1993; Holland and
Cooper 1999). Delta domains, as these docking sites are referred to, are usually twenty residues
away from the phosphorylation site. ETS transcription factors contain D domains, KX2+X3LXL,
which are related to the delta domains (Bardwell and Thorner 1996; Yang et al. 1998b; Holland
and Cooper 1999). The basic amino acids within both D and delta domains interact with the
common docking (CD) domain in MAPKs, which is composed of a cluster of acidic amino acids
at the C-terminus of the MAPK (Kolch 2000; Tanoue et al. 2001). CD domains were so named
because they are the site of interaction with the activating MEKs, the MAPK's substrates, and
the inactivating phosphatases (Kolch 2000; Tanoue et al. 2000). In addition to these docking
domains, some ETS transcription factors contain a FXFP motif near the site of phosphorylation
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that is involved in ERK binding (Holland and Cooper 1999; Jacobs et al. 1999; Kolch 2000).
The D domain and the FXFP motif together have a combinatorial effect. D domains are
recognized by both ERK and JNK MAPKs, while FXFP motifs are ERK specific (Holland and
Cooper 1999). Both the kinase docking sites and the sequence context of the phosphorylation site
contribute to the different specificities of the MAPKs (Yordy and Muise-Helmericks 2000).
5iT phosphorylation of ETS transcription factors
Many ETS transcription factors are known to be S/T phosphorylated (Table 1-1),
including the PEA3 subfamily (PEA3, ER81, ERM) (Fitzsimmons et al. 1996; Janknecht 1996;
Baert et al. 2002; Wu and Janknecht 2002), ERF (Le Gallic et al. 1999), GABPc (Imaki et al.
2003; Rosmarin et al. 2004), TCF subfamily (ELK-, SAPla, SAPlb, FLI-1, NET) (Yang et al.
1998b; Ducret et al. 2000; Wang and Prywes 2000; Yordy and Muise-Helmericks 2000), PU. 1
(Pongubala et al. 1993; Yordy and Muise-Helmericks 2000), the subfamily made up of ETS-1,
ETS-2, and POINTED-P2 (PNT-P2) (Wasylyk et al. 1998; Yordy and Muise-Helmericks 2000),
LIN-1 (Tan et al. 1998; Sharrocks 2001), and the subfamily made up of YAN and TEL (Wasylyk
et al. 1998; Yordy and Muise-Helmericks 2000). I will specifically discuss how YAN and PNT-
P2, ETS-1, and TEL are regulated by phosphorylation
'AN and PNT-P2
Among the best characterized downstream targets of activated MAPK are the Drosophila
ETS-domain transcription factors encoded by pointed (pnt) and yan (O'Neill et al. 1994). pnt
encodes two separate proteins (Klambt 1993), one which functions as a constitutive
transcriptional activator, PNT-P1, and one which is a transcriptional activator that requires
phosphorylation by MAPK in response to RTK/RAS signaling for activity, PNT-P2 (O'Neill et
al. 1994). yan encodes a transcriptional repressor that competes with PNT for access to the
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regulatory regions of target genes (Gabay et al. 1996). The coordinate regulation of these two
antagonistic transcription factors, YAN and PNT, plays a key role in determining specific
differentiative and proliferative responses to RAS/MAPK signaling.
The first evidence that RAS/MAPK signaling regulates YAN came from studies of the
development of the Drosophila eye. YAN is expressed in the nuclei of undifferentiated cells and
appears to act antagonistically to proneural signals. As cells begin to differentiate, YAN
expression is lost, suggesting YAN may function to maintain cells in an undifferentiated state
(Lai and Rubin 1992). Similar studies showed that PNT-P2 is expressed in these same
undifferentiated cells and its expression remains until these cells express markers indicative of
neuronal differentiation (Brunner et al. 1994). PNT-P2 contains a single MAPK phosphorylation
consensus site, PLT 151P, that is phosphorylated by MAPK in vitro (Brunner et al. 1994).
Analysis of mutating T151 to alanine (T151A) suggested that phosphorylation at this site is
necessary for PNT-P2 function, as this mutant can not rescue the pnt-/- phenotypes. T151A
when expressed in a wild-type background, actually inhibits endogenous, wild-type PNT-P2
fiunction, indicating that T151A is competing either directly or indirectly with the wild-type
protein (Brunner et al. 1994). Thus MAPK negatively regulates the transcriptional repressor
YAN and positively, by direct phosphorylation, regulates the activator PNT-P2.
Loss of pnt function results in a complete loss of neuronal differentiation in the
developing Drosophila eye (O'Neill et al. 1994). Genetic analysis showed that PNT functions
downstream of RAS signaling, and transcription assays revealed that activated RAS, RASv , or
partially activated ERK, ERKSEM, increase PNT-P2's ability to activate transcription (O'Neill et
al. 1994). The T151A mutant transcriptional activity is not stimulated by either method,
20
indicating that ERK-mediated phosphorylation at T151 activates PNT-P2's transcriptional
activity (O'Neill et al. 1994).
Utilizing these same transcription assays it was shown that YAN represses the
transcriptional activity of PNT-P1, and that this repression is negatively regulated by RASvl2 and
SEMERK EM . YAN has nine MAPK phosphorylation consensus sites (Baker et al. 2001). In the
12 SEMpresence of RASv 2 or ERKEM , YAN exhibits a slower electrophoretic mobility, indicating a
post-translational modification. Phosphatase treatment results in restoration of normal mobility,
revealing that YAN is phosphorylated in response to RAS/MAPK signaling (O'Neill et al. 1994).
Thus the phosphorylation state of YAN has an inverse relationship to YAN's activity as a
transcriptional repressor.
Mutating eight of the putative phosphorylation sites in YAN to alanine results in
ACT
constitutively active YAN, YAN T , meaning that even in the presence of RAS/MAPK signaling
YANA CT still represses transcription and thus inhibits differentiation (Rebay and Rubin 1995).
Expression of YANACT in Drosophila cultured cells revealed constitutive nuclear localization,
while wild-type YAN is nuclear and becomes cytoplasmic upon addition of RASV 2 (Rebay and
Rubin 1995). Analysis of mutations in specific putative phosphorylation sites showed that
mutating the first phosphorylation site, S 127A, inhibits cytoplasmic localization of YAN in
response to RAS/MAPK signaling, while mutating sites 2-8 has little effect on localization
(Rebay and Rubin 1995). Therefore, this cytoplasmic localization of YAN in response to
RAS/MAPK signaling is likely to require phosphorylation at the first phosphorylation site, S 127.
Transcription assays have revealed that while the first phosphorylation site, S127, is required for
RAS/MAPK pathway responsiveness, phosphorylation at the other sites is important for
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modulating this response (Rebay and Rubin 1995). Thus MAPK-mediated phosphorylation of
YAN at multiple sites is required for proper downregulation of YAN.
The translocation of YAN from the nucleus to the cytoplasm in response to RAS/MAPK
signaling seen in cultured cells has never been observed during Drosophila development, but this
translocation suggested that after YAN is phosphorylated by MAPK, it is exported to the
cytoplasm. Subsequent analysis has shown that nuclear export is essential for downregulating
YAN activity in vivo, as trapping YAN in the nucleus inhibits differentiation (Chapter 2) (Tootle
et al. 2003a). Nuclear export of YAN is mediated by the exportin CRM1, which recognizes the
three leucine rich nuclear export sequences (NESs) at the amino-terminus of YAN (Chapter 2)
(Tootle et al. 2003a). All these data together lead to the model in which nuclear YAN represses
differentiation, upon RAS/MAPK signaling ERK phosphorylates YAN resulting in removal of
its transcriptional repression, activation of PNT-P2, and nuclear export of YAN. As cytoplasmic
YAN is not seen in during development, it is likely that YAN is rapidly degraded, a model
supported by the many high scoring PEST sequences in YAN (Lai and Rubin 1992). PEST
sequences are proline, glutamic acid, serine, threonine rich regions known to target proteins to
the proteasome for degradation (Rechsteiner and Rogers 1996).
How ERK interacts with PNT-P2 and YAN is not known. While the docking sites for
ERK binding to PNT-P2 and YAN have not been characterized, PNT-P2 contains a LXIXXF
motif that is likely to function as the ERK docking site (Seidel and Graves 2002). This motif is
located in the PD next to the phosphorylation site. However, PDs, in general, do not serve as
ERK docking sites (Seidel and Graves 2002).
There is also evidence indicating of an alternate docking mechanism in which MAE
CModulator of Activity of _ETS) mediates the interactions between ERK and YAN, and ERK and
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PNT-P2. MAE interacts with YAN and PNT-P2 by PD-PD mediated interactions (Baker et al.
2001). Transcriptional analysis in mammalian cultured cells revealed that both MAE and
RAS12 are required to remove YAN mediated repression and to activate PNT-P2 transcriptional
activation (Baker et al. 2001). MAE-YAN interaction prevents YAN from binding to DNA and
MAE is necessary for ERK mediated in vitro phosphorylation of S127 on YAN (Baker et al.
2001). MAE has also been shown to play a phosphorylation independent role in mediating the
nuclear export and downregulation of YAN (Chapter 2) (Tootle et al. 2003a). There is a large
amount of data suggesting that MAE indeed mediates ERK-mediated phosphorylation and
downregulation of YAN. However the data indicating that MAE is also involved in mediating
the phosphorylation of PNT-P2 (Baker et al. 2001) is highly contested. Two other laboratories
have independently shown that MAE inhibits PNT-P2 mediated transcriptional activation,
indicating that MAE is involved in the downregulation of PNT-P2, not its activation (Chapter 2)
(Tootle et al. 2003a; Yamada et al. 2003). In vivo analysis has shown that MAE, indeed,
negatively regulates PNT-P2 function (Chapter 3) (Yamada et al. 2003).
Recent work has provided a mechanism for how MAE mediates the phosphorylation of
YAN. YAN, like its mammalian ortholog TEL, forms a PD-PD head to tail oligomer, and this
oligomerization is required for transcriptional repression (Kim et al. 2001; J. Bowie, personal
communication). MAE binding to the PD of YAN results in depolymerization of YAN, which
should expose the critical S 127 phosphorylation site, and thus would facilitate the ERK mediated
phosphorylation of YAN (J. Bowie, personal communication). The residues implicated in
mediating such polymerization are not conserved in PNT-P2 or ETS-1 (Kim et al. 2001). Thus if
MAE facilitates ERK- mediated phosphorylation of PNT-P2 it is occurring by a different
mechanism.
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In the absence of high levels of RAS/MAPK signaling, YAN forms an oligomer (J.
Bowie, personal communication), is bound to the DNA, repressing transcription and maintaining
the cell in an undifferentiated state (Lai and Rubin 1992). Upon RAS/MAPK signaling, MAE
facilitates the ERK-mediated phosphorylation of YAN and YANs removal from the DNA (Baker
et al. 2001), most likely be depolymerizing YAN (Figure 1-lA). PNT-P2 is phosphorylated by
ERK, binds DNA, and activates transcription, sending the cell down the road to differentiation
(O'Neill et al. 1994). It remains possible that MAE is involved in the phosphorylation of PNT-
P2 (Baker et al. 2001). Phosphorylated YAN in a complex with MAE then interacts with CRM1,
resulting in dissociation of MAE and nuclear export of YAN (Tootle et al. 2003a). In a negative
feedback loop, MAE inhibits PNT-P2 mediated transcriptional activation by an unknown
mechanism (Tootle et al. 2003a; Yamada et al. 2003) (Figure -lIB). This provides the cell with
a precisely controlled mechanism by which to achieve the appropriate balance between
transcriptional repression and activation according to the level of signaling.
ETS-1
ETS-1 is the mammalian ortholog of PNT-P2. Like PNT-P2, ETS-1 is directly
phosphorylated by ERK (Treisman 1996). Phosphorylation of ETS-1 at T38, analogous to T151
in PNT-P2, is required for ETS-1 to function with other transcription factors, including AP-1 and
PIT-I, to activate RAS responsive elements (RREs) (Yang et al. 1996; Yordy and Muise-
Helmericks 2000). Utilizing an EBS-reporter it was shown that RAS signaling-mediated
phosphorylation of ETS- 1 is necessary for transcriptional activity, but has no affect on protein
localization or stability (Yang et al. 1996). This phosphorylation could be affecting ETS-l's
DNA binding ability or protein-protein interactions with unknown coactivators. However,
phosphorylation does not affect ETS-l's ability to interact with the coactivators p300/CBP
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Figure 1-1
Model for how YAN and PNT are regulated in response to high levels of RTK signaling. A. The
mechanisms by which YAN is downregulated in response to RTK signaling. In the absence of
high levels of signal, YAN represses transcription by forming a homooligomer and wrapping the
DNA around itself. Upon RTK signaling, MAE is activated or allowed by some unknown
mechanism to interact with YAN, resulting in inhibition of YAN oligomerization. This MAE-
YAN complex is likely to remove YAN from the DNA, and then MAPK can interact with the
MAE-YAN complex, phosphorylating YAN. This results in YAN interacting with CRM1,
ultimately leading to the nuclear export of YAN and its presumed degradation. B. The
mechanisms by which PNT-P2 is activated and subsequently downregulated in response to RTK
signaling. Upon high levels of signal, PNT-P2 is phosphorylated by MAPK, this may or may not
be mediated by interactions with MAE. Phosphorylated PNT can then bind to the DNA and
activate transcription. PNT-P2 is quickly downregulated by interaction with MAE, resulting in
removal of transcriptional activation. The mechanism by which MAE downregulated PNT-P2
remains to be elucidated.
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(Jayaraman et al. 1999). Both PNT-P2 and ETS-1 are positively regulated by direct
phosphorylation by MAPK. Conversely, phosphorylation of ETS-1 by calcium calmodulin
dependent protein kinase II (CAMK II) on six sites, D/E-S-F/Y-D/E, near the ETS DNA binding
domain results in inhibition of DNA binding (Wasylyk et al. 1997; Yordy and Muise-Helmericks
2000; Sharrocks 2001). PNT-P2 lacks these consensus sites, and therefore is unlikely to be
similarly regulated by calcium signaling (Wasylyk et al. 1997). Both PNT-P2 and ETS-1 are
positively regulated by direct phosphorylation by MAPKs, while ETS-1 is also negatively
regulated by phosphorylation in response to calcium signaling. It will be interesting to see
whether other phosphorylation events negatively regulate the activity of PNT-P2.
TEL
TEL is the mammalian ortholog of YAN and the two appear to be regulated by similar
mechanisms. TEL is phosphorylated constitutively at S22 and inducibly at S257. Like YAN,
hyperphosphorylated TEL is exported from the nucleus in a CRM1 and PD dependent manner,
but unlike YAN, TEL is not likely to be degraded as TEL is a very stable protein (Wood et al.
2003). p3 8 binds directly to and phosphorylates TEL, reducing its ability to repress transcription
(Arai et al. 2002). Similarly, YAN is also phosphorylated by p38 in vitro (F. Hsiao, personal
communication). ERK also phosphorylates TEL, at S113 and S257, removing TEL's
transcription repression by decreasing its DNA binding ability (Maki et al. 2004). Mutating
S113 and S257 to E (E213/257) in TEL, to mimic the negative charge of phosphorylation, results
in the complete loss of transcriptional repression due to TEL's loss of DNA binding ability
(Maki et al. 2004). Interestingly, E213/257 functions as a dominant negative, inhibiting wild-
type TEL mediated transcriptional repression. As TEL can homooligomerize, it is likely that
E213/257 oligomerizes with wild-type TEL, inhibiting DNA binding of the oligomer. Both
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YAN and TEL are regulated by specific phosphorylation events that lead to removal of their
transcriptional repressive activities and their nuclear export.
As MAE has been shown to play critical roles in mediating the downregulation of YAN,
it is interesting to note that no mammalian orthologs of mae have been identified yet. However,
a second mammalian TEL-like gene, referred to as TEL2 or TELB, has been isolated (Poirel et
al. 2000; Gu et al. 2001). As TEL2 functions as a transcriptional repressor, and is capable of
oligomerizing with itself and with TEL, TEL2 may serve as a regulator of TEL (Poirel et al.
2000; Potter et al. 2000). Of particular interest with respect to MAE, TEL2 encodes six splice
variants, one of which, TEL2a, yields a protein with just the PD (Gu et al. 2001). TEL2a
structurally resembles MAE, and BLAST results show that the PD of MAE is most closely
related to the PD of TEL2, with 39% identity and 51% similarity. Therefore it seems likely that
TEL2a could regulate TEL activity by a similar mechanism to what has been shown for MAE
regulating YAN (Tootle et al. 2003a).
Yphosphorylation
While Y phosphorylation is a widespread mechanism of post-translational modification
of membrane bound and cytoplasmic proteins (Hubbard and Till 2000), there is little evidence of
tyrosine phosphorylation regulating transcription factors. STATs are the only transcription
factors whose activities are known to be regulated by Y phosphorylation (Darnell 1997;
Brivanlou and Darnell 2002; Calo et al. 2003). STATs are Y phosphorylated on a single Y in the
cytoplasm by receptor tyrosine kinases (RTKs) and RTK associated non-RTKs. Y
phosphorylation results in homo- or hetero-dimerization of STATs via reciprocal SH2 domain-
phosphotyrosine interactions, leading to nuclear localization and transcriptional activation due to
increased DNA binding activity (Darnell 1997; Brivanlou and Darnell 2002; Kisseleva et al.
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:2002; Calo et al. 2003). Nuclear Y dephosphorylation results in inactivation of STATs (Darnell
1997).
Some non-RTKs have been shown to function in the nucleus. For example, c-ABL
t:yrosine kinase phosphorylates the CTD of RNA polymerase II, and such Y phosphorylation
appears to function equivalently to S/T phosphorylation (Baskaran et al. 1999). Therefore, c-
ABL-mediated tyrosine phosphorylation may contribute to the transition from initiation of
transcription to elongation. Additionally, c-ABL is activated by DNA damaging agents, and
regulates the activity of the proapoptotic transcription factor p73 by tyrosine phosphorylation
(Agami et al. 1999; Gong et al. 1999a). Therefore, tyrosine phosphorylation is likely to play
more direct roles in regulating transcription than presently understood.
Intriguingly v-SRC, a non-RTK, relieves TEL mediated repression by facilitating the
nuclear export of TEL (Lopez et al. 2003). This removal of repression depends on v-SRC kinase
activity and the amino-terminus of TEL, as the splice form TEL-M1 but not TEL-M43 is
regulated in this manner. The amino-terminal region of TEL-M1 is not tyrosine phosphorylated
as mutations of the tyrosine residues do not affect v-SRC mediated nuclear export (Lopez et al.
2003). It remains to be determined if v-SRC interacts with the amino-terminus of TEL-M1,
resulting in the phosphorylation of tyrosine residues outside of this region.
Although no ETS transcription factor to date has been shown to be Y phosphorylated, it
seems probable that Y phosphorylation may be a more widespread mechanism of transcriptional
regulation than currently appreciated.
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Ubiquitination/Ubiquitlyation
While there is little information on ubiquitination of ETS transcription factors, it is
important to discuss the general mechanism and roles of ubiquitin modification, as it has recently
been implicated in playing critical roles in regulating transcription factor activity (Figure 1-2).
Brief examples of how ubiquitination regulates specific, non-ETS transcription factors, will be
discussed, as it is likely that similar regulation of ETS transcription factors occurs.
There are two separate ubiquitin modification pathways: classic ubiquitin-dependent
proteolysis, and ubiquitin mediated activation of transcription factors which can be proteolysis
dependent or independent (Conaway et al. 2002). I will first briefly review the general
information about ubiquitin and the enzymes responsible for the modification before discussing
the roles of ubiquitination in regulating transcription factors.
General information on ubiquitination
Ubiquitin is a 9kDa globular protein that is covalently conjugated to lysine (K) residues
of other proteins. In the majority of the studied cases ubiquitination targets these proteins for
degradation by the multisubunit ATP dependent protease, the proteasome (Verger et al. 2003).
El ubiquitin activating enzymes form a thioester bond with the carboxy-terminal glycine of
ubiquitin in an ATP dependent process. The ubiquitin conjugating enzyme (UBC/E2) accepts
ubiquitin from the E1 enzyme by a trans-thiolation reaction with the carboxy-terminus of
ubiquitin. The transfer of ubiquitin from the E2 to the E-amino group of a specific lysine (K) on
the target protein is catalyzed by the E3 ubiquitin protein ligase (Desterro et al. 2000; Weissman
2001; Conaway et al. 2002; Pickart 2004). There are multiple E3 enzyme families, including
HECT domain E3s, which directly transfer ubiquitin to the target protein, and RING finger and
U box domain E3s (Hatakeyama et al. 2001; Hatakeyama and Nakayama 2003), which mediate
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Figure 1-2
Diagram of the many functions the ubiquitin pathway plays in regulating transcription
factors.
the transfer of ubiquitin from the E2 enzyme to the target protein (Weissman 2001; Greer et al.
2003). Specificity is largely determined by the E3 enzyme, alone or with the E2 enzyme
(Weissman 2001). E4 enzymes polyubiquitinate proteins at sites of monoubiquitination.
Ubiquitin-specific processing enzymes (UBPs), a type of deubiquitinating enzyme (DUB),
cleave ubiquitin from proteins and disassemble multi-ubiquitin chains (Weissman 2001; Greer et
al. 2003).
Degradation as a means of regulating transcription factors
Ubiquitin mediated degradation plays a large role in regulating transcription factor
function. One regulatory strategy is to destroy transcription factors when they are no longer
needed and thus ubiquitination is involved in their downregulation (Rodriguez et al. 2000;
Muratani and Tansey 2003). Another strategy is to couple transcription factor activity tightly to
proteolysis, allowing tight control over transcription (Muratani and Tansey 2003).
Ubiquitination can also activate transcription factors by leading to the proteolytic processing of
the transcription factor itself (Aza-Blanc et al. 1997), or the proteolysis of an inhibitory
interacting protein (Palombella et al. 1994; Conaway et al. 2002; Muratani and Tansey 2003).
Similarly ubiquitination can positively or negatively affect protein-protein interactions, in turn
altering the transcriptional activity of the target factor (Conaway et al. 2002; Muratani and
Tansey 2003). Most interesting is the role of ubiquitination in regulating transcriptional
activation domains (TADs).
The half-life of a transcription factor is inversely correlated with the potency of its TAD.
The TADs with the strongest activity are ubiquitinated and degraded by the proteasome the most
rapidly (Molinari et al. 1999; Conaway et al. 2002). Intriguingly, transcription factors are most
efficiently targeted for ubiquitin-mediated degradation when bound to DNA. This suggests there
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is a close association between the degradation and general transcription machinery. In a growing
number of cases the TAD is also the domain that serves as the degradation signal, or degron, that
is recognized by the ubiquitin-mediated degradation machinery (Salghetti et al. 2000; Salghetti et
al. 2001; Conaway et al. 2002; Muratani and Tansey 2003). TAD dependent ubiquitination of
transcription factors not only targets the protein for destruction but is also required for
transcriptional activation (Conaway et al. 2002).
Not all TADs are also degrons. Pulse-chase experiments revealed that activation
domains in general do not signal for proteolysis (Salghetti et al. 2000). Most of the TADs that
also serve as degrons are composed of a high percentage of acidic amino acids. Interestingly,
degrons from nontranscriptional regulators can also function as TADs; these are not acidic
domains but are known to be phosphorylated (Salghetti et al. 2000). Thus either the negative
charge of the phosphorylation mimics that acidic TAD or the acidic TAD mimics the negative
charge of phosphorylation. It is notable that two domains with very different purposes can
perform the same functions, and indicates the importance of linking potent transcriptional
activators to ubiquitin-mediated proteolysis.
Non-degradation roles of ubiquitination in transcriptional regulation
The first evidence that ubiquitination activates transcription factors came from the study
of the viral synthetic activator VP16. VP16 dependent ubiquitination by SCFMet3 0 E3 ligase is
required for both VP16 turnover and transcriptional activity (Salghetti et al. 2001; Conaway et al.
2002). Fusion of a single ubiquitin moiety to VP16 rescues the requirement of SCFM et30 E3
ligase in transcription, but has no effect on protein turnover (Salghetti et al. 2001). This suggests
that monoubiquitination is enough to activate VP16. VP16 can bind to promoters in the absence
of SCFM e t30 E3 ligase, indicating that SCFMet30 E3 ligase may be targeted to VP16 on the DNA
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(Salghetti et al. 2001). Thus, in addition to transcription factor TADs serving as degradation
signals, components of the degradation machinery are recruited to promoters, emphasizing the
need for the association of these two seemingly different processes, transcription and
degradation. Analysis of VP16 in mammalian cells reveals that both ubiquitination and a
functioning proteasome are required for efficient transactivation, indicating that transcription is
associated with proteolysis (Zhu et al. 2004). Therefore, both recruitment of the E3 ligase to the
promoter and the subsequent monoubiquitination of the transcription factor, and proteasome
activity are required for VP16 transcriptional activation.
Evidence linking ubiquitination to transcription in higher eukaryotes comes from a study
on the transcriptional coactivator CIITA, a MHC class II transactivator. CIITA is the master
regulator of all members of the MHC class II gene complex and is involved in initiation,
propagation and regulation of adaptive immune responses (Greer et al. 2003).
Monoubiquitination of CIITA enhances the recruitment of CIITA to the complex on the
promoter and thus facilitates transcriptional initiation. Additional ubiquitination results in
polyubiquitination and degradation (Greer et al. 2003). Acetyltransferases and
deacetyltransferases are involved in controlling the ubiquitination of CIITA (Greer et al. 2003).
The acetyltransferases, CBP and P/CAF, enhance the ubiquitination and function as coactivators
of CIITA; but it remains to be determined whether this is due to acetylation of CIITA or
histones. There is evidence that p300/CBP can function as E4 ligases to mediate
polyubiquitination (See above, dual function transcriptional regulators) (Grossman et al. 2003).
Alternatively, acetylated histones might recruit ubiquitinating enzymes to chromatin.
Ubiquitination plays two different roles in regulating CIITA, activating transcription and
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mediating degradation. This example illustrates how various post-translational modifications
and the enzymes that mediate them can coordinately affect transcription factor function.
Myc is another example of a transcription factor that is regulated by ubiquitination, both
for protein turnover and transcriptional activity. Myc, with a half-life of about 30 minutes, is an
unstable protein. Skp2, an F-box protein that is part of an E3 ligase, associates with the TAD of
Myc, controlling Myc levels by ubiquitin-mediated degradation, and activating induction of Myc
responsive genes (Jin and Harper 2003). Skp2 and Cull, another part of the E3 ligase, co-
immunoprecitate with Myc on the cyclin D2 promoter, as do 19S proteasome subunits and the
(x2 subunit of the 20S proteasome (Jin and Harper 2003). While the 19S subunit is known to
possess transcriptional activity (see below), recruitment of subunits of the 20S proteosomal core
is novel. It is possible that the entire proteasome is at the promoter. It is evident from these few
examples that many components of the ubiquitination machinery and the 26S proteasome are
implicated in having direct roles in mediating transcription.
Degradation machinery or general transcription factor?
As mentioned above, many components of ubiquitin-mediated degradation are recruited
to promoters, where they appear to function beyond simply modifying transcription factors
(Figure 1-3). For example, E3 ubiquitin ligases function as part of the RNA polymerase II
machinery. Rsp5/hPRF1 (Imhof and McDonnell 1996) and E6-AP (Nawaz et al. 1999) function
as coactivators of nuclear receptors (Conaway et al. 2002), interact with TADs, and ubiquitinate
the largest subunit of RNA polymerase II (Salghetti et al. 2000). As phosphorylation of RNA
polymerase II leads to its ubiquitination and phosphorylation is required for transcriptional
elongation (Beaudenon et al. 1999; Mitsui and Sharp 1999), it is likely that ubiquitination plays a
role in the transition from initiation of transcription to elongation (Muratani and Tansey 2003).
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In addition, TAF11250, a component of the general transcription machinery, possesses
monoubiquitinating ability (see the above discussion of dual function transcriptional regulators)
(Pham and Sauer 2000; Conaway et al. 2002).
Subunits of the 19S regulatory complex of the 26S proteasome have been implicated in
transcriptional regulation (Ferdous et al. 2001; Conaway et al. 2002; Gonzalez et al. 2002;
Muratani and Tansey 2003). At least five 19S subunits are recruited to actively transcribed
genes in yeast (Swaffield et al. 1992; Muratani and Tansey 2003). Two such subunits, Sugl, an
AAA-type ATPase, and Sug2, interact with TADs (Swaffield et al. 1995; Russell et al. 1996;
vom Baur et al. 1996; Wang et al. 1996; Masuyama and MacDonald 1998) as well as the general
transcription factors TBP (Melcher and Johnston 1995; Makino et al. 1999) and TFIIH (Weeda
et al. 1997) (Salghetti et al. 2000; Muratani and Tansey 2003). The roles of Sugl and Sug2 in
transcription are independent of their proteasomal roles, and are most likely involved in
transcriptional elongation (Conaway et al. 2002; Muratani and Tansey 2003).
The large number of proteins possessing roles in mediating both ubiquitin-mediated
proteasomal degradation and transcription indicates the importance of linking these two
activities. Highly acidic TADs, which also function as degrons, signal efficient transcriptional
elongation (Muratani and Tansey 2003). As open chromatin is associated with ubiquitinated
histones, the transcriptional activators may function to recruit the components of the degradation
machinery to modify histones, in addition to modifying basal transcription factors, and ultimately
the activators themselves (Salghetti et al. 2000). Ubiquitination leads to association of the
transcription factor, the proteasome, and general components of transcription (Zhu et al. 2004).
Degradation of the activator would allow rapid reprogramming of transcription or alternatively
allow transcriptional elongation to proceed. When proteolysis of the transcription factor is
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complete, subunits of the proteasome are likely to engage in the elongation step of transcription
(Zhu et al. 2004).
Ubiquitination of ETS transcription factors
ELK-1 is the only ETS transcription factor that has been shown to be ubiquitinated and
the functional consequences of this modification are not understood (Fuchs et al. 1997) (Table 1-
2). In addition, it has been suggested that ER81 undergoes ubiquitin-mediated degradation (Goel
and Janknecht 2003) and ELF-1 is degraded by the proteasome (Juang et al. 2002a). YAN, in
response to phosphorylation by MAPK, appears to be degraded (Lai and Rubin 1992; Rebay and
Rubin 1995; Tootle et al. 2003a). As YAN contains many high scoring PEST sequences, which
can serve as signals for ubiquitin-mediated proteasomal degradation, it is likely that YAN is
ubiquitinated. It is likely that many more ETS transcription factors are ubiquitinated, leading to
both degradation of the protein and activation of transcription, depending on the context.
Sumoylation
It is becoming apparent that sumoylation is a widespread mechanism of post-translational
modification. I will briefly review the mechanism and enzymes responsible for sumo-
conjugation, overview which ETS transcription factors are or are likely to be sumoylated (Table
1-2), and discuss in greater depth how sumoylation regulates the two ETS transcription factors
TEL and ELK-1.
General information on sumoylation
SUMO is an 1 kDa ubiquitin-like small polypeptide modifier that covalently attaches to
K residues, within the consensus sequence of W-K-X-E (=large hydrophobic residue like I/V).
Sumoylation can affect the stability, activity, and localization of its targets (Muller et al. 2001;
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Seeler and Dejean 2001; Gill 2003; Verger et al. 2003). SUMO and ubiquitin are only 18-20%
identical, yet structural studies reveal a common three dimensional structure (Bayer et al. 1998;
Muller et al. 2001). However, there is an amino-terminal extension found on SUMO that is not
present in ubiquitin (Muller et al. 2001). Yeast and Drosophila have only one sumo gene, while
mammalian species possess three genes (Seeler and Dejean 2001). SUMO-2 and SUMO-3, like
ubiquitin, can form multimeric chains on target proteins, while SUMO-1 mono-modifies proteins
(Saitoh and Hinchey 2000; Tatham et al. 2001; Gill 2003; Verger et al. 2003).
Sumoylation occurs by an analogous process to ubiquitination. Like ubiquitin, SUMO is
synthesized as an inactive precursor that is activated by a carboxy-terminal cleavage event
mediated by ubiquitin-like protein processing enzyme (ULP) or SUMO-specific proteases
(Muller et al. 2001). This cleavage exposes a glycine residue at the carboxy-terminus that forms
an isopeptide bond between SUMO and the e-amino group of the K residue on the target protein
(Muller et al. 2001). The SUMO-E1 enzyme is a heterodimer of AOS1 and UBA2. UBA2 is
similar in sequence to the carboxy terminus of UBA1, the E1 ubiquitin-conjugating enzyme,
while AOS 1 is related to the amino-terminus of UBA1 (Johnson et al. 1997; Desterro et al. 1999;
Gong et al. 1999b; Muller et al. 2001). The E1 enzyme, in an ATP-dependent process, forms a
high-energy thioester bond between the carboxy-terminal residue of SUMO and the E1 enzyme
(Seeler and Dejean 2001).
Activated SUMO is then transferred to the sole SUMO-E2 conjugating enzyme, UBC9.
A conserved cysteine residue within UBC9 forms the thioester linkage with SUMO (Seeler and
Dejean 2001). UBC9 is similar in sequence to ubiquitin E2 enzymes, except for the important
difference that the surface which binds the negatively charged surface of SUMO is positively
charged, while the surfaces of ubiquitin E2 enzymes are either negatively charged or neutral
41
(Giraud et al. 1998; Liu et al. 1999; Muller et al. 2001). As a result of this UBC9 can not bind
ubiquitin. UBC9 can directly transfer activated SUMO to the c-amino group of the specific K in
the target protein, however a specific E3 ligase may be required in vivo (Verger et al. 2003).
There are two classes of SUMO-E3 ligases, the Protein Inhibitor of Activated STAT
(PIAS) family and RanBP2/Nup358. PIAS members have RING-like domains with similarities
to the RING finger of ubiquitin E3 ligases, while RanBP2 is a component of the nuclear pore
complex with no similarity to other E3 ligases (Verger et al. 2003). As with ubiquitination, the
E3 ligases are thought to confer the specificity of the modification.
SUMO modification is a dynamic and reversible process. Removal of conjugated SUMO
from its protein targets is catalyzed by SUMO proteases, whose localization determines their
substrate specificity in vivo (Gong et al. 2000; Nishida et al. 2000; Nishida et al. 2001; Best et al.
2002; Hang and I)asso 2002; Gill 2003). These proteases are the same enzymes that process
immature SUMO (See above) (Verger et al. 2003).
Sumoylation of ETS transcription factors
The ETS transcription factors TEL and ELK-1 are sumoylated in vivo. As UBC9 is the
only E2 SUMO-conjugating enzyme identified, it is likely that most, if not all, of its known
interactors are sumoylated. The ETS members that have been shown to interact with UBC9 are
ETS-1, FLI-1, ELF-1, PU. 1, and NET (Hahn et al. 1997) (Table 1-2). UBC9 interacts directly
with ETS-1 and increases its the transcriptional activation activity, while having no effect on
protein stability (Hahn et al. 1997). Future work should elucidate whether these and other ETS
transcription factors are sumoylated, and how such modification affect their activities.
TEL
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TEL, the human ortholog of Drosophila YAN, is a transcriptional repressor of the ETS
family of transcription factors. Similar to YAN, TEL has an amino-terminal PD, that is involved
in both homo- and hetero- typic protein-protein interactions (Jousset et al. 1997; Kwiatkowski et
al. 1998), and a carboxy-terminal ETS DNA binding domain.
The E2 conjugating enzyme UBC9 interacts with the PD of TEL but not with the PD of
YAN (Chakrabarti et al. 1999). At the time it was believed that the main function of UBC9 was
as another E2 enzyme involved in ubiquitin-mediated degradation. However, mutating the
residues within UBC9 that would be important for ubiquitin conjugation and protein degradation
did not affect the interaction between UBC9 and TEL (Chakrabarti et al. 1999). Instead of the
interaction with UBC9 leading to degradation of TEL, it was found that UBC9 directly inhibits
TEL mediated repression (Chakrabarti et al. 1999). This interaction is transient and is not
required for TEL's DNA binding activity (Chakrabarti et al. 1999).
Evidence was emerging that UBC9 was involved in the conjugation of SUMO-1 to target
proteins. Initial analysis of the effects of SUMO-1 on the subcellular localization of TEL
revealed no obvious effect (Chakrabarti et al. 1999). However, it was later shown that the PD of
TEL interacts with SUMO-1 via yeast two-hybrid analysis and in cell culture (Chakrabarti et al.
2000). In 10% of the cells SUMO-modified TEL localizes to nuclear bodies termed TEL-bodies,
which are transient structures formed during S phase (Chakrabarti et al. 2000). TEL-bodies are
distinct from other known nuclear bodies containing SUMO-1, such as PML bodies. The PD of
TEL is required for nuclear localization and SUMO-1 modification, and K99 within the PD is the
predominant SUMO-1 modification site (Chakrabarti et al. 2000). PDs are not the only domains
capable of interacting with UBC9 as two of the five ETS members that interact with UBC9 do
not contain PDs.
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SUMO may regulate the subcellular localization of TEL by facilitating nuclear export.
Endogenous TEL localizes to both the nucleus and the cytoplasm, with only a small percentage
being SUMO conjugated. Analysis revealed that TEL is actively exported from the nucleus in a
CRM1 and PD dependent manner (Wood et al. 2003). The PD of TEL is known to mediate
dimerization, and mutations inhibiting dimerization localize to the nucleus, indicating
homodimerization is needed for nuclear export. Dimerization mutants are not sumoylated,
suggesting dimerization may be needed for SUMO conjugation (Wood et al. 2003). It is unclear
whether the role of dimerization in mediating the nuclear export of TEL is simply due to its
necessity for sumoylation or whether dimerization is otherwise required for export. TEL K99R,
which can not be sumoylated, can not be exported from the nucleus or localize to TEL-bodies,
but can interact via its PD with the corepressor Sin3A and even functions as a better
transcriptional repressor than wild-type TEL (Wood et al. 2003). These data suggest that SUMO
modification contributes to the downregulation and nuclear export of TEL and that TEL bodies
may be loading sites for nuclear export.
Hyperphosphorylated TEL is predominantly cytoplasmic, indicating phosphorylation
may also contribute to the nuclear export of TEL (Wood et al. 2003). Thus both phosphorylation
and sumoylation are involved in mediating the nuclear export of TEL. Intriguingly the other
ETS members known to be regulated by phosphorylation-mediated nuclear export, NET and
YAN, contain putative SUMO acceptor sites (Wood et al. 2003). This suggests that
phosphorylation and sumoylation may generally work in concert to mediate the downregulation
nuclear export of transcription factors. Future work will hopefully determine whether this is the
case, and whether, indeed, NET and YAN are also sumoylated.
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The order in which TEL is phosphorylated and sumoylated is unclear, as is whether one
modification is required for the next to occur or whether they have no effect on each other. It is
important to understand the relationships of these modifications and how they, together, mediate
the nuclear export and downregulation of TEL.
Chromosomal rearrangements of the tel locus, along with deletion of the second tel allele,
are frequently found in cases of human leukemias, as well as solid tumors (Maroulakou and
Bowe 2000). Mouse knockout analysis reveals that while TEL is not essential for initiation of
embryonic angiogenesis, TEL is required for the development and maintenance of complex
vasculature (Bartel et al. 2000). In addition TEL is essential for adult hemotopoiesis (Bartel et
al. 2000). The leukemia associated fusion protein TEL/acute myeloid leukemia 1 (AML1)
transcription factor, is sumoylated and localizes to nuclear speckles during S phase (Chakrabarti
et al. 2000), while AML1 alone normally localizes to larger, distinct nuclear bodies. Thus one
consequence of the chromosomal rearrangement resulting in the TEL/AML1 fusion protein is
altered nuclear localization of AML1 (Chakrabarti et al. 2000). TEL/AML1 fusions can also
localize to the cytoplasm, while wild-type AML1 is predominantly nuclear (Wood et al. 2003),
adding another possible reason for such a fusion to lead to leukemia development. The resulting
mislocalization of the transcription factor results in alterations in gene expression, ultimately
causing the disease state.
Sumoylation of TEL is involved in regulating its subcellular localization and thus its
transcriptional activity. SUMO-TEL localizes to nuclear TEL bodies and results in nuclear
export of TEL. Thus TEL is removed from the DNA, removing its repression. By these same
mechanisms TEL PD fusions with transcription factors, caused by chromosomal translocations,
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result in altered localization of these factors, removing them from the DNA, and thus aberrantly
downregulating them, ultimately resulting in disease.
ELK-1
ELK-1 belongs to the ternary complex factor (TCF) subfamily of the ETS transcription
factors. TCFs act through a ternary nucleoprotein complex composed of a TCF, a serum
response factor (SRF), and a serum response element (SRE), which is composed of the DNA
binding sites for these two factors (Sharrocks 2002; Shaw and Saxton 2003). In response to
growth signals and cellular stress, MAPK signaling leads to the phosphorylation of TADs of
TCFs and induction of their activities as transcriptional activators (Sharrocks 2002; Shaw and
Saxton 2003). In the absence of MAPK signaling, the ETS domain along with an inhibitory
domain, called the R motif in ELK-1, suppresses the activity of the TAD, maintaining the TCF in
an inactive state (Sharrocks 2002; Shaw and Saxton 2003).
Alanine scanning mutagenesis of the R motif in ELK-1 revealed that the conserved
residues K249 and E251 are important for the repressive activity of this domain (Yang et al.
2003). These residues are within a potential SUMO modification site (Verger et al. 2003).
Sequence analysis revealed an additional SUMO consensus site within the R motif, K230.
Blocking sumoylation by mutating the SUMO modification sites (K230R/K249R), expressing
dominant negative UBC9, or expressing the SUMO specific protease SSP3 increases ELK-1
transcriptional activity in the absence of MAPK activation, suggesting that sumoylation plays a
role in repressing the basal level the ELK-1 transcriptional activity (Yang et al. 2003).
Activation of the ERK MAPK pathway synergizes with the above conditions, indicating that the
ERK and SUMO pathways function antagonistically to control ELK-1 transactivation potential
(Yang et al. 2003). Of the two potential sumoylation sites, K249 is the major modification site in
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vitro and in vivo (Yang et al. 2003). Activation of the ERK MAPK pathway leads to an increase
in the level of phosphorylation and a decrease in the level of sumoylation of ELK-1 (Yang et al.
2003). Thus the activity of the autonomous repression domain of ELK-1, the R motif, is
controlled by the SUMO pathway, which is in turn regulated by MAPK-mediated
phosphorylation of the TAD of ELK-1.
The repressive properties of the R motif are due to its recruitment of the histone
deacetylases 1 and 2 (HDAC-1 and HDAC-2). Blocking sumoylation by the K249R ELK-1
mutation removes the repression mediated by the HDACs (Yang and Sharrocks 2004).
Chromatin immunoprecipitation reveals that the ELK-1 K249R mutation leads to reduced
HDAC-2 recruitment to promoters (Yang and Sharrocks 2004). These data suggest that
sumoylation of ELK-1 is required for HDAC recruitment to the promoter and subsequent
transcriptional repression. Stimulation of the ERK MAPK pathway reduces SUMO-1 and
HDAC-2 promoter occupancy and enhances the level of histone H4 acetylation at the promoter
(Yang and Sharrocks 2004). Thus phosphorylation is the switch that changes ELK-1 from a
repressor to an activator.
Additional studies on ELK-1 sumoylation have revealed that SUMO has intrinsic
repressive properties (Yang et al. 2003). This repression is not affected by activation of the
MAPK pathway outside the context of ELK-1. Therefore, sumoylation of transcription factors
may be a general mechanism of mediating transcriptional repression.
ELK-1 can function as both a transcriptional activator and repressor in the same cells.
Sumoylation of ELK-1 results in recruitment of corepressors, resulting in Elk-1 repressing
transcription. MAPK-mediated phosphorylation of ELK-1 inhibits sumoylation and results in
ELK-1 functioning as a transcriptional activator.
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It is intriguing that like TEL, ELK-1 is regulated by phosphorylation and sumoylation
and these two modification appear to affect each other. In the case of TEL, both function to
mediate the downregulation of TEL, while in the case of ELK-1, phosphorylation and
sumoylation act antagonistically. It is likely that, as discussed above, other ETS transcription
factors are dually regulated by these two modifications. Further work is needed determine the
interplay between phosphorylation, sumoylation, and other post-translation modifications with
respect to regulation of transcription factor function.
Acetylation
Although acetylation is best known for its involvement in regulating histones and thus the
state of chromatin, it is a common modification involved in regulating transcription factors. I
will review the enzymes which mediate this modification, overview the protein-protein
interaction domains which recognize acetylated lysines, discuss the roles of specific
acetyltransferases as transcriptional coactivators, overview the ETS transcription factors which
are acetylated (Table 1-2), and discuss how ER81 and ETS 1 are regulated by acetylation.
General information on acetylation
Acetyltransferases transfer an acetyl group from acetyl-Coenzyme A (acetyl-CoA) to the
e-amino group of a specific K on the target protein (Sterner and Berger 2000). Modification by
acetylation was originally thought to be restricted to histones. K acetylation of histone tails
partially neutralizes their positive charge, weakening histone-DNA interactions and resulting in
chromatin "opening" (Sterner and Berger 2000; Wang et al. 2000).
There are several families of acetyltransferases, including p300/CBP, GNAT (P/CAF
/GCN5), TAF11250, p 160 steroid receptor coactivator (SRC) family (SRC1/p 160/NCoA-1,
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ACTR/Rac3/AIB1/ TRAM-1/pCIP, TIF2/GRIP1/NCoA-2), and MYST (MOZ, Ybf2/Sas3, Sas2,
Tip60) (Bannister and Miska 2000; Sterner and Berger 2000). As very few Ks within a
particular protein are acetylated, it is likely that acetyltransferase have specificity. A possible
consensus sequence for acetylation is GK (Kouzarides 2000). Acetyltransferases are known to
self-modify, possibly regulating their cellular localization (Creaven et al. 1999; Bannister and
Miska 2000; Kalkhoven et al. 2002), and their activity may be regulated by extracellular
signaling events (Kouzarides 2000).
Like most post-translational modifications, acetylation is reversible and the enzymes
responsible are deacetylases. All known deacetylases are histone deacetylases, of which there
are two families. The first family composed of HDAC1, HDAC2, and HDAC3 is related to
yeast deacetylase RPD3, and contains a highly conserved catalytic domain. The other family is
related to yeast HDA1 and is composed of HDAC4, HDAC5, and HDAC6 (Kouzarides 2000).
It is not known whether there is specificity and site selection by deacetylases. HDACs have been
shown to deacetylate transcription factors (Kouzarides 2000). In addition, as HDACs can
associate with various transcriptional corepressors, their interactions with transcription factors
could result in recruitment of these corepressors to promoters along with deacetylation or
"closing" of the chromatin (Pazin and Kadonaga 1997).
Bromodomains, which recognize and bind acetylated Ks, are found in many chromatin
associated proteins and all acetyltransferases. NMR studies revealed that bromodomains
fimunction as acetyl-K binding domains by forming a specific hydrogen-bond between the oxygen
of the acetyl carbonyl group and the side chain of the amide nitrogen of the conserved
asparagines within the domain (Hudson et al. 2000; Zeng and Zhou 2002). In general
bromodomains recognize acetylated Ks that are neighbored by aromatic or hydrophobic residues.
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][ndividual bromodomains possess specificity, as the GCN5 bromodomain recognizes the
acetylated K, and the Y/F at +2 to the acetylated K(Hudson et al. 2000), while P/CAF recognizes
the Y at -3 and the Q at +4 (Mujtaba et al. 2002; Zeng and Zhou 2002). These domains function
to tether acetyltransferases to specific chromosomal sites and assemble multi-protein complexes.
Acetyltransferases which function as coactivators
Many acetyltransferase families function as transcriptional coactivators, including
p300/CBP, P/CAF and nuclear receptor coactivators. p300/CBP are structural and functional
homologs that were originally characterized as transcriptional coactivators (Janknecht and
Hunter 1996) and were later found to possess intrinsic acetyltransferase activity (Bannister and
Miska 2000; Sterner and Berger 2000). As coactivators they act as scaffolds between the
transcription factors and the general transcription machinery. Many transcription factors interact
with the same site on p300/CBP, indicating there could be competition for limiting amounts of
this coactivator (Janknecht and Hunter 1996). p300/CBP acetyltransferase activity is required
for its function as a transcriptional coactivator (Benkirane et al. 1998; Vanden Berghe et al.
1999; Sterner and Berger 2000). The central regions of p300/CBP contain a bromodomain and
p300/CBP interact with other acetyltransferases, GCN5, P/CAF, and nuclear receptor
coactivators (Bannister and Miska 2000; Sterner and Berger 2000). Therefore, p300/CBP can
acetylate transcription factors and the general transcription machinery in addition to recruiting
other coactivators/acetyltransferases to the promoter and thereby amplifying its effects.
P/CAF, as mentioned above, can form a complex with p300/CBP to regulate
transcription, and can itself function as a coactivator in an acetyltransferase dependent manner
(Benkirane et al. 1998; Sterner and Berger 2000). P/CAF contains a bromodomain, which is
required for its full acetyltransferase activity (Sterner and Berger 2000).
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The nuclear receptor coactivators SRC-1 and ACTR are known to possess
acetyltransferase activity, while this function has never been shown for TIF2. Both SRC-1 and
ACTR interact with nuclear hormone receptors and stimulate their transcriptional activation
(Chen et al. 1997a; Ding et al. 1998; Sterner and Berger 2000). They also interact with
p300/CBP and P/CAF, and are acetylated by p300/CBP. In most cases acetylation of
acetyltransferases have positive effects on their activities, however acetylation is known to
inhibit ACTR's function as a coactivator (Chen et al. 1999b; Sterner and Berger 2000).
These three families of acetyltransferases fall into the category of factor
acetyltransferases (FATs). FATs acetylate architectural DNA binding elements, general
transcription machinery, and site specific DNA binding factors (Bannister and Miska 2000).
Acetylation can regulate protein-DNA interactions, as well as protein-protein interactions,
possibly by affecting protein conformation similar to how it affects histone conformation
(Bannister and Miska 2000; Sterner and Berger 2000).
Acetylation of ETS transcription factors
The ETS transcription factors ER81 and ETS 1 are known to be acetylated. In addition
ELK1 and PU. 1 are known to interact with p300/CBP (Nissen et al. 2001 and Yamamoto et al.
1999, respectively), and it remains to be determined whether these interactions lead to
acetylation of these transcription factors (Table 1-2). As the majority of ETS transcription
factors are activators it is likely that many more interact with coactivator acetyltransferases, and
may themselves be acetylated.
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ER81
Acetylation of ER81 increases protein-protein interactions, protein-DNA interactions,
transcriptional activity, and protein stability. Additionally ER81 activity is not only regulated by
acetylation, but is also regulated by phosphorylation and ubiquitin-mediated degradation.
The first indication that ER81 might be modified by acetylation was the discovery of
interactions between ER81 and p300/CBP (Papoutsopoulou and Janknecht 2000; Bosc et al.
2001; Wu and Janknecht 2002). p300/CBP function as adaptors between transcription factors
and the general transcription machinery; in addition p300/CBP possess intrinsic acetyltransferase
activity. Therefore p300/CBP may directly regulate chromatin structure and/or may modify
other proteins such as the transcription factors and general transcriptional machinery associated
with it. Later work has shown that in addition to p300/CBP, P/CAF, and members of the p160
steroid receptor coactivator (SRC) family, SRC-1, ACTR and GRIP-1, interact with and
acetylate ER81 (Goel and Janknecht 2003 and Goel and Janknecht 2004, respectively).
ER81 and p300/CBP associate both in vitro and in vivo, where this association leads to
increased ER81 transcriptional activity (Papoutsopoulou and Janknecht 2000). P/CAF also
interacts with ER81 in vivo, and the region of interaction between P/CAF and ER81 partially
overlaps with the region of interaction between p300/CBP and ER81 (Goel and Janknecht 2003).
However, P/CAF-ER81 interaction does not inhibit p300/CBP binding. Therefore, all three
proteins, ER81, p300 and P/CAF, may form a complex, leading to transcriptional activation.
ER81 is acetylated in its amino-terminal TAD at K33 and K1 16 (Goel and Janknecht
2003). Acetylation at K116 enhances ER81's affinity for DNA, most likely due to a
conformational change allowing the ETS domain to bind DNA better (Goel and Janknecht 2003).
Acetylation also increases the potency of ER8 I's amino-terminal TAD (Goel and Janknecht
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2003). This may be due to recruitment of cofactors or chromatin remodeling complexes that
interact with acetylated lysines through bromodomains. Additionally, acetylation of either K33
or K1 16 also increases the in vivo half-life of ER81 (Goel and Janknecht 2003). A common
mechanism for acetylation increasing protein stability is by modifying the Ks that are to be
ubiquitinated, and thus preventing protein degradation (Freiman and Tjian 2003). However this
is not the case for ER81, suggesting that acetylation at K33 and K1 16 prevents the ubiquitination
of other lysines by either inducing a conformational change, or allowing or preventing
interaction with proteins that shield ER81 from or target to ubiquitin ligases (Goel and Janknecht
2003).
In addition to being modified by acetylation, ER81 is also phosphorylated due to RAS
signaling downstream of the HER2/Neu receptor tyrosine kinase (Bosc et al. 2001).
Interestingly, p300 expression leads to increased ER81 phosphorylation but phosphorylation
does not affect p300/CBP binding to ER81 (Papoutsopoulou and Janknecht 2000). Mutation of
either the two acetylation sites or the five phosphorylation sites reduces HER2/Neu mediated
activation of ER81, while mutation of both practically eliminates all activity (Goel and Janknecht
2003). Therefore., both phosphorylation and acetylation are required for maximal transcriptional
activation by ER81. HER2/Neu and the downstream components RAS and RAF, induce the
acetyltransferase activity of p300 but not P/CAF by direct phosphorylation, and thus increases
the in vivo acetylation of ER81 (Goel and Janknecht 2003). HER2/Neu signaling leads to
phosphorylation of ER81 and p300, activating p300's acetyltransferase activity and leading to
acetylation of ER81, ultimately resulting in increased ER81-dependent transcriptional activation.
Phosphorylation leads to the acetylation of ER81, which results in enhancement of both
protein-protein and protein-DNA interactions, increased transcription activity, and increased
53
protein stability. ER81 is a prime example for how different post-translational modifications, in
this case acetylation and phosphorylation, of transcription factors, and other protein classes for
that matter, should not be looked at in exclusion but rather should be studied together to
determine whether there is synergism or antagonism between the different modifications.
ETS1
Turnover of extracellular matrix (ECM) proteins is necessary for embryogenesis, the
female reproductive cycle, angiogenesis, and tissue repair. Abnormal turnover of ECM proteins
is observed in adults during tumorigenesis and arthritis (Trojanowska 2000). TGF3 signaling
induces the expression of ECM proteins, while ETS transcription factors ETS 1 and the
E1AF/PEA3 subfamilies play roles in inducing ECM turnover by activating transcription of
serine proteases (uPA) and matrix metalloproteinases (MMP-1, 3, 9) (Altieri et al. 1995;
Westermarck et al. 1997; Watabe et al. 1998; Trojanowska 2000).
p300/CBP are recruited by ETS 1 to the mmp-J promoter, contributing to its
transcriptional activation. The interaction and cooperation between ETS-1 and p300/CBP are
not affected by phosphorylation (Jayaraman et al. 1999). Two separate regions of p300/CBP,
which do not possess acetyltransferase activity, independently interact with and coactivate ETS-
1. This indicates that p300/CBP enhancement of ETS-1 mediated transcriptional activation does
not require acetyltransferase activity.
TGF3 and ETS 1 act antagonistically to regulate ECM proteins. For instance, TGF[3
signaling inhibits mmp-1 expression, while ETS 1 can overcome this inhibition and activate mmp-
1 expression (Czuwara-Ladykowska et al. 2002). Like ETS1, TGF3 transcriptional stimulation
is enhanced by p300, but unlike ETS-1, this stimulation requires p300's acetyltransferase
activity; this enhancement is inhibited by ETS 1 (Czuwara-Ladykowska et al. 2002). As ETS-1 is
54
known to interact with p300/CBP, it is likely that ETS-1 inhibition of TGF3-dependent
transcriptional activation is due to ETS-1 sequestering away p300/CBP.
TGF[3 stimulation leads to rapid and prolonged acetylation of ETS 1, but has no affect on
the phosphorylation of ETS 1 (Czuwara-Ladykowska et al. 2002). Acetylation of ETS- 1 results
in dissociation of the p300/CBP-ETS 1 complex. Thus, under normal cellular conditions TGF[3
signaling leads to acetylation of ETS-1, resulting in release of p300/CBP which can then interact
with transcription factors downstream of TGF3 signaling, SMADs, to activate transcription.
The abnormally high levels of ETS-1 expressed in fibroblasts (Czuwara-Ladykowska et
al. 2002) result in an altered cellular response to TGF3 signaling, specifically resulting in the
sequestrating of p300/CBP by ETS-1 and subsequently inhibiting TGF[3 dependent transcription.
Thus increased ETS-1 expression in these cells is likely to be a contributing factor in the
pathology of tumor progression and arthritis.
Acetylation in the case of ETS-1 negatively affects protein-protein interactions, resulting
in the downregulation of ETS-1 mediated transcriptional activation. The competition for
limiting amounts of p300/CBP exhibited by ETS-1 and TGF3 signaling components is a
mechanism of regulation that is used repetitively to regulate transcription factor activity.
Methylation
While no lETS transcription factors are yet known to be methylated, I will briefly review
the mechanism and roles of methylation in regulating other transcription factors. Future work is
likely to reveal that ETS transcription factors are regulated by methylation.
General information on methylation
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Methylation of non-histone proteins occurs at arginine (R) residues. There are three
forms of methylarginine, NG-monomethylarginine (MMA), NGNG (asymmetric)
climethylarginine (aDMA), and NGNG (symmetric) dimethylarginine (sDMA), modification of
guanidino nitrogen atoms (McBride and Silver 2001). aDMA occurs on R in RGG, RXR, and
RG motifs, while MMA only occurs at RGG tripeptides (Najbauer et al. 1993; Rawal et al. 1995;
McBride and Silver 2001). While R methylation does not change the charge of the residue, it
increases steric hindrances and decreases hydrogen bonding capability (McBride and Silver
2001).
R methyl transferases are likely to function as dimers and contain a S-adenosyl
methionine (AdoMet) binding motif and a less conserved carboxy-terminal domain that is
involved in substrate recognition (Weiss et al. 2000; Zhang et al. 2000; McBride and Silver
2001; Rho et al. 2001; Komoto et al. 2002). All R methyl transferases are capable of
monomethylating, type I can asymmetrically dimethylate, and type II can symmetrically
dimethylate (McBride and Silver 2001). The majority of R-methylation is mediated by the
subfamily of R methyl transferases including hPRMT1 (yeast HMT1/RMT1). Most PRMTs are
type I enzymes, while hPRMT5/JBP1 is a type II enzyme (McBride and Silver 2001).
Coactivator associated arginine methyltransferase 1 (CARM1) functions as a secondary
coactivator which interacts directly with primary coactivators of the p160 family, which possess
acetyltransferase activity (see above). CARM1 methyl transferase activity is required for
coactivator function (Chen et al. 1999a). It is interesting that acetyltransferases p300/CBP and
Pi/CAF also function as secondary coactivators, suggesting that primary coactivators in general
may serve to recruit enzymes to post-translationally modify nearby proteins, including histones
and transcriptional regulators. As discuss above (Dual function transcriptional regulators), it is
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emerging that some transcription factors themselves possess enzymatic activity to mediate such
post-translation modifications.
Unlike the other post-translational modifications, R methylation has not been shown to be
reversible, indicating that the regulation of this modification has to occur at the level of the R
methyl transferase (McBride and Silver 2001). However, analysis of histone methylation
suggests that although no demethylating enzymes have been identified, methylation is likely to
be reversible (Ma et al. 2001; Davie and Dent 2002).
R methylation is an important regulator of mammalian skeletal muscle differentiation
(Chen et al. 2002), erythroid differentiation (Bakker et al. 2004), and is likely to play a role in
neuronal differentiation (Cimato et al. 2002). Mouse knockout experiments have revealed that
loss of PRMT1 results in death at embryonic day 6.5 (Pawlak et al. 2000), and loss of CARM1
results in decreased size and perinatal death (Yadav et al. 2003). This analysis has also shown
that CARM1 is essential for estrogen responsive transcriptional activation, definitively showing
that R methylation is involved in transcriptional regulation (Yadav et al. 2003).
R methylation is known to affect protein-protein interactions and nuclear import/export
(McBride and Silver 2001). SAM68, a SRC kinase adaptor protein, has SH3 and WW domains
flanked by RG repeats that are aDMA, resulting in inhibition of SH3 domain binding but having
no effect on WW domain interactions (Bedford et al. 2000). Thus R methylation can
differentially regulate protein-protein interactions. PRMT1 has a positive role in interferon
(IFN) xc and [3 signaling, and specifically methylates STAT1 in response to interferon
stimulation. R methylation of STAT1 results increased interaction with its inhibitor PIAS 1, an
E3 SUMO-ligase, leading to decreased DNA binding (Mowen et al. 2001), and decreased
interaction with the nuclear tyrosine phosphatase TcPTP, leading to increased protein stability
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(Zhu et al. 2002). This suggests that methylation can affect other post-translation modifications
on the modified protein. Interestingly the coactivator and acetyltransferase CBP is R methylated
in vivo. This methylation is important for CBP coactivator function in relation to steroid
hormone dependent transcription, but not for other promoters (Chevillard-Briet et al. 2002).
Aberrant regulation of methylation has been associated with cardiovascular disorders and
autoimmune diseases, including multiple sclerosis and lupus erythematosis (McBride and Silver
2001).
No ETS transcription factors have been shown to be methylated. However, as
methylation is just beginning to be understood as a means of regulating transcription factors, it is
likely that future research will reveal that ETS transcription factors are regulated by such
modifications.
Glycosylation
Originally thought to only be a modification found on membrane associated proteins,
glycosylation is emerging as a post-translational modification of both cytoplasmic and nuclear
proteins. I will discuss the interplay of glycosylation and phosphorylation, review the enzymes
which mediate it, overview the ETS transcription factors modified by glycosylation, and discuss
how glycosylation regulates ELF-1.
Glycosylation vs. phosphorylation
Complex N- and O-linked glycosylation occur on membrane bound and secreted proteins
that are synthesized in the endoplasmic reticulum (ER) or Golgi apparatus (Vosseller et al. 2001;
Wells et al. 2001). Contradicting the dogma that carbohydrate modifications can only occur in
the ER and Golgi apparatus, it was found that many nuclear and cytoplasmic proteins are
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modified at multiple S or T hydroxyl groups by a simple monosaccharide modification of a
single 3-N-acetylglucosamine (O-GlcNAc) moiety (Torres and Hart 1984; Hart 1997; Comer
and Hart 2000; Wells et al. 2001; Zachara and Hart 2002). O-GlcNAc modification is found in
all eukaryotes studied, but not in prokaryotes (Zachara and Hart 2002). While there is no
consensus motif for O-GlcNAc attachment, many of the sites are identical to those recognized by
S/T protein kinases (Hart 1997; Comer and Hart 2000; Zachara and Hart 2002).
Phosphorylation and O-GlcNAc occur at the same or adjacent hydroxyl moieties. Every
protein modified by O-GlcNAc is known to be phosphorylated and to form reversible multimeric
protein complexes by associations that are regulated by phosphorylation (Hart 1997; Comer and
Hart 2000; Vosseller et al. 2001). O-GlcNAc may mediate protein-protein interactions either
directly or indirectly; however, there is no known domain which specifically binds to O-GlcNAc
(Vosseller et al. 2001). Phosphatase inhibitors and kinase activators decrease the levels of O-
GClcNAc modification, while kinase inhibitors increase these levels (Griffith and Schmitz 1999;
Vosseller et al. 2001). These data indicate that O-GlcNAc and phosphorylation play competing
and antagonistic roles. Most curious is that many of the O-GlcNAc modification sites are within
high scoring PEST sequences (Comer and Hart 1999; Zachara and Hart 2002). PEST sequences
are associated with signaling proteasome mediated degradation either constitutively, or by a
phosphorylation induced mechanism. O-GlcNAc may neutralize the effect of the PEST
sequence by preventing phosphorylation and subsequent degradation (Comer and Hart 1999;
Zachara and Hart 2002). As both modifications can occur at the same residues, it complicates
interpretations of phosphorylation site mutants as mutations of such residues prevent both types
of modification.
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General information on glycosylation
The enzyme responsible for O-GlcNAc modification, uridine diphospho-N-
acetylglucosamine polypeptide -N-acetylglucosaminyl transferase or O-GlcNAc transferase
(OGT), localizes to the cytoplasm and the nucleus (Hart 1997; Comer and Hart 2000; Vosseller
et al. 2001; Kamemura and Hart 2003). OGT represents a novel enzyme, with no obvious family
members, that is 80% homologous between humans and C. elegans (Zachara and Hart 2002).
OGT has eleven tetratricopeptide repeats (TPRs) at its amino terminus which mediate both
trimerization of the catalytic subunits and interactions with other proteins (Hart 1997; Kreppel et
al. 1997; Kreppel and Hart 1999; Comer and Hart 2000; Zachara and Hart 2002; Iyer and Hart
2003; Kamemura and Hart 2003). There is some evidence suggesting that these repeats are also
important for substrate selectivity. OGT is itself modified by O-GlcNAc and tyrosine
phosphorylation (Kreppel et al. 1997; Kreppel and Hart 1999; Comer and Hart 2000; Zachara
and Hart 2002), and purifies with an unknown S/T phosphatase (Zachara and Hart 2002).
O-GlcNAc is a dynamic and reversible modification, with a turnover rate similar to that
of phosphorylation (Comer and Hart 2000). O-GlcNAcase, a cytoplasmic and nuclear 13-N-
acetylglucosaminidase, functions optimally at a neutral pH and exhibits selectivity towards O-
linked GlcNAc. -GlcNAcase is phosphorylated and purifies as part of a larger complex (Wells
et al. 2002; Zachara and Hart 2002). Known inhibitors of this enzyme increase the levels of O-
GlcNAc modified proteins (Comer and Hart 2000). The proximity of both OGT and O-
GlcNAcase to their substrates allows rapid regulation of existing proteins (Vosseller et al. 2001).
O-GlcNAc modification is likely to have protein and even modification site specific
influences (Vosseller et al. 2001). Known targets of this widespread modification include
nuclear pore proteins, chromatin associated proteins, RNA polymerase II and its transcription
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factors, hormone receptors, phosphatases and kinases (Zachara and Hart 2002). It is intriguing
that many chromatin associated proteins, particularly histones, are glycosylated. Like
modification by acetylation, glycosylation may regulate the transition from transcriptionally
inactive or "closed" chromatin to transcriptionally active or "open" chromatin (Kelly and Hart
1989; Comer and Hart 1999).
Practically all of the RNA polymerase II transcription factors that have been studied in
detail are modified by O-GlcNAc. There is evidence indicating O-GlcNAc plays roles in nuclear
transport, regulating protein turnover, and regulating transactivation activities of transcription
factors (Hart 1997; Comer and Hart 2000). It may mediate assembly of transcriptional
complexes and may even directly regulate protein translation (Comer and Hart 2000).
Mouse knockout studies have shown that OGT is required for cell viability, indicating
that O-GlcNAc modifications play essential roles (Comer and Hart 2000; Shafi et al. 2000;
Zachara and Hart 2002). Loss of O-GlcNAcase is also toxic to cells (Fang and Miller 2001;
Zachara and Hart 2002). Aberrant O-GlcNAc modifications have been associated with type II
diabetes (Yki-Jarvinen 1998; Comer and Hart 2000; Akimoto et al. 2001; Vosseller et al. 2001),
neurodegenerative diseases including Alzheimer's disease (Griffith and Schmitz 1995; Comer
and Hart 2000), and even cancer (Zachara and Hart 2002).
Glycosylation of ETS transcription factors
ELF-1 is the only ETS transcription factor known to be glycosylated and is one of the
few proteins known to be phosphorylated and glycosylated at the same time (Juang et al. 2002a).
Many ETS transcription factors are known to be S/T phosphorylated, and as glycosylation can
occur at the same site as phosphorylation, it is probable that many more ETS transcription factors
are regulated by glycosylation.
61
ELF-1 mediates the induction of various genes in hematopoietic cells, including cd4, gm-
csf, IgH enhancer gene, and tcr aand chains (Tsokos, 2003 #99]. Predicted to be 68 kDa,
ELF- has the apparent molecular weights of 80 and 98 kDa. This apparent molecular weight is
not due to a high ratio of charged amino acids and therefore indicates that post-translational
modifications are likely to be the cause of the increased weight.
The 80 kDa form of ELF-1 is cytoplasmic, while the 98 kDa form is nuclear (Juang et al.
2002a). The retinoblastoma (Rb) protein is known to sequester ELF-1 in the cytoplasm (Wang et
al. 1993) and in agreement with this, Rb binds the 80 kDa form of ELF-1 more so than the 98
kDa form (Juang et al. 2002a). Upon phosphorylation of Rb, ELF-1 is no longer bound to Rb
and is translocated to the nucleus (Wang et al. 1993). Thus the conversion of the 80 kDa form to
the 98 kDa form decreases interactions with Rb and contributes to nuclear localization. The 98
kDa form of ELF.-1 is phosphorylated and the kinases responsible are likely to belong to the
protein kinase C family (Juang et al. 2002a). Phosphorylation of both the cytoplasmic scaffold
Rb and ELF- itself leads to nuclear localization of ELF-1.
As phosphorylation alone can not make up for the ELF-1 size discrepancy, glycosylation
was analyzed. Both forms of ELF-1 are O-GlcNAc, but the 98 kDa form has eight-fold more O-
GlcNAc modifications. The ability of ELF-1 to bind to one of its target promoters, the TCR ~-
chain promoter, requires both O-GlcNAc and phosphorylation modifications (Juang et al.
2002a), indicating these modifications occur at different sites. The nuclear, 98 kDa form of
ELF-1 is the main form bound to DNA. Proteasome inhibitors lead to increased cytoplasmic
levels of the 98 kDa form, indicating that this form of ELF-1 is constantly degraded through the
proteasome pathway. These inhibitors had no affect on the amount of the 80 kDa form of ELF-1
(Juang et al. 2002a). Thus glycosylation may also contribute to the degradation of ELF-1. Both
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phosphorylation and glycosylation contribute to the nuclear localization and DNA binding
affinity of ELF-1.
Patients with the autoimmune disease systemic lupus erythematosus (SLE) exhibit
defective expression of TCR 4-chain protein and mRNA (Liossis et al. 1998), a known
transcriptional target of ELF-1. 83% of SLE patients have normal cytoplasmic levels of the 80
kDa form, while one-third of the patients have decreased levels of the nuclear 98 kDa form of
ELF-1 (Juang et al. 2002b). Nuclear extracts from the latter patients exhibit defective DNA
binding and decreased TCR 4-chain expression. It is thought that the decreased amount of active
ELF-1 is due to decreased levels of phosphorylation (Juang et al. 2002b). It is also likely the
glycosylation plays a role in the disease state.
O-GlcNAc modication of ELF-1 leads to increased DNA binding, and may be involved
in regulating protein-protein interactions and nuclear localization. ELF-1 is unique in that it is
known to be both glycosylated and phosphorylated at the same time, indicating that the sites of
modification can be different. This is another example of how multiple post-translational
modifications are used to regulate various aspects of transcription factor function.
Concluding remarks
Extracellular signaling events ultimately regulate gene expression to promote a specific
outcome. Therefore, signaling pathways must regulate the activities of transcription factors.
Transcription factors function downstream of many different signaling cascades, and thus
mechanisms must exist for different signaling events to differentially regulate transcription
factors. A common method of regulating transcription factor function is by post-translational
modifications, including phosphorylation, ubiquitination, sumoylation, acetylation, methylation
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and glycosylation (Figure 1-4). Post-translational modifications can regulate both the activity
and the specificity of transcription factors. This regulation of specificity is particular important
for the ETS transcription factor family, as the more than 30 mammalian members of the family
all recognize the same core DNA sequence.
Just from the above examples of how various post-translational modifications
individually affect ETS transcription factor function, it is apparent that specific modifications
should not be looked at in isolation as one modification can affect another, either positively or
negatively. A particular modification may lead to a subsequent modification by altering the
subcellular localization, the conformation of the protein, or protein-protein interactions. By
these same mechanisms one modification can prevent another. Competition for a particular
residue is another means by which modifications negatively regulating each other.
Ubiquitination, sumoylation, and acetylation all occur at lysine residues, and thus modification
by one of these will prevent other modifications at the same site. Similarly glycosylation and
phosphorylation can target the same serine/threonine residues. It is important to note that in
some cases there is competition for a particular residue, while in other cases, although they target
the same amino acid, they modify different sites within a protein. In the latter case these
modifications can regulate modifications at other sites within the target protein by the ways
discussed above.
Often when one studies a transcription factor and how it is regulated one look at one step
in the process. One needs to be aware that many mechanisms exist to regulate the functions of
the protein, including the many types of post-translation modifications. A protein can be
modified at multiple sites by a particular post-translation modification and by more than one type
of post-translation modification at a time. The number of sites for each modification and the
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Figure 1-4
Signaling cascades
Y phosphorylation
L sumoylation
L polyubiquitination
L monoubiquitination
L acetylation
Transcription factor
Figure 1-4
Schematic of how signaling events regulate post-translational modifications of transcription
factors and thus regulate their activities.
I
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combinations of modifications possible is extremely high, yielding immense regulatory
opportunities that the cell is most likely taking advantage of. Additionally, the timing and order
in which modifications occur adds other levels of regulation.
The order, timing, and combinations in which the multitude of post-translational
modifications can occur provide the cell with an enormous amount of regulatory options.
Although many years of research have yielded insights into how ETS transcription factors are
regulated by post-translational modifications, we are probably only beginning to understand how
these transcriptional regulators are controlled by these modifications. Broader analysis of how
and why these factors are post-translationally modified in conjunction with how such
modifications affect other modifications is needed. Particularly intriguing are the growing
number of transcriptional regulators that possess the enzymatic activities to mediate these
modifications.
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Dual function transcriptional regulators
Evident fom the examples above, post-translation modification play critical roles in
regulating transcription factors, and the combinations of modifications that can occur on
individual transcription factors yield immense regulatory possibilities. It is emerging that a
small, but growing number of transcriptional regulators possess enzymatic activity and mediate
post-translational modifications. I will review the enzymatic functions of the transcriptional
regulators EYA, DBP1, ERK5, p300, and TAF11250.
Transcription factors as phosphatases
EYA
EYA is an evolutionarily conserved transcriptional coactivator in the Retinal
Determination (RD) Network and a protein phosphatase. The RD network encompasses a
signaling cascade of transcriptional regulators best known for their necessity during Drosophila
eye development. Additionally the RD network is deployed in both vertebrates and invertebrates
in many developmental contexts outside of eye development. The RD network functions in a
hierarchical manner in that Twin on Eyeless (TOY) turns on the expression of Eyeless (EY),
which in turn leads to expression of EYA and Sine oculis (SO), who turn on Dachshund (DAC)
(Figure 1-5) (Chen et al. 1997b; Pignoni et al. 1997; Czerny et al. 1999; Hauck et al. 1999).
EYA was originally characterized as the founding member of a novel family of
transcriptional regulators, and contains two evolutionarily conserved domains, the carboxy-
terminal EYA domain (ED), and the tyrosine rich EYA domain 2 (ED2) (Figure 1-6A) (Xu et al.
1997; Zimmerman et al. 1997). The ED2 resides within a larger proline, serine, threonine or
PST rich region that is necessary for transcriptional activation (Silver et al. 2003). The ED has
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Schematic of the Retinal Determination Network cascade.
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Figure 1-6
EYA's role as a protein phosphatase. A. Diagram of the EYA protein, pointing out the known
domains and their respective functions. B. How EYA's activity as a protein phosphatase may be
involved in regulating the activity of RNA polymerase II. RNA polymerase II binds to the DNA
as part of the preinitiation complex. Phosphorylation on the CTD repeats of RNA polymerase II
contributes to the transition from initiation to elongation of transcription. Dephosphorylation of
RNA polymerase II, possibly mediated by EYA, leads to its removal from the DNA, allowing it
to be recycled and bind to the promoter for another round of transcription. C. Schematic
illustrating that DACH1 and SIX1 together repress transcription, addition of phosphatase active
EYA switches this complex from functioning as a repressor to an activator. D. Graphic
representation and schematic showing that DAC can enhance transcription from a native
promoter mediated by the EYA-SO transcription factor, independent of EYA's phosphatase
activity.
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been shown to directly mediate protein-protein interactions with SO and DAC (Pignoni et al. 199
and Chen et al. 1997b, respectively). In the case of SO, the interaction with EYA results in the
formation of a bipartite transcription factor (Ohto et al. 1999), with the homeodomain of SO
providing the DNA binding activity and the PST rich region of EYA providing the
transactivation (Silver et al. 2003). As DAC has recently been shown to possess
D)NA binding ability (Kim et al. 2002), it is possible that DAC acts like SO and recruits the
transactivator EYA to the DNA, forming an active transcription factor. However the interaction
between the ED of EYA and DAC is highly contested (Ikeda et al. 2002; Silver et al. 2003),
suggesting that if such an association occurs it is likely to be context specific. Recent work
indicates that under certain conditions SO, EYA, and DAC may form a tripartite factor to
regulate transcription (Li et al. 2003;S. Silver, personal communication; see discussion below).
Multiple groups have shown that EYA, in addition to functioning as a transcriptional
coactivator, is the defining member of a new family of protein phosphatases. The catalytic
domain, the ED, was defined by homology to haloacid dehalogenases, a family of enzymes
possessing a broad range of activities (Thaller et al. 1998; Collet et al. 1999). There is some
discrepancy as to what type of protein phosphatase EYA is, as one group, utilizing full-length
EYA, found that EYA is a dual specific phosphatase that can dephosphorylate both phospho-
serine/threonine (S/T) and phospho-tyrosine (Y) (Li et al. 2003) residues, while two groups show
that ED alone constructs are only capable of dephosphorylating phospho-tyrosine residues
(Rayapureddi et al. 2003; Tootle et al. 2003b). It is possible that the amino-terminus of EYA is
necessary for EYA to function as a dual specific phosphatase. Mutating residues known to be
important for HAD enzyme catalytic function, results in a severe reduction or complete loss of
EYA's phosphatase activity. In vivo analysis has shown that EYA's phosphatase activity is
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required for Drosophila eye development (Chapter 4) (Rayapureddi et al. 2003; Tootle et al.
2003b). Therefore, EYA possesses two functions, one as a transcriptional coactivator and one as
a protein phosphatase, both of which are required in vivo.
EYA is the first eukaryotic transcriptional activator shown to possess protein phosphatase
activity. The only two known substrates of EYA are itself (Chapter 4) (Tootle et al. 2003b), and
RNA polymerase II (Li et al. 2003). EYA dephosphorylates itself on tyrosine residues, while it
dephosphorylates S/T residues on RNA polymerase II. The functional relevance of these
dephosphorylation events are not known.
Analysis of EYA has yielded some insight into how tyrosine phosphorylation and
dephosphorylation may regulate EYA's activities. Tyrosine phosphorylation could influence one
or both of EYA's functions by affecting its protein-protein interactions, conformation,
subcellular localization, or stability. EYA phosphatase mutants, collectively called EYAHAD,
exhibit higher levels of tyrosine phosphorylation and have reduced function in vivo (Chapter 4)
(Tootle et al. 2003b). Some EYAHAD mutants exhibit decreased transcriptional activity with SO
in cell culture based transcription assays utilizing a reporter driven by a SO responsive segment
of the lozenge promoter (LMEE-reporter) (S. Silver, personal communication). Both of these
effects could solely be due to the loss of dephosphorylation of other substrates of EYA, but could
also be partially due to the loss of dephosphorylation of EYA. Thus tyrosine phosphorylation of
EYA may be a means of negatively regulating its activities. Both Drosophila EYA (Chapter 4)
(Tootle et al. 2003b) and Mouse EYA3 (MmEYA3) are tyrosine phosphorylated (Chapter 5)
when expressed in Drosophila cultured cells, suggesting that tyrosine phosphorylation is likely
to have functional and conserved consequences.
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Additionally EYA is positively regulated by MAPK-mediated serine/threonine
phosphorylation, and it is possible that EYA can dephosphorylated itself on both Y and S/T
residues. There are two MAPK phosphorylation sites (P-X-S/T-P) about 80 bp upstream of the
ED; these sites are strictly conserved in EYA1, the first site is strictly conserved and the second
site is only S/T-P in EYA2 and EYA4, while only the second site is S/T-P in EYA3 (Hsiao et al.
2001). Analysis of phosphorylation mutants by utilizing the ectopic eye induction assay
indicates that phosphorylation at these sites positively regulates EYA's activity in the Drosophila
eye, while analyses with multiple transcriptional reporter systems reveals that direct
phosphorylation of EYA results in increased transactivation (Silver et al., 2003; S. Silver
personal communication). It is possible that EYA negatively regulates its own activity by
altering its S/T phosphorylation levels.
EYA dephosphorylates S/T residues in the carboxy-terminal domain (CTD) repeats of
RNA polymerase II (Li et al. 2003). Phosphorylation of the CTD repeats of RNA polymerase II
is necessary for the transition from preinitiation of transcription to elongation (Dahmus 1996).
Dephosphorylation is thought to play a key role in the recycling of the polymerase, quickly
releasing it from the DNA when it has finished transcribing the gene and allowing it to rebind to
the promoter and transcribe the gene again (Majello and Napolitano 2001), a property important
for transcriptional activation. Therefore, one of EYA's functions as a coactivator may be to
dephosphorylate RNA polymerase II to allow recycling of the polymerase (Figure 1-6B).
It is possible that the only targets of EYA's phosphatase activity are itself and RNA
polymerase II, however most phosphatases exhibit a fairly broad range of substrates. As SO and
DAC family members are known to interact with EYA, they may also be targets of EYA's
protein phosphatase activity. Murine DACH1, a homolog of DAC, complexes with SIX1, a
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homolog of SO, and functions as both a transcription co-activator and co-repressor in
mammalian cultured cells. The switch from repressor to activator appears to be mediated by
EYA and requires its phosphatase activity (Li et al. 2003) (Figure 1-6C). This is the first
evidence that EYA's phosphatase activity has a direct role in regulating transcription, however,
the proteins dephosphorylated in this context are unknown.. Alternatively, utilizing the LMEE-
reporter discussed above, Drosophila DAC has been shown to synergize with the EYA-SO
transcription factor to further stimulate transcription, and this synergism is not dependent on
EYA's ability to act as a phosphatase (Figure 1-6D) (S. Silver, personal communication). These
different findings may be due to the nature of the reporters used or the cellular context of the
assays. Thus, just as the EYA-DAC interactions are likely to be context specific, so are the
effects of EYA's phosphatase activity. Additionally human SIX1 (HSIX1) is differentially S/T
phosphorylated throughout the cell cycle by casein kinase II (Ford et al. 2000). Similarly
Drosophila SO is known to be phosphorylated (E. Davies, personal communication). Therefore,
SO family members may also be targets of EYA's protein phosphatase activity.
How the two functions of EYA are utilized throughout development, and whether one
fimunction depends on or inhibits the other is not known. Evolutionarily it appears that EYA
originally possessed only phosphatase activity, as plant homologs are comprised of only the ED,
while planarian to human homologs have substantial amino-terminal extensions. EYA has
evolved to possess two functions as a transcriptional coactivator and as a nuclear protein
phosphatase known to be in close association with the DNA. The two known substrates of EYA,
itself and RNA polymerase II, are both intimately involved in regulating transcription, and their
respective activities are known to be regulated by phosphorylation. Indeed phosphorylation is
the most common means by which signaling events regulate transcription factor function (see
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below). Therefore it is very probable that other unknown substrates of EYA's protein
phosphatase activity are also involved in transcriptional regulation.
Two groups have independently found that EYA is specifically a protein tyrosine
phosphatase (Rayapureddi et al. 2003; Tootle et al. 2003b). Tyrosine phosphorylation of
transcription factors is a poorly studied area (see below). Therefore, it will be important to
determine the substrates of EYA's protein tyrosine phosphatase activity and how EYA's
transcription coactivator function is affected by tyrosine phosphorylation. These studies will
yield insight into the mechanisms and breadth of the use of tyrosine phosphorylation and
dephosphorylation as a means of regulating transcription.
D)BP1
DBP1, DNA-binding protein phosphatase 1 from tobacco, regulates the transcription of
pathogen-defense related genes, including CEVI1, and possesses phosphatase activity (Carrasco
et al. 2003). The amino-terminus of DBP1 has homology to the DNA binding motif of the
general transcription factor TFIIB. In vitro assays have shown that DBP1 has sequence specific
DNA binding activity, and antisense experiments reveal that DBP1 is needed for proper gene
expression of CEVI1 (Carrasco et al. 2003). In addition, the carboxy-terminus of DBP1 has
homology to PP2C phosphatases and has intrinsic Mg2+ dependent protein phosphatase activity
(Carrasco et al. 2003). The function of this phosphatase activity is not known. DBP1 is the first
DNA binding protein shown to possess protein phosphatase activity.
To date there are two transcriptional regulators, DBP1 and EYA, which possess intrinsic
protein phosphatase activity. Both are nuclear proteins that are highly associated with DNA,
making it very likely, as discussed above, that their respective phosphatase activities are
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involved in regulating transcription. This is not surprising, as phosphorylation appears to be the
most common mechanism by which signaling cascades regulate downstream transcription
factors. As the phosphatase activities of DBP1 and EYA have only recently been elucidated, it is
possible that many more transcriptional regulators also possess such activities.
Kinases as transcription factors
ERK5
The MAPK ERK5 or Big MAP Kinase 1 (BMK1) has an amino-terminal kinase domain
and a 400 amino acid carboxy-terminal domain that interacts with the transcription factor
myocyte enhancer factor 2 (MEF2). Interestingly, this carboxy-terminal domain also appears to
function as a transcriptional activation domain (TAD) (Figure 1-7A) (Kasler et al. 2000). For
example, the carboxy-terminal domain (664-789 a.a.) of ERK5 is rich in acidic amino acids and
can function as a TAD when fused to the GAIA-DNA binding domain (Figure 1-7B). Similarly
when the MEF2 DNA binding domain is fused to this region of ERKS, the resulting protein can
activate endogenous MEF2 target genes (Figure 1-7C). Intriguingly, ERK5 also directly
phosphorylates MEF2 at serine 387, resulting in enhancement of MEF-2-mediated
transcriptional activation (Figure 1-7D) (Kato et al. 1997). Therefore ERK5 is both a kinase and
a transcriptional coactivator, with both activities implicated in regulating MEF2 function.
Again there is evidence of how transcriptional activity is highly influenced by
phosphorylation. ERK5 is a S/T kinase that is also a transcriptional coactivator, and above I
have discussed two distinct transcriptional regulators that possess phosphatase activity. These
examples suggest it may be important to exert local control over post-translational modifications,
particularly phosphorylation, as a means of quickly regulating transcription. It is well
77
Figure 1-7
A ERK5
TAD 
B
D
Figure 1-7
ERK5 is both a kinase and a transcriptional coactivator. A. Diagram of the ERK5 protein,
illustrating that it possess both a kinase domain and a transcriptional activation domain (TAD).
B. Schematic showing that if the TAD of ERK5 is fused to the GAL4 DNA binding domain
DI)BD), the fusion protein can activate transcription. C. Schematic showing that if the TAD of
ERK5 is fused to the DNA binding domain of the transcription factor MEF2, the fusion protein
activates transcription from endogenous target promoters. Thus, this region of ERK5 is indeed
a TAD. D. Schematic illustrating how ERK5 enhances MEF2-mediated transcriptional
activation by directly phosphorylating MEF2 and by serving as a transcriptional coactivator.
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established that by having transcriptional regulators present but inactive due to a modification or
lack there of, activity shifts can be achieved quickly by altering these modifications in response
to specific signaling cascades. The rate of response to a signaling event may be further increased
by having the protein responsible for the modification also playing a role in mediating
the transcriptional response, thus requiring one less protein to be recruited (essentially
eliminating the middleman).
Transcription factors as acetyltransferases and parts of the ubiquitin pathway
p300
p300, a known acetyltransferase, is also involved in ubiquitin-mediated degradation
(Grossman et al. 2003). This is particularly interesting because both acetylation and
ubiquitination occur on lysine residues, and often modify the same lysines within a particular
protein. Intriguingly, p300 differentially regulates the transcription factor p53, a key mediator of
cell cycle arrest and apoptosis in response to DNA damage, by both acetylating and
ubiquitinating p53 on the same lysine residues (Figure 1-8). In the absence of DNA damage,
p300 facilitates p53 polyubiquitination, resulting in p53 being targeted to the proteasome for
degradation. In contrast, following DNA damage, p300 acetylates and coactivates the
transcription factor p53 (Grossman 2001). In addition p300 cooperates with the E1A
oncoprotein, a multifunctional protein originally identified in as Adenovirus 5 early region 1A,
to stabilize p53, preventing its degradation (Chiou and White 1997; Querido et al. 1997; Zhu et
al. 2001). Thus p300 plays dual roles in regulating the transcription factor p53 by both
acetylating p53 and contributing to its transcriptional activation, and by facilitating p53's
degradation when it is no longer needed.
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Figure 1-8
p300 mediates both the degradation of p53 and the activation of p53-mediated
transcription by its two enzymatic activities, as an acetyltransferase and an E4 enzyme.
A. Schematic illustrating how in the absence of DNA damage, MDM2, an ubiquitin
ligase, monoubiquitinates p53. p300 can then polyubiquitinate p53, resulting in p53
being targeted for degradation. B. Upon DNA damage, EIA and p300 stabilize the p53
protein, and p300() then acetylates p53, resulting in increased p53-mediated
transcriptional activation.
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Purified p300 and endogenous p300 have intrinsic ubiquitin ligase activity (Grossman et
al. 2003). See below for a review of the ubiquitin modification pathway. The amino-terminal
595 amino acids possess potent ubiquitin ligase activity, while amino acids 671-1196 have much
weaker activity (Grossman et al. 2003). The amino-terminus has no homology to known
ubiquitin ligases but does have a cysteine/histidine rich sequence resembling a HECT domain
(Grossman et al. 1998). HECT domain E3 ubiquitin ligases transfer ubiquitin from the E2
enzyme to their active site cysteine forming a thio-ester that then functions as the donor for the
amide bond formation with the substrate. The HECT-like domain of p300 has been shown to
interact with Mouse Double Minute 2 (MDM2), an ubiquitin ligase that mono- but not poly-
ubiquitinates p53 (Rodriguez et al. 2000; Lai et al. 2001), and this association has been
implicated in p53 stability (Grossman et al. 1998). Thus the cysteine/histidine rich region of
p300 may directly bind ubiquitin and transfer it directly to the substrate protein.
In the absence of DNA damage MDM2 monoubiquitinates p53 at numerous lysines and
p300 can act as an E4 enzyme, which recognizes and polyubiquitinates sites of
monoubiquitination, and polyubiquitinate p53 at these sites of monoubiquitination, resulting in
p53 degradation (Figure 1-8A) (Grossman et al. 2003). In response to cellular stresses, like
DNA damage, E1A directly interacts with p300 and inhibits p300 from polyubiquitinating p53
(Grossman et al. 2003), thereby stabilizing the protein. By an unknown mechanism p300 can
also acetylate and activate p53, possibly by an interaction between p53 and the E1A-p300
complex (Figure 1-8B).
p53 is acetylated and ubiquinated at the same lysine residues (Ito et al. 2002), and one
modification on a particular lysine prevents other modifications from occurring at this residue.
This allows strict regulation of the modified protein's activity, much like an on/off switch. In the
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case of p53, ubiquitination is the on switch for degradation and the off switch for transcriptional
activity, while acetylation is the on switch for transcriptional activation and the off switch for
degradation. Intriguingly, monoubiquitination of transcription factors, like MDM2-mediated
mnonoubiquitination for p53, has been associated with transcription activation (see below). This
suggests that MDM-2 monoubiquitination of p53 may play a role in p53-mediated transcriptional
activation in addition to its role in facilitating p53 degradation.
TAFIn250
TAF11250 is the largest subunit of the general transcription factor TFIID and possess a
wide range of functions, including acting as an acetyltransferase, a kinase, and an E1/E2 enzyme
in the ubiquitin pathway. I will first review the general role of TFIID in transcription, and then
discuss the three enzymatic functions of TAF11250.
TFIID is a complex of the TATA-binding protein (TBP) and ten TBP associated factors
(TAFs) (Struhl and Moqtaderi 1998). TFIID recognizes the promoters of all protein-coding
genes, either through the sequence specific binding of the TBP or by the interactions of its
various TAFs with downstream promoter elements called initiators, and subsequently recruits the
rest of the preinitiation complex to the promoters, including RNA polymerase II (Verrijzer and
Tjian 1996; Struhl and Moqtaderi 1998; Sterner and Berger 2000). The TBP of TFIID mediates
a basal level of transcription, while the TAFs are required for activation of transcription
(Verrijzer and Tjian 1996).
TAF11250 homologs from yeast (yTAF11 30), Drosophila (dTAF.1 230), and human all
possess intrinsic acetyltransferase activity (Mizzen et al. 1996). All three homologs exhibit
specificity and acetylate histones H3 and H4 (Mizzen et al. 1996). Amino acids 1-1140 of
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TAFI250 are important for acetyltransferase activity, with amino acids 885-1140 being critical
(Mizzen et al. 1996). TAF11250 proteins have no sequence homology to known
acetyltransferases and therefore define a new family of acetyltransferases. Like other
acetyltransferases, TAF11250 homologs from humans and Drosophila have bromodomains; but
these domains are dispensable for in vitro acetyltransferase activity (Mizzen et al. 1996).
TAF11250 acetyltransferase activity is negatively regulated by interactions with TAF1155,
another component of TFIID. This results in inhibition of TAF11250 dependent MHC class I
gene transcription (Gegonne et al. 2001). Therefore modulation of TAF11250's acetyltransferase
activity has direct affects on the transcriptional output of specific promoters.
A temperature sensitive mutation in the acetyltransferase domain of TAF11250 (hamster
cell line t13) arrests cells in GI. The mutant protein has reduced acetyltransferase ability and
exhibits decreased transcription of certain genes including GI cyclins, but can still interact with
TBP and other TAFs at the restrictive temperature (Dunphy et al. 2000). This indicates that
TAF11250 acetyltransferase activity is required for cell cycle progression and is involved in the
regulation of transcription of proliferative control genes, but is not required for the transcription
of all protein encoding genes (Figure 1-9A).
Other TAFIls are components of acetyltransferase complexes, SAGA (SPT-ADA-GCN5-
acetyltransferase) (Grant et al. 1998), and the P/CAF complexes (Struhl and Moqtaderi 1998), in
addition to the TFIID complex. Not all of the TAF1 s found in TFIID are in the other complexes,
in particular TAF 11250 and TAF11130 are not in the SAGA and P/CAF complexes. All three
complexes share some TAF11s, but they each have a different acetyltransferase enzyme and
different DNA binding proteins (Struhl and Moqtaderi 1998). This indicates that the different
acetyltransferase complexes are likely to target different promoters. These complexes all
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Figure 1-9
TAF11250 possesses three activities, acetyltransferase, kinase, and E1/E2 enzyme activity, which
differentially regulate transcriptional activation from distinct sets of promoters. A. Schematic
illustrating that TAF11250 is thought to mediate transcription via its acetyltransferase activity by
directly acetylating chromatic associated proteins, like histones, and resulting in an "open"
chromatic state. B. Schematic showing that TAF11250 kinase activity is important for the
phosphorylation of the RAP70 subunits of TFIIF, resulting in recruitment of RNA Polymerase II,
and thus transcriptional activation. C. Schematic illustrating that TAF11250 E1/E2
monoubiquitinating activity is important for Dorsal-mediated transcriptional activation. The
target of this ubiquitinating activity is unknown, but could include histones, general transcription
machinery, or even the transcription factor.
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promote acetyl-CoA dependent transcriptional activation from promoters occupied by
nucleosomes, suggesting such complexes function to regulate chromatin structure. It is
interesting that structurally the various TAF1s resemble histones, and thus the histone-like folds
of these TAF1s in the various acetyltransferase complexes may play important roles in
interacting with nucleosomes.
In addition to possessing acetyltransferase activity, TAF11250 has two kinase domains,
one at the amino-terminus (1-434 a.a.) and one at the carboxyl terminus (1423-1893 a.a.)
(Dikstein et al. 1996). Both domains can autophosphorylate TAF11250, and are required for
efficient serine phosphorylation of RAP74. RAP74 is the largest subunit of TFIIF, a tetramer of
two RAP30 and two RAP74 molecules (Dikstein et al. 1996). This phosphorylation is not a non-
specific activity of TAF11250, as it does not phosphorylate other general transcription factors or
common phosphoproteins. Phosphorylation of RAP74 by TAF11250 occurs in the context of the
TFIID complex (Dikstein et al. 1996), and thus is likely to play a role in mediating the formation
of the preinitiation complex. The RAP74 subunits interact directly with RNA polymerase II to
recruit it to the promoter, and remain associated with the polymerase during elongation
(Rossignol et al. 1999). Hyperphosphorylated TFIIF is associated with transcription activation
and therefore, phosphorylation of RAP74 may be one mechanism of regulating transcription
(Figure 1-9B).
Mutations in the amino-terminal kinase domain of TAF11250 result in inhibition of
autophosphorylation but do not block all kinase activity. These TAF1i250 mutants can still be
incorporated into TFIID complexes but have reduced ability to rescue a temperature sensitive
acetyltransferase TAF11250 mutant cell line (ts13), and exhibit decreased transcription from
cyclin A and cdc2 promoters (O'Brien and Tjian 1998). This indicates that both the
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acetyltransferase and kinase functions of TAF11250 are required for the regulation of some
promoters.
Gene profiling of acetyltransferase versus kinase TAF11250 mutants revealed that these
activities in general regulate nonoverlapping gene sets (O'Brien and Tjian 2000). Expression of
1.8% of the genes analyzed is disrupted by acetyltransferase mutations, while the expression of
6% of the genes is affected by mutations within the amino-terminal kinase domain. Only 1.3%
of the genes analyzed were affected by both mutations (O'Brien and Tjian 2000). Therefore,
both activities of TAF11250 are important for transcriptional regulation, and appear to be
differentially utilized depending on the promoter.
In addition to TAF 11250 functioning as both an acetyltransferase and a kinase, it is also
involved in ubiquitination (Pham and Sauer 2000; Hicke 2001). Drosophila embryo extracts
analyzed for enzymes that ubiquitinate histones identified dTAF1i250. dTAF11250 specifically
ubiquitinates histone H1 in the absence of an E1 enzyme, indicating that TAF11250 possesses E2
activity. This along with the fact that TAF11250 can conjugate with ubiquitin by a thiolester bond
indicates that TAF11250 possesses both E1 and E2 enzymatic activities (Pham and Sauer 2000;
Hicke 2001). In agreement with this, TAF11250 has sequence similarities to both E1 and E2
enzymes. In vitro ubiquitination assays also revealed that TAF11250 monoubiquitinates histone
Hi, and the catalytic domain is encoded within amino acids 768-1218.
TAF11250's El/E2 activity is required for activation of transcription from specific
promoters. For example, dTAF11250 mediates the activation of the maternal activator Dorsal,
which in turn activates the expression of genes necessary for mesodermal determination.
Mutations within the catalytic domain, V1072D and R1096P, inhibit TAF11250 El/E2 enzymatic
activity (Pham and Sauer 2000). In vivo these TAF11250 mutants inhibit mesodermal marker
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expression, indicating that dTAF11250's E1/E2 activity is necessary for Dorsal-dependent
transcriptional activation (Figure 1-9C) (Pham and Sauer 2000; Hicke 2001). TAF11250 is
unique in that it possesses both E1 and E2 enzymatic activities, and this combination enzyme
may be specific for monoubiquitination. As discussed in depth below, monoubiquitination of
transcription factors has been associated with transcriptional activation. It will be interesting to
see whether TAF11250 is generally responsible for monoubiquitinating transcription factors
regulated in this manner, or whether TAF11250's El/E2 enzyme displays specificity.
TAF11250 is a component of TFIID and is thus required for the transcription of all protein
coding genes. In addition, TAF11250 possesses three distinct enzymatic activities as a kinase, an
acetyltransferase, and an E1/E2 monoubiquitinating enzyme. None of these activities have been
shown to be required for the transcription of all protein-encoding genes, indicating that the
different activities are likely utilized to regulate transcription from different promoters. Some
mechanism(s) must exist to determine the specificity of each activity. TAF11250 is the best
studied example to date of how mediation of post-translational modifications are associated with
transcriptional regulation.
Concluding remarks
Through these examples of multifunctional enzymes it is clear that an increasing number
of proteins involved in transcriptional regulation are also likely to be involved in
mediating/regulating post-translational modifications. As post-translational modifications are
the main mechanisms by which signaling cascades regulate downstream transcription factors it is
not surprising that such multifunctional transcriptional regulators exist. It will be critical to the
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understanding of how transcription is regulated to elucidate and understand the exact roles of
such multifunctional proteins.
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Chapter 2
CRM1-mediated nuclear export and regulated activity of the Receptor Tyrosine Kinase
antagonist YAN require specific interactions with MAE.
Tina Tootle, Philina Lee, and Ilaria Rebay.
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Summary
ETS family transcription factors serve as downstream effectors of signal transduction
pathways, mediating cellular proliferation, differentiation, and when misregulated,
tumorigenesis. The transcriptional repressor YAN prevents inappropriate responses to Receptor
Tyrosine Kinase signaling by outcompeting POINTED for access to target gene promoters. We
demonstrate that the molecular mechanism underlying downregulation of YAN involves CRM1-
mediated nuclear export and define a novel role in this context for MAE, a cofactor previously
implicated in facilitating MAPK phosphorylation of YAN. In addition to promoting YAN
downregulation, MAE also participates in an inhibitory feedback loop that attenuates POINTED-
P2 activation. Thus we propose that MAE plays multiple independent roles in fine-tuning the
levels of POINTED and YAN activity in accordance with changing RTK signaling conditions.
Introduction
One pathway used reiteratively throughout development is the receptor tyrosine kinase
(RTK) signaling network (Tan and Kim, 1999). RTKs signal through the evolutionarily
conserved GTPase RAS and the mitogen activated protein kinase (MAPK) cascade (Marshall,
1994; Zipursky and Rubin, 1994). Among the best characterized downstream targets of activated
MAPK are the Drosophila ETS-domain transcription factors encoded by pointed (pnt) and yan
(O'Neill et al., 1994). Use of two separate transcriptional start sites within pnt produces two
distinct protein products, referred to as PNT-P1 and PNT-P2 (Klambt, 1993). Both function as
transcriptional activators, but whereas PNT-P1 activity is not regulated by MAPK, PNT-P2
requires phosphorylation by MAPK in response to RTK/RAS signaling for activity (O'Neill et
al., 1994). yan encodes a transcriptional repressor that competes with PNT for access to the
regulatory regions of target genes (Gabay et al., 1996). In response to RTK activation, MAPK-
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mediated phosphorylation abrogates YAN repressor activity (O'Neill et al., 1994), allowing PNT
to prevail in the competition for promoter access and turn on genes formerly repressed by YAN.
Thus the coordinate regulation of these two antagonistic transcription factors plays a key role in
determining specific differentiative and proliferative responses to RTK signaling.
Both YAN and PNT-P2 appear to be evolutionarily conserved, serving as critical
regulators of RTK signaling in other systems, including mammals (Hsu and Schulz, 2000). For
example, the human orthologs, TEL and ETS 1, respectively, are both oncoproteins (Hsu and
Schulz, 2000). Like YAN, TEL functions as a transcriptional repressor (Lopez et al., 1999) and
appears to be regulated by phosphorylation (Poirel et al., 1997). Translocations and deletions of
the tel locus are the most frequent chromosomal aberrations associated with leukemia, implying
an important function in proliferation control (reviewed in Rubnitz et al., 1999). The
transcriptional activator ETS 1 acts as a positive effector of RAS/MAPK signaling (Yang et al.,
1996) and plays a significant role in mediating the invasiveness and angiogenesis of a variety of
cancers (reviewed in Dittmer and Nordheim, 1998).
YAN is a general inhibitor of RTK-mediated signaling in Drosophila, functioning
downstream of and negatively regulating multiple RTK pathways in both neuronal and non-
neuronal cell types (Rebay and Rubin, 1995). Consistent with its role in mediating specific
developmental transitions, YAN expression is highly regulated (Lai and Rubin, 1992; Price and
Lai, 1999). In general, nuclear YAN expression is apparent in undifferentiated tissues, but
disappears abruptly as the cells begin to differentiate (Lai and Rubin, 1992; Price and Lai, 1999).
This pattern suggests that rapid degradation of YAN may alleviate the YAN-mediated block to
differentiation. Supporting such an hypothesis, sequence analysis reveals YAN is rich in PEST
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sequences, a motif characteristically found in proteins with short or dynamically regulated half-
lives (Lai and Rubin, 1992; Rechsteiner and Rogers, 1996).
Experiments both in vivo and in cultured cells have suggested that phosphorylation of
YAN by activated MAPK in response to RTK-initiated signaling may serve as the trigger for
dismantling the YAN-mediated block to differentiation. Mutating the phosphoacceptor residues
of the MAPK phosphorylation consensus sites in YAN produces a constitutively "activated"
allele, YAN CT, that cannot be down-regulated (Rebay and Rubin, 1995). For example, while
wild-type Yan is rapidly excluded from the nucleus in RAS/MAPK stimulated cultured cells,
YAN' CT remains nuclear. Further mutational analyses indicated that the first MAPK
phosphorylation consensus site, Serine 127, is necessary for redistribution of YAN from the
nucleus to the cytoplasm in response to pathway activation in cultured cells. These data have led
to the hypothesis that a primary consequence of MAPK-mediated phosphorylation might be
nuclear export of YAN (Rebay and Rubin, 1995); however the mechanism and potential in vivo
relevance have not been determined.
MAPK-mediated recognition and phosphorylation of YAN at Serinel27 is thought to be
facilitated by a protein called Modulator of the Activity of ETS (MAE) (Baker et al., 2001).
Mechanistically, MAE binds to YAN via a protein-protein interaction motif found at the N-
terminus of YAN and the C-terminus of MAE (Baker et al., 2001), referred to as the Pointed
Domain (PD) (Klambt, 1993). Interestingly, Baker et al. (2001) also suggest that MAE binds to
the PD of PNT-P2, and enhances PNT-P2's transcriptional activation, leading them to propose
that MAE promotes PNT-P2 phosphorylation by MAPK. Thus, they speculate that by promoting
phosphorylation events that simultaneously down-regulate YAN and upregulate PNT-P2, MAE
facilitates downstream responses to RTK signaling.
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While it is clear that MAPK phosphorylation initiates YAN downregulation, the ensuing events,
with respect to both YAN and PNT-P2, remain poorly understood. Here we show that nuclear
export, via CRMI, is an essential step in downregulating YAN both in cell culture and in vivo. In
this context, the PD of YAN plays a dual role in maintenance of nuclear localization in the
absence of signaling and regulation of nuclear export upon RAS/MAPK activation. By
manipulating the levels of mae expression in cells coexpressing specifically designed structural
variants of YAN, we demonstrate that MAE plays a critical role in mediating YAN's nuclear
export, independent of its role in promoting MAPK phosphorylation. Consistent with previous
reports (Baker et al., 2001), we find that overexpression of MAE decreases YAN's
transcriptional repressor activity. However, whereas PNT-P2's transcriptional activity was
proposed to be stimulated by MAE co-expression (Baker et al., 2001), we find that
overexpression of MAE inhibits PNT-P2's ability to activate transcription. Thus we propose that
MAE mediates downregulation of both YAN and PNT-P2. In the case of YAN, MAE facilitates
MAPK-mediated phosphorylation and subsequent nuclear export, while in the case of PNT-P2,
MAE could participate in a negative feedback loop that attenuates transcriptional activity.
Materials and Methods
Molecular biology
pUAST YAN NLS was made by ligating the annealed product of the two
oligonucleotides (5' ACCCCACCTAAGAAGAAGCGCAAGGTGGAGGACTCCCAG 3' and
5' GAGTCCTCC ACCTTGCGCTTCTTCTTAGGTGGGGTCTGG 3'), into the N-terminal
BstXI site of pUAST YAN. pUAST YANInt NLS was made by ligating the annealed product of the
two oligonucleotides (5'GATCTACCCCGCCAAAGAAGA AGCGCAAGGTGGAGGACG 3'
and 5'GATCCGTCCTCCACCTTGCGCTTCTTCTT TGGCGGGGTA 3') into the unique
110
internal BamHI site of pUAST YAN. The underlined residues were changed from A to C, and
from T to G to create pUAST YAN Mu tNLS. Transgenic lines were generated as previously
described (Rebay et al., 1993).
ANES ANESI,2 ANES3+PD -7 -8 8YAN E s , YAN Es l ', YAN ,N E 3 + and YANAN' have amino acids 1-17, 1-48, 48-
117, and 1-117 deleted, respectively. Unless otherwise noted, these and all other constructs were
expressed under the metallothionein promoter using the plasmid pRMHa-3.
YANMUt Ets was made using Stratagene's QuikChange Site-Directed Mutagenesis system
with oligonucleotlides 5' GGACTGGCAAAGTTGGGAGGCATCCAGGGGAA
CCATCTGTCC 3' and its reverse complement. The underlined nucleotides indicate the mutated
base pairs, which result in W438G and K443G.
Myc-MAE was generated by PCR amplifying mae out of a cDNA library using primers
5' CAAGTGGAATCGAGCTATACC 3' and 5' CTATGATAGCAGGGCCAT TGCTCGG 3'.
The product was N-terminally tagged with a Myc epitope, verified by sequencing, and shuttled
into both pRMHa3 and pUAST.
pUAST flag PNT-P2 was generated by adding an N-terminal FLAG epitope tag to the
full length PNT-P2 coding sequence.
The EBS-luciferase reporter was created by placing 6 tandem copies of an ETS binding
site (O'Neill et al., 1994) upstream of the luciferase gene.
Additional subcloning details available upon request.
Immunohistochem istry
Fixation and staining of S2 cells and embryos were performed as previously described
(Fehon et al., 1990). S2 cells stainings were performed using Anti-YAN MAb 8B12 at 1:250 or
anti-myc MAb 9E10 (a gift from R. Fehon) at 1:100, with CY3 conjugated goat anti-mouse
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secondary (1:10000) and DAPI (100 gg/ml at 1:5000). Staining of double-labeled embryos was
performed using 8B12 (1:750), CY3 goat anti-mouse (1:1000), rat anti-ELAV MAb 7E8A10
(1:500), and CY2 conjugated goat anti-rat (1:2000). All secondary antibodies were from Jackson
lmmunoResearch. Monoclonal supernatants were generated by growing hybridoma lines
obtained from the Developmental Studies Hybridoma Bank in DMEM supplemented with 10%
fetal bovine serum and 10-% NCTC-109 (Gibco).
Transcription Assays
Drosophila S2 cells were transfected using the calcium phosphate method as previously
described (Pascal and Tjian, 1991). pAc5.1-lacZ (Invitrogen) was used as a transfection control.
Transfected cells were harvested, washed with media, and lysed by rocking at 4°C for 20
minutes in 250 gl of lysis buffer (Tropix/Applied Biosystems). Quantitation of luciferase and 3-
galactosidase activity was done using a Luciferase Assay Kit (Tropix/Applied Biosystems) or
Galacto-Star Assay kit (Tropix/Applied Biosystems) in a tube luminometer (EG&G Berthold
AutoLumat LB953). Each transfection was performed in quadruplicate, tested in triplicate, and
the data points averaged. The average luciferase/[3-galactosidase signal for EBS-luciferase alone
was set to 1 and the experimental averages were normalized relative to this value. Data were
analyzed and graphed using Microsoft Excel.
RNAi
dsRNAs were generated using PCR primers containing T7 polymerase recognition
sequences (5' GAATTAATACGACTCACTAT 3') at the 5' ends followed by 21 nucleotides of
the target sequence, and were designed to span -500 bp of coding sequence (crnnl 5' T7-
ATGGCGACAATGTTGACA 3', 5' T7-TTGTTCATGCACAGGC 3'; mae 5'
CAAGTGGAATCGAGCTATACC 3', 5' CTATGATAGCAGGGCCATTGC 3'). The PCR
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products were extracted from 1% agarose gels and purified using Qiagen's QIAquick PCR
purification kit. dsRNAs were made according to the directions of Ambion's MEGAscript in
vitro transcription kit. RNAi experiments in S2 cells were performed by adding 10 gg of dsRNA
to the transfection mix. Cells were analyzed at 3-7 days post transfection, as determined for
maximum effect (3 days for RNAi of cnnrm] and 7 days for RNAi of mae). RNAi was injected
into embryos according to standard injection protocols (Rebay et al., 1993) at a concentration <5
[tM.
Histology
Adult flies were prepared for scanning electron microscopy by fixation in 1%
glutaraldehyde 1%o paraformaldehyde in 0.1 M sodium phosphate pH 7.2 for 2 hours. The fixed
tissue was dehydrated through an ethanol series. Samples were Critical Point Dried, sputter
coated, and pictures taken on a scanning electron microscope (JEOL 5600LV). Fixation and
tangential sections of adult eyes was performed as previously described (Tomlinson et al., 1987).
Co-immunoprecipitation
Transfected cells were harvested, and lysed by rocking at 4°C for 20 minutes in 1 ml of
lysis buffer (100 rnM NaCl; 50 mM Tris, pH7.5; 2 mM EDTA; 2 mM EGTA; 1% NP-40 + one
Complete, Mini protease inhibitor cocktail tablet(Roche)/10 ml). Clarified lysates were subjected
to immunoprecipitation (anti-myc 1:50 for 3 hours at 4°C), followed by the addition of 20 tl of
Protein-A Sepharose beads (Zymed) (1.5 hours at 4°C). Beads were washed twice with lysis
buffer and twice with PBS. The immunoprecipitates were boiled in 40 pl of 2x SDS buffer, and
western blotting was carried out as previously described (O'Neill et al., 1994) (anti-myc 1:100,
anti-YAN 1:500, anti-flag 1:50000).
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Results
CRM1 mediates YAN nuclear export
Although redistribution of YAN from the nucleus (Figure 2-1A) to the cytoplasm (Figure
2-1B) upon RAS/MAPK activation in S2 cultured cells is suggestive of nuclear export, it is
formally possible this shift results from degradation of YAN in the nucleus, coupled with a
failure of newly synthesized and phosphorylated YAN to enter the nucleus. To determine if the
cytoplasmic accumulation of YAN in RASv 2 stimulated S2 cultured cells is a consequence of
nuclear export, we asked whether blocking the nuclear export machinery would result in nuclear
retention of YAN. YAN, predicted to be 78 kDa, is too large to diffuse through the nuclear pore,
and thus its export must occur by facilitated transport. CRM1, a common exportin, mediates
translocation of nuclear export sequence (NES) containing proteins from the nucleus (Fornerod
et al., 1997). We found that in RASV12 stimulated S2 cultured cells, YAN was retained in the
nucleus in the presence of Leptomycin B (LMB) (data not shown), a drug that specifically binds
and inhibits CRM1 (Wolff et al., 1997), or dsRNA interference (RNAi) to knock down crml
expression (Figure 2-1C). These data indicate that the cytoplasmic accumulation of YAN
induced by RAS/MAPK activation is the result of CRM1-dependent nuclear export.
Nuclear export is necessary for downregulation of YAN in vivo
Because cytoplasmic accumulation of YAN has never been detected in developing
Drosophila tissues (I. Rebay, unpublished; Lai and Rubin, 1992), it was possible that the nuclear
export demonstrated in S2 cultured cells (Figure 2-lA-C) did not reflect the actual
downregulation mechanism used in vivo. To address this, the SV40 large T antigen nuclear
localization signal (NLS) (Kalderon et al., 1984) was inserted into YAN. Insertions were made
either near the amino terminus (YAN NLS) or in the middle of the protein (YANI ntNLs and
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Figure 2-1
Nuclear export of YAN is mediated by CRM1 and blocked by insertion of a NLS into
YAN. (A-C, E-L) S2 cultured cells transfected with various YAN constructs and stained with
anti-YAN. (A'-C', E'-L') DAPI staining of the same cells. (D) Schematic of YAN showing
predicted domains and sites of SV40 Large T-antigen NLS insertions. For each experiment (A-C,
E-L), the percentage of transfected cells exhibiting nuclear localization (A, C, E-K) or
exclusively cytoplasmic localization (B, L) is indicated. n refers to the number of cells scored in
each experiment. (A-C') YANW; (E-F') YANInt NLS; (G-H') YAN2X NLS; (I-J) YANN' NLS; (K-L')
Mut NLS V12YANM u t NL s. (A, E, G, I, K) YAN localization in the absence of RASv l2. (B, F, H, J, L) YAN
V12 V12localization in the presence of RASv . (C) YAN localization in the presence of RAS T and
RNAi of crnn]. (C) YAN localization is restricted to the nucleus in the presence of RASV 2 and
RNAi of crml. (F, H) Internal NLS insertions completely inhibit nuclear export of YAN in the
presence of RAS' 12 , while the N-terminal insertion only partially prevents export (J). (L)
Insertion of a nonfunctional NLS into YAN has no effect on export.
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YAN2 NS) (Figure 2-1D). As a control, a mutated and hence non-functional version of the NLS
(Kalderon et al., 1984) was inserted into the middle of the protein (YANMUt NLS). These
constructs were placed under the control of the UAS promoter, which allows expression both in
cell culture and in vivo when combined with an appropriate GAL4 driver (Brand and Perrimon,
1993).
We first demonstrated that the NLS insertions were capable of rendering YAN refractory
to nuclear export in response to RAS/MAPK signaling in transiently transfected S2 cultured
V12
cells. In the presence of RASv , the internal NLS insertions effectively overcame the export
signals and completely restricted YAN to the nucleus (Figure 2-1E-H). YAN NLS appears less
potent, presumably due to insertion in a less accessible region of the protein, and only partially
restricted YAN to the nucleus (Figure 2-1I,J). The control experiment, in which YANMUt NLS
behaved indistinguishably from wild-type YAN, localizing to the nucleus in unstimulated cells
(Figure 2-1K) and becoming cytoplasmic in RASV12 stimulated cells (Figure 2-1L), indicated that
the insertion alone does not disrupt regulation of YAN localization. Given the reduced efficiency
of the YANN' NLS insertion relative to that of YANIn t NLS and YAN2 x NS, only the internal
insertions were used for in vivo analyses.
Having demonstrated that insertion of a NLS tag is sufficient to prevent nuclear export,
transgenic flies expressing these constructs were generated and used to examine the role of
nuclear export of YAN in vivo. For these experiments ELAV GAL4 was used to drive
expression in the central nervous system (CNS), a tissue whose differentiation requires precisely
timed downregulation of YAN (Rebay and Rubin, 1995). We reasoned that if nuclear export is
necessary for downregulation of YAN, restricting YAN to the nucleus should prevent this and
result in a phenotype resembling YANACT. Specifically, nuclear YAN expression should beresult in a phenotype rese bling  . ecificall , clear  e ressi  s l  be
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detected in the region of the developing brain and ventral nerve cord of stage 11 embryos (Figure
2-2A,A') and CNS development should be inhibited as visualized by reduced expression of
neuronal markers (Figure 2-2A") (Rebay and Rubin, 1995). Alternatively, if nuclear export is not
required, then the NLS tagged YAN should be down-regulated as effectively as overexpressed
wild type YAN, resulting in a lack of YAN staining in the presumptive ventral nerve cord and
correspondingly normal CNS development (Figure 2-2B,B',B").
Supporting the first model, expression of either YANt NLS (Figure 2-2C,C',C") or
YAN2x NLS (Figure 2-2D,D',D") resulted in a YANACT phenotype (Figure 2-2A,A',A").
Analogous results were obtained in the eye (data not shown), where downregulation of YAN is
necessary for photoreceptor differentiation (Lai and Rubin, 1992), indicating an essential role for
nuclear export in downregulating YAN in multiple cell types in vivo. The control construct,
YANM ut NLS , exhibited wild-type YAN regulation (Figure 2-2E,E') and neuronal differentiation
(Figure 2-2E"). This NLS-mediated restriction of YAN to the nucleus, and subsequent inhibition
of downregulation and differentiation, strongly suggests nuclear export plays a central role in
downregulation of YAN in vivo.
The PD is necessary for regulating the subcellular localization of YAN
Having demonstrated a requirement for nuclear export in YAN downregulation in vivo,
we sought to determine which domains of YAN are involved. Analysis of the YAN protein
sequence (Lai and Rubin 1992) reveals three N-terminal-leucine-rich putative nuclear export
sequences (NES) (Wen et al., 1995) that resemble canonical CRM1 binding sites (Fornerod et
al., 1997) (Figure 2-1D). Two of the putative NESs reside within the Pointed Domain (PD),
suggesting this motif could be involved in regulating export.
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Figure 2-2
Figure 2-2
NLS insertions restrict YAN to the nucleus in vivo. (A-E") Confocal images of germband
extended Drosophila embryos double labeled with anti-YAN (A-E, A'-E') and anti-ELAV (A"-
E"). (A'-E') Higher magnification views of regions boxed in A-E with normal or failed YAN
downregulation highlighted by bracket. ELAV GAL4 was used to drive expression of (A, A',
A") UAS YANACT; (B, B', B") UAS YANWT; (C, C', C") UAS YANInt NLS; (D, D', D") UAS
YAN2x It NLS; (E E', E") UAS YANMut NLS. YANWT is down-regulated normally in the ventral
nerve cord (B, B'), allowing neuronal differentiation to proceed (B"). Just like YANACT (A, A',
A"), insertion of an NLS restricts YAN to the nucleus (C, C' and D, D'), thereby blocking CNS
development(C", D").
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A series of deletion constructs was made and assayed for nuclear export competence in
S2 cultured cells. The deletion of the first NES (YANAN ES l) or the first and second NES
(YAN E s l '2) had no effect on regulated YAN localization (Figure 2-3A,B and D, E respectively,
as compared to Figure 2-1A,B). Deletion of the third NES and the majority of the PD
(YANANES3+PD) resulted in partial export in the absence of signaling and a slight increase in
export upon RAS stimulation (Figure 2-3G,J and H,K). However, strictly cytoplasmic
localization was never seen with YANANES3+PD. Export of these constructs appeared to be
regulated in the same manner as wild-type YAN, as inhibition of CRM1 resulted in the deletions
being restricted to the nucleus (Figure 2-3C,F,I). Finally, the deletion of the whole amino
terminus (YAN AN), including all three NESs and the PD, localized to the nucleus and remained
nuclear in the presence of RASvl2 (Figure 2-3L,M). These results suggest that while individually
the NESs may be redundant for nuclear export, together the NESs mediate export. The data also
implicate the PD as necessary for regulated subcellular localization of YAN.
Because phosphorylation by MAPK has been shown to be a prerequisite for redistribution
of YAN (Rebay and Rubin, 1995), it was important to rule out the possibility that the
mislocalization of YAN NES 3+ PD and YAN N ' reflected an inability of the proteins to be
phosphorylated, rather than a defect in export. To test this, we used the previously published
observation that phosphorylation of YAN in response to RAS/MAPK signaling abrogates YAN's
ability to repress PNT-P1 mediated activation of an ETS reporter construct (O'Neill et al., 1995).
ACTIf YAN cannot be phosphorylated, as was shown for YANa c t , then transcriptional repression
continues unabated even in the presence of RAS stimulation.
Therefore, to verify that YANANE S 3+PD and YANAN' are responsive to RAS/MAPK
signaling, transcriptional assays were performed. Both YANaNES3+PD, which is partially exported
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Figure 2-3
CRM1-mediated nuclear export of YAN requires both the NESs and the PD. (A-M) S2
cultured cells transfected with various YAN deletion constructs and stained with anti-YAN. (A'-
M') I)API staining of the same cells. For each experiment (A-M), the percentage of transfected
cells exhibiting nuclear localization (A, C, D, F, G-I, L, M), both nuclear and cytoplasmic
localization (J, K) or exclusively cytoplasmic localization (B, E) is indicated. n refers to the
number of cells scored in each experiment. (A-B, D-E) Deletion of the first or first and second
NES has no effect on export. (G-H, J-K) Deletion of the third NES and majority of the PD results
in inappropriate export in the absence of signaling, and impairs export in the presence of RASVl2.
(L-M) Deletion of the whole N-terminus completely inhibits export. (C, F, I) RNAi-mediated
V12knock-down of crmnl restricts YAN to the nucleus in the presence of RAS 2. (O) Transcription
assays with YAN A ' and YAN N 3+PD show that both deletions repress transcription and are
responsive to RAS V12.
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in the absence of signaling, and YANAN, which is completely restricted to the nucleus, were
capable of repressing transcription, but not to the extent of wild-type YAN (Figure 2-30). This
repression could be relieved by RASv 2. The significant, albeit reduced, transcriptional
repression exhibited by these constructs argues that the N-terminal deletions have not
compromised the structure or function of the remainder of the protein. It also suggests that the
PD may play a role in mediating transcriptional repression. Retention of normal RAS/MAPK
responsiveness indicates that both proteins are likely to be phosphorylated and that their nuclear
restriction reflects a specific failure in export. Thus phosphorylation of YAN by MAPK,
although it abrogates transcriptional repression, is not sufficient to induce nuclear export; rather,
nuclear export of YAN requires a functional N-terminus, presumably to mediate dynamic
interactions with CRM1 and possibly other cofactors in response to RAS/MAPK stimulation.
MAE is necessary, for YAN downregulation in vivo
We have shown that loss of the PD and NES motifs results in inappropriate YAN
localization. PDs are involved in protein-protein interactions (Chakrabarti and Nucifora,
1999;Carrere et al., 1998; Baker et al., 2001). MAE, a PD family member, has been shown in
vitro to bind YAN via a PD-PD interaction, leading to phosphorylation of YAN at Serine127
(Baker et al., 2001), the phosphorylation site necessary for redistribution of YAN in S2 cultured
cells (Rebay and Rubin, 1995). If promoting YAN downregulation were its primary function,
MAE would be predicted to play a positive role in the RTK signaling cascade, although
curiously mae mutations have not been isolated in RTK pathway genetic interaction screens (for
example, Dickson et al., 1996; Karim et al., 1996; Rebay et al., 2000; Simon et al., 1991).
To confirm that MAE contributes to RTK signaling in vivo, we looked first for genetic
interactions with known pathway components. Transgenic flies expressing RASV1 2 under the
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control of the Sevenless promoter (Sev-RASVl2 ) exhibit rough adult eyes (Karim et al., 1996)
(Figure 2-4B, compared to Figure 2-4A). Heterozygosity for mae, with either a P-element
insertion ((2)k06602) or a deficiency uncovering the locus (Df(2R)PC4), dominantly suppressed
the Sev-RASv l2 rough eye phenotype (Figures 2-4C,D), consistent with MAE's proposed
function as a positive component of the pathway. Quantitation of this suppression by counting
the number of R7 photoreceptors per ommatidium in tangential adult eye sections confirmed the
interaction. Relative to the wild-type control which has 1.0 R7/ommatidium (Figure 2-4E), Sev-
RAS V12 exhibits 3.0 R7/ommatidium (Figure 2-4F), while Sev-RASVl 2/l(2)kO6602 and Sev-
RASVl 2 /Df(2R)PC4 exhibit 2.0 R7/ommatidium and 1.6 R7/ommatidium respectively (Figure 2-
4G,H). Further supporting a positive role in the pathway, a reduction in dose of mae mildly
enhanced the Sev-YAN ACT rough eye phenotype (data not shown). The ability of mae to
suppress Sev-RASvl2 and enhance Sev-YANACT suggests that loss of mae function decreases
signaling through the pathway and that MAE plays a positive role in RTK signaling in vivo.
We then asked whether the reduced RTK signaling associated with loss of mae function
might result from improper YAN localization and downregulation. Initially we addressed this
question in S2 cultured cells where MAE has been shown to be endogenously expressed (Baker
et al., 2001). RNAi of mae resulted in restriction of YAN to the nucleus in the presence of
RAS12 (Table 2-1), consistent with the model whereby MAE facilitates MAPK-mediated
phosphorylation of YAN as a prerequisite for nuclear export. To assess the effect of mae loss of
function in Drosophila we examined YAN localization in embryos homozygous for either
1(2)k06602 (Figure 2-4I,I'), Df(2R)PC4 (data not shown), or transheterozygotes (data not
shown). YAN is not down-regulated in mae mutant embryos, exhibiting nuclear expression in
the brain and ventral nerve cord (Figure 2-4I,I' as compared to Figure 2-4J,J'). Consistent with
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Figure 2-4
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Figure 2-4
MAE acts as a positive component of the RTK pathway and loss of mae function inhibits
the downregulation of YAN. (A-D) Scanning electron micrographs of adult Drosophila eyes
showing that loss of mae dominantly suppresses the rough eye phenotype of Sev-RASV12. (E-G)
Tangential sections of adult Drosophila eyes. The average number of R7 photoreceptors per
ommatidium is indicated below, with n referring to the total number of ommatidia scored. (A, E)
Wild-type; (B, F) Sev-RASVl2/+; (C, G) Sev-RASVl2/1l(2)kO6602; (D, H) Sev-
RASVl 2 /Df(2R)PC4. Confocal images of germband extended embryos double labeled with anti-
YAN (I, J, with high magnification of boxed region shown in I', J') and anti-ELAV (I",J"). (I, I',
I") show that in mae mutants, YAN fails to be downregulated in the CNS (I', bracketed region)
and ELAV expression is inhibited (I"). (I, I', I") (2)kO6602/l(2)k06602; (J, J',J") wild-type.
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Trable 2-1: MAE is necessary for nuclear export of YAN
YAN Localization n= Nuc. Nuc. Cyto.
+Cyto.
YAN 347 88.2% 7.2% 4.6%
YAN + RASVI2 318 2.8% 3.5% 93.7%
YAN + RASv12 + RNAi crml 305 96.1% 3.9% 0%
YAN + RASv12 + RNAi mae 340 52.6% 26.2% 21.2%
YAN mut Ets 343 0.3% 4.4% 95.3%
YANMut Ets + RNAi crml 323 74.5% 19.5% 6.2%
YAN utEt s+ RNAi mae 324 50.9% 21.6% 27.5%
YAN localization in S2 cultured cells is indicated as the percentage of transfected
cells exhibiting nuclear (Nuc.) localization, both nuclear and cytoplasmic
(Nuc.+Cyto.) localization, or exclusively cytoplasmic (Cyto.) localization. n refers
to the number of cells scored in each experiment.
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the presence of aberrant YAN expression in the CNS, neuronal differentiation was inhibited in
mae mutants (Figure 2-4I" compared to J"). RNAi of mae performed in embryos produced
identical phenotypes (data not shown). We therefore conclude that mae function is necessary to
down-regulate YAN in vivo.
MAE is required for nuclear export of YAN independent of its role in facilitating MAPK
phosphorylation
Previous work has shown that MAPK mediated phosphorylation of YAN is necessary for
nuclear export, with Serinel127 serving as the key phosphorylation site (Rebay, 1995). MAE is
thought to be necessary for phosphorylation of YAN at this site (Baker et al., 2001), and our
results suggest that MAE is also required for nuclear export. We therefore wanted to determine
whether MAE's role in export was simply a secondary consequence of it being necessary for
phosphorylation, or whether it reflected an independent requirement.
To address this, we needed to establish an experimental context in which nuclear export
of YAN is uncoupled from the RAS/MAPK signal that normally triggers it. We reasoned that
localization of YAN to the DNA was likely to be necessary for proper regulation of subcellular
localization, perhaps by masking the N-terminal NES sequences from recognition by CRM1.
Therefore, we introduced two point mutations into the ETS domain of YAN (W439G and
K443G, YANMUt ETS) that have been shown previously to be important for DNA binding but not
for nuclear localization (Kodandapani et al., 1996). YANMUt Ets, which is no longer able to bind
DNA, might be accessible to CRM1, even in the absence of RAS/MAPK signaling, and might
therefore be constitutively exported, giving us a situation in which export was uncoupled from
signaling.
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We found that even in the absence of RAS v l2 activation, YAN mut ETS localized to the
cytoplasm in S2 cultured cells, indicating that YAN must be bound to DNA to maintain its
nuclear localization (Table 2-1). Furthermore, inhibition of CRM1 mediated export resulted in
localization of YANM ut ETs to the nucleus (Table 2-1), suggesting YANM utETs initially localized
properly to the nucleus but due to its inability to bind DNA was promptly exported. Thus, under
conditions in which YAN is not phosphorylated by MAPK, CRM1-mediated nuclear export
regulates localization of YANMUt ETS. Colocalization and coimmunoprecipitation experiments
confirmed that the point mutations in YANM Ut ETS do not compromise its ability to bind MAE
(data not shown).
We exploited these findings to ask whether MAE plays a role in nuclear export separate
from that proposed by Baker et al. (2001) in facilitating phosphorylation. We found that RNAi of
mae restricted YAN u Ets to the nucleus (Table 2-1). This suggests that MAE has a second
function with respect to CRM1-mediated nuclear export of YAN, independent of its earlier role
ill promoting YAN phosphorylation in response to RAS/MAPK signaling.
RAS/MAPK signaling regulates MAE localization by modulating interactions with its binding
partners YAN and PNT-P2
Our results indicate that MAE plays a significant role in the downregulation of YAN,
both in cell culture and in vivo. To investigate the function(s) and regulation of MAE in more
detail we first asked whether the RAS/MAPK pathway might directly control the subcellular
localization of MAE. To address this question, a MYC-epitope tagged MAE was generated and
expressed in S2 cultured cells. We found that MAE was ubiquitously expressed throughout the
cell in both the absence and presence of RASv l2 (Figure 2-5C,D). Furthermore, inhibition of
CRM1-mediated nuclear export had no effect on MAE subcellular localization (Figure 2-5E,F),
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consistent with its predicted ability to diffuse freely through the nuclear pore based on its small
(-19 KDa) size and lack of a recognizable NES. Therefore, MAE's localization does not appear
to be influenced directly by RAS/MAPK signaling, nor is it dependent upon CRMl-mediated
export.
These results led us to hypothesize that any dynamic RAS/MAPK-mediated regulation of
MAE was likely to be mediated through specific interactions with its binding partners, YAN and
PNT-P2. Therefore, we looked for RASv2-induced changes in MAE localization in cells
cotransfected with YAN and PNT-P2. Cotransfection of YAN with MAE alters MAE
distribution. In the absence of RASVl2 , MAE was predominantly nuclear (Figure 2-5G) due to
being bound to YAN (Figure 2-5A, lane 2) and then became both nuclear and cytoplasmic in the
presence of RAS 1 2 (Figure 2-5H). This suggests that MAPK phosphorylation of YAN may
result in destabilization of the YAN-MAE complex, allowing MAE to reassume uniform
distribution. Coimmunoprecipitation experiments supported this interpretation, as the amount of
YAN bound to MAE appeared to be significantly reduced in RASv 2 stimulated cells (Figure 2-
5A, lane 4 as compared to lane 2; note that the total amount of YAN present is comparable +/-
RASV 2 , lanes 1 and 3).
We speculated that destabilization of the YAN-MAE complex upon RAS/MAPK
activation might require intervention from an additional YAN binding partner, potentially
CRM1. To address this possibility, we examined the effects of inhibiting CRM1-mediated export
in RASv l 2 stimulated cells expressing YAN and MAE. Under these conditions, MAE remains
nuclear, suggesting that interactions with CRM1 or some other associated factor, is needed to
dissociate MAE firom YAN (Figure 2-50). These results indicate that MAE localization is
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Figure 2-5
MAE localization in S2 cells depends on its binding partners' distribution. (A-C) Immuno-blots
of myc-IPs visualized with anti-Myc (MAE), anti-YAN, and anti-flag (PNT-P2). MAE
complexes with YAN in the absence of RAS/MAPK signaling (A) and with PNT in the both the
absence and presence of signaling (B). Lanes are from the same gel and immunoblot, but have
been rearranged. Lanes 1, 3, 5 are non-IPed lysates; Lanes 2, 4, 6 are the corresponding IPs.
Specificity of the anti-Myc IP is demonstrated in Lane 6 of A and B, where in the absence of
MAE, YAN or PNT-P2 are not precipitated. (C-O) Anti-MYC staining of S2 cells transfected
with MYC-mae. (C'-O') DAPI staining of the same cells. (C, E, G, I, K, M) Absence of
v2 v12 - h ecnaeoRAS" . (D, F, H. J, L, N, O) Presence of RAS l . For each experiment (C-O), the percentage of
transfected cells exhibiting nuclear localization (G, K-O), or both nuclear and cytoplasmic
localization (C-F, H-J) is indicated. n refers to the number of cells scored in each experiment. (C,
D) MAE; (E, F) MAE+RNAi crml; (G, H) MAE+YAN; (I, J) MAE+YAN '; (K, L)
MAE+YANAC ; (M, N) MAE +PNT-P2; () MAE+YAN+RNAi crml. MAE is ubiquitously
expressed in S2 cells (C,D), except when YAN or PNT-P2 is cotransfected. When MAE is
cotransfected with wild-type YAN, MAE is nuclear in the absence of signaling (G) and becomes
nuclear and cytoplasmic in the presence of RASVl2 (H). CRM1 does not mediate the export of
MAE (E, F). However, when YAN is cotransfected with MAE and CRM1 mediated export is
inhibited by RNAi, MAE remains nuclear (O). MAE interacts with YAN via the PD, as MAE is
ubiquitously expressed when YANaN is coexpressed (I, J). Cotransfection of MAE with
YANA CT restricts MAE to the nucleus in the absence and presence of RAS V 12 (K, L). Similarly,
PNT-P2 restricts MAE to the nucleus (M, N).
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dependent on a dynamic balance between its own expression level, the expression level of YAN,
the presence of additional YAN binding partners, and RAS/MAPK signaling.
To characterize further the interaction between YAN and MAE we analyzed MAE
localization when cotransfected with several different mutants of YAN. It has been shown in
vitro that MAE interacts with YAN via a PD-PD interaction (Baker et al., 2001). To confirm this
we examined MAE localization in the presence of YANAN ' and found that MAE was
ubiquitously expressed throughout the cell (Figure 2-5I,J). Therefore, restriction of MAE to the
nucleus by YAN requires the PD. We also looked at MAE localization in YANACT expressing
cells. YANACT cannot be phosphorylated by MAPK and therefore remains restricted to the
V12 ACT
nucleus in the presence of RAS . Cotransfection of YANA c restricted MAE to the nucleus in
the absence and presence of RASv2 (Figure 2-5K,L), suggesting phosphorylation of YAN is
necessary for redistribution of MAE.
Because YAN appears to play a significant role in regulating MAE localization, we next
asked whether PNT-P2, the other known binding partner of MAE (Baker et al., 2001), might also
be involved. Cotransfection of PNT-P2 and MAE resulted in restriction of MAE to the nucleus
and formation of a MAE-PNT-P2 complex that can be co-immunoprecipitated in the absence and
presence of RASv 12 (Figures 2-5M,N and 2-5B, lanes 2,4). Together these results suggest that
MAE localization is not subject to direct regulation by CRM1 and RAS/MAPK signaling, but
rather is determined by the presence or absence of nuclear binding partners YAN and PNT-P2 in
accord with changing signaling conditions.
MAE inhibits both YAN's ability to repress and PNT-P2's ability to activate transcription
Baker at al. (2001) have proposed that overexpression of MAE inhibits YAN's ability to
repress transcription and stimulates PNT-P2's ability to activate transcription. Because their work
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placed these Drosophila proteins in a potentially physiologically inappropriate mammalian
cultured cell environment, we felt it was important to test MAE's function in the Drosophila
system used in our assays. With respect to regulation of YAN mediated repression, our results
concur with those of Baker et al. (2001). In Drosophila S2 cells, overexpression of MAE
inhibited YAN mediated transcriptional repression, and slightly enhanced the RAS V12 mediated
removal of transcriptional repression (Figure 2-6A).
However, our results disagree with Baker et al.'s (2001) conclusion that MAE stimulates PNT-
P2's ability to activate transcription. We found that overexpression of MAE completely inhibited
PNT-P2 mediated activation of transcription (Figure 2-6B). Therefore, MAE could have a role in
downregulating, rather than stimulating, PNT-P2's ability to activate transcription.
Discussion
Precisely modulated competition between the two ETS-domain transcription factors
POINTED and YAN plays a critical role in determining specific differentiative and proliferative
responses to RTK signaling. Here we demonstrate that CRM1-mediated nuclear export of YAN
is an essential step in its downregulation, and that this process requires a functional interaction
between YAN and MAE. Our results suggest a second unexpected role for MAE in
downregulating PNT-P2 to prevent uncontrolled signaling in response to RTK activation. Thus
we propose that MAE participates at multiple independent steps in the cellular mechanisms that
fine-tune the levels of POINTED and YAN activity in accordance with changing RTK signaling
conditions.
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Figure 2-6
MAE inhibits the ability of both YAN and PNT-P2 to regulate transcription. (A)
Transcriptional repression assays with YAN. (B) Transcriptional activation assays
with PNT-P2. Overexpression of MAE inhibits YAN mediated transcriptional
repression (A) and PNT-P2 mediated activation (B).
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Regulation of YAN localization in the absence of RAS/MAPK activation: achieving a balance
between nuclear retention and nuclear export
In unstimulated or undifferentiated cells, YAN localizes to the nucleus (Lai and Rubin,
1992; Rebay and Rubin, 1995). For both YAN and its mammalian orthologue TEL, the DNA
binding domain serves as a nuclear localization sequence (NLS) (I. Rebay, unpublished; Poirel et
al., 1997). We have shown that upon RTK stimulation, YAN is actively exported from the
nucleus via CRM1 recognition of its N-terminal NES motif. The presence of both NLS and NES
motifs within YAN raises the question of how each domain is either recognized or masked under
different signaling conditions.
Our results lead us to propose that proper YAN subcellular localization involves dynamic
regulation of its DNA binding affinity via modulation of protein-protein interactions in response
to changing RTK signaling levels. Consistent with this model, we find that nuclear localization
requires that YAN be bound to the DNA, as a mutation that abolishes DNA binding
(Kodandapani et al., 1996), YANMut ETS, results in CRM1-dependent cytoplasmic accumulation
of YAN. The PD, an N-terminal protein-protein interaction motif, also plays a pivotal role in
determining the subcellular localization of YAN, as loss of the PD (YANANES3+PD) results in
partial CRM1-mediated export in the absence of signaling. In addition, YAN ANE S3 +PD exhibits a
30% decrease in repression activity relative to wild type YAN, suggesting a weaker or less
productive interaction with DNA. Together these data suggest that PD-mediated protein-protein
interactions may be crucial in facilitating productive DNA binding and/or masking inappropriate
CRM1 recognition of the NES's.
Our finding that PD-mediated interactions are crucial for YAN's transcriptional
repression ability agrees with similar experiments with TEL (Lopez et al., 1999), but disagrees
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with the results of Baker et al. (2001) who find that compromised PD function has no significant
effect on YAN's transcriptional repression. Presumably this discrepancy reflects the use of the
mammalian Cos7 cell line to study YAN (Baker et al., 2001), as opposed to the more
physiologically relevant Drosophila S2 cell line used in our experiments.
One explanation for how YAN's PD might be involved in DNA binding affinity,
transcriptional repression, and maintenance of nuclear localization comes from structural studies
of TEL's PD. This work suggests that DNA binding and transcriptional repression may be
mediated by a PD-PD homo-oligomeric complex of TEL that wraps the target DNA around itself
(Kim et al., 2001). Because the residues necessary for TEL oligomerization are conserved in
YAN (Jousset, 1997 #64), and YAN has been shown to self-associate via its PD (I. Rebay,
unpublished), it is possible that oligomerization of YAN could be critical for DNA
binding/nuclear localization.
In addition to promoting homotypic YAN-YAN interactions, PD-mediated binding to
heterologous proteins may also influence YAN localization and activity. MAE, the only
published interactor with YAN's PD (Baker et al., 2001), appears to serve such a function. Co-
immunoprecipitation experiments confirmed that MAE can bind to YAN in the absence of
signaling, and showed that the complex is destabilized in the presence of RAS/MAPK activation.
However, because MAE inhibits YAN mediated transcriptional repression, we expect that in the
absence of signaling, not all YAN will be bound to MAE. The finding that MAE can also be co-
immunoprecipitated with PNT-P2, suggests a mechanism for sequestering MAE away from
YAN to allow efficient repression and prevent inappropriate differentiation in the absence of
signaling.
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Regulation of YAN localization in response to RAS/MAPK activation: shifting the balance
towards nuclear export
Upon activation of the RAS/MAPK cascade, dual phosphorylated MAPK enters the
nucleus and phosphorylates YAN, triggering a cascade of events that ultimately leads to the
removal of transcriptional repression. Recent work by Baker et al. 2001 demonstrated that MAE
is needed for MAPK mediated phosphorylation of YAN at Serinel127 in vitro, the same site
previously shown to be critical for initiating YAN downregulation both in cell culture and in
vivo (Rebay and Rubin, 1995). Our study sheds new light on the sequence of steps in this
process.
Here we show that CRM1-mediated nuclear export is a necessary step in downregulation
of YAN. How is this achieved? Our results support a model whereby in response to pathway
stimulation, the PNT-P2-MAE complex is phosphorylated, releasing PNT-P2 to activate
transcription and MAE to interact with YAN. Binding to MAE inhibits YAN's transcriptional
repression (this work), and may facilitate phosphorylation of Serine 127 by activated MAPK
(Baker et al., 2001), although the order in which these two events happen remains to be
determined. Our data suggest MAE then plays a third role in presenting YAN to CRM1, thereby
promoting nuclear export.
In support of this model, loss of mae function, both in vivo and in cell culture, restricts
YAN to the nucleus. However, since MAPK phosphorylation of YAN is a prerequisite for export
(Rebay and Rubin, 1995) and requires MAE (Baker et al.2001), our result could simply reflect a
failure of YAN to be phosphorylated. Arguing against this, RNAi of mae also results in nuclear
Mut ETS
retention of YANMu t ETS, which normally localizes to the cytoplasm in a CRM1 dependent
manner, even in the absence of RAS stimulation. Thus in a situation where MAPK
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phosphorylation is not involved, MAE plays an active role in presenting YAN to CRM1. Thus
we favor the interpretation that MAE has an essential function in regulating nuclear export,
independent of its earlier postulated role in facilitating MAPK phosphorylation of YAN.
These same two events mediated by MAE, MAPK phosphorylation and CRM1
recognition of YAN, in turn lead to destabilization of the YAN-MAE complex. For example,
inhibition of CRM1 mediated export results in MAE remaining nuclear when cotransfected with
YAN, even upon RASv 2 stimulation. Because we have shown that MAE localization is not
directly regulated by CRM1 or by RAS pathway activation, we interpret this result to indicate
that CRM1 is needed to disrupt the YAN-MAE complex. It has recently been shown that in
certain cases, phosphorylation of the cargo protein is necessary for CRM1 recognition (Ishida et
v12
al., 2002). In agreement with this, in the presence of RASv 2, MAE remains nuclear when
ACT
expressed with YANA c , which has all the MAPK phosphoacceptor residues mutated to alanine.
This leads to the model that phosphorylation of YAN, when in the YAN-MAE complex, leads to
interaction with the exportin CRM1. This in turn disrupts the YAN-MAE complex, with YAN
being actively exported by CRM1, and MAE being free to diffuse uniformly throughout the cell.
A negative feedback loop attenuates PNT-P2 activity in response to RTK signaling
The ultimate outcome of this complex series of events is abrogation of YAN-mediated
repression of target genes and freeing the promoters for interaction with POINTED. In
unstimulated cells, unphosphorylated PNT-P2 localizes to the nucleus in a complex with MAE,
but is effectively out competed for binding to target gene promoters by YAN (Flores et al., 2000;
Halfon et al., 2000; Xu et al., 2000). Upon activation of the RAS/MAPK cascade,
phosphorylation of PNT-P2 transforms it into a potent transcriptional activator (O'Neill et al.,
1994). Baker et al. (2001) show in vitro experiments in which MAE binding to PNT-P2 leads to
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activation of transcription, and assume that this occurs via MAE promoting MAPK
phosphorylation, and hence activation, of PNT-P2. However Seidel et al. (2002) demonstrate that
PNT-P2 contains a MAPK binding site, suggesting PNT-P2 interacts directly with MAPK
without requiring a facilitator protein. Consistent with this second scenario, we find that MAE
inhibits PNT-P2 transcriptional activation. However it is formally possible that MAE could have
dual and antagonistic roles with respect to PNT-P2 regulation, first stimulating its activity by
promoting MAPK phosphorylation and later limiting its ability to activate transcription.
Definitive validation of either model will require in vivo analysis of the role of MAE with
respect to PNT-P2 regulation.
Superficially, this proposed role in antagonizing PNT-P2 function seems to disagree with
the finding that loss of mae function suppresses the rough eye phenotype of Sev-RASVl2.
However, in the absence of MAE, YAN cannot be down-regulated. Thus the effect of loss of
mae function on PNT-P2 regulation is irrelevant in this context, as the target sites will still be
occupied by YAN. However, MAE's dual function as both a positive and a negative regulator of
RTK signaling may explain the relatively weak suppression of Sev-RASv12 and the fact that it
has not been isolated in any of the numerous RTK pathway based genetic modifier screens.
In summary, our data lead to a model (Figure 2-7) in which in unstimulated cells, YAN
binds with high affinity to the DNA (Figure 2-7A) and blocks PNT-P2 from contacting and
activating the promoters of downstream target genes (Figure 2-7D). Upon stimulation by RAS,
MAPK phosphorylation of YAN and PNT-P2 allows CRM1 to interact with and export YAN, in
a process that disrupts YAN and MAE binding (Figure 2-7C) and disrupts the PNT-P2-MAE
complex, allowing PNT-P2 to bind to the DNA and activate transcription (Figure 2-7E). Free
MAE could then interact again with PNT-P2, resulting either in its removal from the DNA,
141
Figure 2-7
Yan Regulation
PNT-P2 Regulation
Figure 2-7
Model. (A-C) The model for the downregulation of YAN. (D-E) The model for the activation
and subsequent clownregulation of PNT-P2. (A) In the absence of signaling YAN localizes to
DNA, repressing transcription. (B) Upon RTK signaling phosphorylated MAPK enters the
nucleus, interacts with YAN-MAE complex, and phosphorylates YAN. YAN is removed from
the DNA, although the exact timing of this event is not yet clear. (C) The YAN-MAE complex
then interacts with CRM1, causing release of MAE and CRM1 mediated export of YAN through
the nuclear pore. (D) In the absence of signaling PNT-P2 can bind to MAE and is prevented from
activating transcription, either as a consequence of its interaction with MAE, or because it is out
competed by YAN, or both. (E) Upon RTK activation, phosphorylated MAPK enters the nucleus
and phosphorylates PNT-P2. This allows PNT-P2 to bind DNA and activate transcription of the
target genes now freed from YAN repression. (F) To prevent runaway signaling, a negative
feedback loop may occur in which MAE binds to PNT-P2 and inhibits transcriptional activation.
This could occur by MAE binding causing PNT-P2 to no longer bind DNA (option 1), or by
MAE binding resulting in dephosphorylation of PNT-P2 (option 2), resulting in inhibition of
transcriptional activation.
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inhibition of transcriptional activation, or interaction with a phosphatase that returns it to an
inactive state (Figure 2-7F). Thus a negative feedback loop would be created to prevent runaway
signaling by PNT-P2. An alternative, and not necessarily mutually exclusive, mechanism with
respect to PNT-P2, is that MAE's interaction with PNT-P2 might prevent efficient
phosphorylation by MAPK, thereby limiting the pool of activated PNT-P2 and keeping the
signaling response in check. It is likely that additional cofactors that bind MAE, YAN and/or
PNT-P2 will be required for fine-tuning activation and downregulation in response to changing
RTK signaling conditions.
Evolutionarily conserved mechanisms of YAN downregulation
Precise regulation of RTK pathway activity appears critical for achieving a proper
balance between cellular proliferation, differentiation and survival in all metazoan animals.
Excessive or continuous activation of the pathway has been linked to carcinogenesis in
mammals, underscoring the importance of tightly controlled signaling. For example, numerous
deletions and translocations involving TEL, the mammalian ortholog of YAN, have been
associated with leukemias, and in some cases with solid tumors (reviewed in Rubnitz et al.,
1999). Our studies indicate striking similarities between the regulation of TEL and YAN. Like
YAN, TEL localizes to the nucleus (Poirel et al., 1997), where it functions as a transcriptional
repressor (Lopez et al., 1999). YAN and TEL both require the PD for maintaining nuclear
AN3+PDlocalization and transcriptional repression (YAN N 3+ P D, this study; Chakrabarti et al., 2000).
Both proteins become phosphorylated in response to activation of signaling cascades (O'Neill et
al., 1994; Poirel et al., 1997). Although the functional consequences of TEL phosphorylation
remain to be investigated, our results predict that phosphorylation may down-regulate TEL
repression activity.
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In the context of TEL downregulation, it is interesting to note that no mammalian
orthologs of mae have been identified yet. However, a second mammalian TEL-like gene,
referred to as TEL2 or TELB, has been isolated (Gu et al., 2001; Poirel et al., 2000). TEL2 also
functions as a transcriptional repressor, is capable of oligomerizing with itself and with TEL, and
may thus serve as a regulator of TEL (Poirel et al., 2000; Potter et al., 2000). Of particular
interest with respect to our work defining the role of MAE, TEL2 encodes six splice variants,
one of which, TEL2a, yields a protein with just the PD (Gu et al., 2001). TEL2a closely
resembles the structure of MAE, and BLAST results show that the PD of MAE is most closely
related to the PD of TEL2, with 39% identity and 51% similarity. Thus it seems likely that
TEL2a may regulate TEL activity with a mechanism similar to what we have shown for MAE
regulating YAN. With respect to the interactions we have demonstrated between PNT-P2 and
MAE, it will be interesting to investigate whether TEL2a also interacts with and regulates other
PD containing ETS family transcriptional activators, such as ETS 1, the mammalian ortholog of
PNT-P2.
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MAE, a dual regulator of the EGFR signaling pathway, is a target of the Ets transcription
factors PNT and YAN
Pavithra Vivekanand', Tina L. Tootle , Ilaria Rebay
'These authors contributed equally to this work
Tina Tootle performed the overexpression of MAE analysis in cultured cells and Drosophila eye
tissue. Initial analysis of mae expression by in situ hybridization was performed by Tina Tootle,
further analysis yielding Figure 3-2 was by Pavithra Vivekanand. Pavithra Vivekanand
performed all transcriptional assays.
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Abstract
Ets transcription factors play crucial roles in regulating diverse cellular processes
including cell proliferation, differentiation and survival. Coordinated regulation of the
Drosophila Ets transcription factors YAN and POINTED is required for eliciting appropriate
responses to Receptor Tyrosine Kinase (RTK) signaling. YAN, a transcriptional repressor, and
POINTED, a transcriptional activator, compete for regulatory regions of common target genes,
with the ultimate outcome likely influenced by context-specific interactions with binding
partners such as MAE. Previous work in cultured cells has led us to propose that MAE
attenuates the transcriptional activity of both YAN and POINTED, although its effects on
POINTED remain controversial. Here we describe a new layer of complexity to this regulatory
hierarchy whereby mae expression is itself directly regulated by the opposing action of YAN and
POINTED. In addition, we report that MAE can antagonize POINTED function during eye
development, a finding that suggests MAE operates as a dual positive and negative regulator of
RTK-mediated signaling in vivo. Together our results lead us to propose that a combination of
protein-protein and transcriptional interactions between MAE, YAN and POINTED together
establishes a complex regulatory circuit that ensures that both down-regulation and activation of
the RTK pathway occur appropriately according to specific developmental context.
Introduction
Signaling through the Receptor Tyrosine Kinase (RTK) pathway leads to two primary
developmental outcomes, proliferation or differentiation (Tan and Kim, 1999). Activation of the
RTK is relayed to the nucleus through the evolutionarily conserved GTPase RAS and mitogen-
activated protein kinase (MAPK) cascade (Marshall, 1994; Zipursky and Rubin, 1994). In the
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nucleus, activated MAPK phosphorylates downstream signaling effectors, such as the two Ets
family transcription factors POINTED (PNT) and YAN (O'Neill et al., 1994). pointed encodes
two different proteins, PNTP1 and PNTP2 (Klambt, 1993); while both function as transcriptional
activators that bind to ETS consensus sites, PNTP2 activity requires phosphorylation by MAPK
in response to RTK/RAS signaling (O'Neill et al., 1994). YAN, a transcriptional repressor,
functions as an RTK pathway antagonist by competing with PNT for access to target sequences
(Flores et al., 2000; O'Neill et al., 1994; Xu et al., 2000). Under conditions of minimal RTK
induction, high affinity binding of YAN to the DNA effectively outcompetes PNT and inhibits
inappropriate differentiation or proliferation (O'Neill et al., 1994; Rebay and Rubin, 1995).
Upon RAS/MAPK stimulation, MAPK-mediated phosphorylation of YAN results in abrogation
of YAN repressor activity, allowing PNT to activate transcription of formerly repressed genes
(O'Neill et al., 1994).
Multiple regulatory mechanisms are employed to fine-tune not only the competition
between YAN and PNT for access to the promoter regions of target genes but also their
transcriptional activities. One key component involved in these processes is MAE, a gene
product structurally related to YAN and PNT by virtue of a shared protein-protein interaction
motif called the pointed domain (PD) (Baker et al., 2001; Tootle et al., 2003). MAE has been
shown to interact with both YAN and PNT via heterotypic PD-PD associations (Baker et al.,
2001; Tootle et al., 2003; Yamada et al., 2003). While the mechanistic consequences of YAN-
MAE and PNT-MAE complexes are not fully understood, MAE appears to contribute critical
regulation that modulates the balance between YAN-mediated repression and PNT-mediated
activation of downstream target genes.
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We and others have recently shown that MAE plays multiple independent roles in
modulating YAN activity. Specifically, MAE facilitates both MAPK phosphorylation (Baker et
al., 2001) and nuclear export (Tootle et al., 2003) of YAN in response to RTK pathway
activation, and antagonizes YAN's repressor activity in the absence of pathway activation
(Tootle et al., 2003). Although MAE has been proposed to positively influence PNT activity
(Baker et al., 2001), transcriptional activity studies in cultured cells have led to a competing
hypothesis whereby MAE participates in a negative feedback loop that downregulates PNT
(Tootle et al., 2003; Yamada et al., 2003). Based on this capacity to inhibit the transcriptional
properties of both YAN and PNT, MAE could potentially play dual positive and negative roles in
modulating transcriptional responses downstream of the RTK signaling pathway.
Here we report that superimposed on the complex web of protein level interactions
whereby MAE modulates YAN and PNT function, is a transcriptional regulatory network in
which YAN and PNT directly regulate mae transcription. These results reveal an important new
mechanism for precisely modulating MAE levels in order to ensure appropriate transcriptional
responses to RTK/Ras/MAPK pathway activation during development and highlights the
extraordinary complexity of the meshwork of interactions and feedback loops that fine tunes and
coordinates the activities of YAN, PNT and MAE in vivo. To explore these regulatory
circuitries further, we have investigated the mechanisms whereby MAE antagonizes the
transcriptional output of YAN and PNT by examining the consequences of overexpressing MAE
in both cultured cells and in vivo. We find that while increased MAE expression abrogates
YAN-mediated repression, it does not do so by facilitating nuclear export and down-regulation
of YAN, suggesting instead a direct interference with transcription. In the eye imaginal disc, we
find that elevated MAE expression antagonizes PNT function, arguing that one function of MAE
152
in vivo could be to limit the transcriptional output of PNT, a model consistent with our previous
work in cultured cells. Together our results suggest that multiple layers of regulatory feedback
loops involving the nuclear effectors MAE, YAN and PNT ensure finely-tuned and context-
appropriate RTK signaling levels.
Results
YAN and PNT regulate mae expression
Because mae expression in wild-type embryos is reminiscent of the expression patterns of
genes such as argos (aos) and orthodenticle (otd) that have been shown to be regulated by
Epidermal Growth Factor Receptor (EGFR) signaling (Gabay et al., 1996), we decided to
investigate whether mae expression might be similarly regulated by the downstream EGFR
pathway effectors, YAN and PNT. Analysis of the genomic region around mae reveals two
clusters of ETS DNA binding consensus sites (EBS; defined as GGAA/T; Nye et al., 1992), one
upstream of the transcription start site (MaeEBS1) and the other in the intron of mae (MaeEBS2)
(Figure 3-1A), further suggesting that YAN and PNT might regulate mae expression. To explore
this possibility, in situ hybridization experiments were performed to determine whether mae
expression was affected by altering the dosage of YAN and PNT. As predicted based on the
presence of EBS clusters in the mae genomic region, mae expression is significantly increased in
yan mutant embryos (Figure 3-2B compared to 3-2A), while it is lost in pnt mutant embryos
(Figure 3-2C). Conversely, ubiquitous overexpression of YANACT or PNT results in down-
(Figure 3-2E) and up- regulation (Figure 3-2F) of mae expression respectively (compare to
Figure 3-2D). Taken together, these results suggest that mae expression is regulated by the Ets
transcription factors PNT and YAN.
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Figure 3-1
PNT and YAN directly regulate mae transcription. A) Two EBS clusters, one upstream of
the mae transcription start site and the other in the intron of mae are predicted by Cister (Cis-
element cluster finder). (B) Transcription assays with MaeEBS-luciferase show that PNTP1,
YAN and PNTP2 regulate mae. PNTP1 and PNTP2+RASV12 activate transcription while
addition of YAN results in transcriptional repression.
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To determine whether PNT and YAN regulate mae levels directly, the EBS clusters were
cloned upstream of a minimal promoter and luciferase cDNA to generate two different MaeEBS-
luciferase reporters, MaeEBS 1-luciferase (upstream cluster, Figure 3-1A) and MaeEBS2-
luciferase (intronic cluster, Figure 3-1A). This enabled us to assess the effects of PNT and YAN
on these putative regulatory elements by performing transcription assays in Drosophila S2 cells.
If PNT and YAN directly regulate mae transcription, then the prediction would be that PNT and
YAN would bind to the EBSs and activate and repress transcription of the reporter, respectively.
Both the upstream and the intronic EBS clusters behaved similarly in these luciferase
reporter assays. Addition of the constitutively activated form of PNT, PNTP1, resulted in
activation of the reporter, while co-transfection of YAN with PNTP1 resulted in two to three fold
repression in transcription (Figure 3-1B). Similarly, co-transfection of PNTP2 and RASvl2
resulted in transcriptional activation of the reporter (Figure 3-iB). The transcriptional
modulation of the MaeEBS-luciferase reporters by PNT and YAN supports our hypothesis that
mae expression is directly regulated by PNT and YAN in vivo.
MAE-mediated antagonism of YAN repression activity does not involve nuclear export of YAN
Based on our previous finding that overexpression of MAE inhibits YAN's ability to
repress transcription (Tootle et al., 2003), we decided to investigate further the underlying
mechanisms. One possibility was that MAE overexpression might disrupt YAN's nuclear
localization. In Drosophila S2 cultured cells YAN localizes to the nucleus (Figure 3-3A), and
upon activation of the RAS/MAPK cascade is exported to the cytoplasm (Figure 3-3B) (Rebay
and Rubin, 1995). Previous analyses revealed that MAE is necessary for nuclear export of YAN,
as YAN remains restricted to the nucleus in the absence of mae both in cultured cells and in vivo
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Figure 3-2
mae expression is modulated by PNT and YAN. (A-F) in situ hybridizations with mae
DNA probe in (A, D) wild-type; (B) yan mutant; (C) pnt mutant; (E) Ub-GAL4; UAS-YANACT;
(F) Ub-GAL4; UAS-PNTP2 embryos. mae expression is upregulated in yan mutant (B) and in
embryos over-expressing PNTP2 (F) while its expression is down-regulated in pnt mutant (C)
and in embryos over-expressing YANACT (E) when compared to wild-type embryos.
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(Tootle et al., 2003). Therefore we asked whether the abrogation of YAN-mediated repression
that; results from MAE overexpression (Tootle et al., 2003) could be the result of premature
nuclear export of YAN. However, no effect on nuclear YAN localization was observed (Figure
3-3C). In order to rule out the possibility that the MYC epitope tag on MAE was interfering with
normal MAE function to produce a misleading result, we confirmed the finding using a non-
tagged MAE construct (Figure 3-3D). Thus the mechanism whereby MAE antagonizes YAN-
mediated repression appears to involve a more direct interference with transcriptional activity,
rather than simply inducing inappropriate nuclear export.
Genetic interactions between mae and yan suggest MAE is both a positive and a negative
regulator of RTK signaling in the eye
The Drosophila eye provides a powerful and sensitive system in which to unravel the
molecular circuitries underlying RTK-mediated signaling events. For example, the rough eye
phenotype that results from expression of a constitutively active allele of yan (referred to as sev-
YAN CT (Rebay and Rubin, 1995); Figure 3-4A) has been used successfully as a dose-sensitive
background to demonstrate genetic interactions with novel components of the EGFR/Ras/MAPK
pathway (Rebay et al., 2000). Using this sensitized system, we recently demonstrated that
heterozygosity for mae mildly enhances the severity of the YANACT rough eye phenotype,
consistent with its role in downregulating YAN activity and positioning it as a positive regulator
of RTK-mediated signaling events (Figure 3-4B; Tootle et al., 2003).
If, as predicted by Baker et al. 2001, MAE functions exclusively as a positive pathway
component, then excess MAE should suppress the sev-YANA CT phenotype. However if MAE
serves dual positive and negative functions, as suggested by its ability to inhibit transcriptional
output of both YAN and PNT, then depending on which role prevails in this context, either
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MAE-YAN complexes in cultured cells are refractory to normal YAN downregulation. (A-D)
Transient transfections of Drosophila S2 cultured cells expressing YAN and the indicated
constructs stained with anti-YAN. (A'-D') DAPI staining overlaying YAN antibody staining of
the same cells. The percentage of transfected cells exhibiting nuclear localization (A, C-D) or
exclusively cytoplasmic localization (B) is indicated, n>250. (A, C-D) YAN localization in the
absence of RASVl2 . (B) YAN localization in the presence of RASVl2 . (C, D) Coexpression of
MYCMAE or MAE has no effect on the nuclear localization of YAN.
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Figure 3-4
MAE is a dual positive and negative regulator of EGFR signaling in the eye. (A-D) Scanning
electron micrographs of adult Drosophila eyes. (A) sev-YANACT; sev-GAL4; (B) sev-YANACT;
1(2)k06602/+; (C) sev-YANACT;UAS-MYCMAE/ sev-GAL4; (D) UAS-MYCMAE/ sev-GAL4.
Both loss of function and overexpression of mae enhance the rough eye phenotype of activated
YAN, although the system appears more sensitive to increased MAE levels.
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suppression or enhancement might be observed. Intriguingly, we found that sev-GAL4 driven
MAE strongly enhanced the severity of the sev-YANACT rough eye phenotype (Figure 3-4C,
compared to A). Confirming that the enhancement was not due to an additive effect,
overexpression of MAE alone using sev-GAL4 exhibited a wild-type eye (Figure 3-4D). This
result argues that MAE is a dual regulator of RTK signaling, and that in this context, its function
as a pathway antagonist appears to prevail.
MAE antagonizes POINTED function in the developing eye
If MAE has a role as an RTK pathway antagonist during eye development, given its close
functional association with YAN and PNT (Tootle et al., 2003), three possible mechanisms of
action can be considered: MAE could directly antagonize PNT function, a model consistent with
cell culture transcription assays and with the enhancement of sev-YAN A CT (Tootle et al., 2003;
Yamada et al., 2003; Rebay et al., 2000); MAE could potentiate YAN activity, a mechanism that
would not be predicted by our previous work (Tootle et al., 2003); or MAE could simultaneously
impair activity of both PNT and YAN in such a way that the overall effect is to reduce pathway
output. Because loss of mae results in a failure to down-regulate YAN (Tootle et al., 2003), the
presence of a stable repressor completely damps down signaling output and makes it impossible
to assess whether PNT activity is directly compromised in this context. Therefore to address the
possibility that MAE might antagonize PNT activity in vivo, we examined in further detail the
consequences of overexpressing MAE in the developing eye. Although MAE expression driven
by a weak sev-Gal4 driver has no phenotypic consequences (Figure 3-4D), using the stronger
GMR-Gal4 driver we found that overexpression of MAE results in gross disorganization of the
external morphology of the adult eye (Figure 3-SB, compared to GMR-Gal4 alone in 3-SA).
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To determine the developmental cause(s) of the phenotype, eye imaginal discs from GMR-
GAL4; UAS-MAE larvae were examined. We first looked at expression of the neuronal marker
ELAV, which is expressed in the developing photoreceptors (Figure 3-SD), and found a
substantial reduction in the number recruited (Figure 3-5E), a phenotype consistent with a
reduction in RTK/RAS pathway function. ELAV expression in the first three recruited
photoreceptors, R8, R2 and R5 appeared least affected while the later specified photoreceptors,
R3, R4, R1, R6 and R7, were most frequently lost. Although loss of these photoreceptors would
be predicted to result in a rough eye, the severity of the adult phenotype (Figure 3-SB) suggests
that many more cell types are affected. Therefore, we also examined whether cone cell
recruitment was compromised and found that overexpression of MAE significantly reduces the
number of cone cells (Figure 3-SH compared to 3-5G). As the cone cells are essential for
recruiting all subsequent cell types, the severity of the adult rough eye likely reflects the loss of
the non-neuronal support cells.
Another factor that could contribute to the decreased number of photoreceptors that is
brought about by MAE overexpression is cell death, another characteristic of reduced RTK
signaling output. In wild-type eye imaginal discs there is a small amount of cell death
immediately anterior to the furrow (Figure 3-SJ). Overexpression of MAE results in increased
cell death posterior to the furrow (Figure 3-5K). Therefore, both the loss of differentiated cell
types and ectopic cell death during eye development contribute to the severe rough eye seen in
the adult.
We also asked whether elevated MAE levels altered YAN expression in the eye disc.
YAN is normally expressed strongly in the morphogenetic furrow and at slightly lower levels in
the basally localized nuclei of undifferentiated cells posterior to the furrow (Figure 3-SM).
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Interestingly, we found that YAN expression at the furrow was slightly elevated, while basal
YAN expression posterior to the furrow was distinctly reduced (Figure 3-5N).
To determine whether MAE exerts independent effects on YAN and PNT in this context,
we asked whether we could rescue some or all of the MAE overexpression phenotypes by
coexpressing PNTP2. We were unable to perform the converse test, because overexpression of
YAN results in lethality, even with eye specific drivers (T.T. and I.R., unpublished). Our results
suggest that the phenotypic consequences of overexpressing MAE occur primarily due to loss of
pnt-p2 function.
Specifically we generated recombinant UAS-PNTP2, UAS-MAE flies and expressed the
transgenes using GMR-GAL4. The control experiment indicated that overexpression of PNTP2
alone using the GMR-GAL4 driver results in normal photoreceptor recruitment, extra cone cells,
wild-type levels of cell death, and increased basal YAN expression compared to wild-type (data
not shown). Overexpression of PNTP2 completely rescues the severe rough eye of GMR-GAL4;
UJAS-MAE (Figure 3-5C) and at the cellular level restores normal recruitment of photoreceptors
and cone cells (Figure 3-SF, I), reduces cell death to wild-type levels (Figure 3-5L), and returns
YAN expression to normal levels (Figure 3-50). Therefore, the phenotypes associated with
overexpression of MAE in the eye appears to be due to loss of PNTP2 function, strongly
suggesting that MAE can antagonize RTK pathway output by attenuating PNTP2 activity.
Discussion
A precise balance between the opposing activities of the repressor YAN and the activator
POINTED is essential for achieving appropriate transcriptional response both in the presence and
in the absence of RTK signaling (Rebay and Rubin, 1995). MAE, a small PD containing protein
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MAE inhibits PNTP2 function in the eye. (A-C) Scanning electron micrographs of adult
Drosophila eyes. (D-O) Various stainings of third instar larval eye imaginal discs. (A, D, G, J,
M) GMR-GAL4; (B, E, H, K, M) GMR-GAL4; UAS-MYCMAE; (C, F, I, L, O) GMR-GAL4;
IJAS-MYCMAE, UAS-PNTP2. (D-F) Anti-ELAV staining. (G-J) Anti-cut staining. (J-L)
Acridine orange staining. (M-O) Basal anti-YAN staining. Overexpression of MAE results in a
complete loss of eye tissue in the adult fly due to loss of photoreceptor and support cell
recruitment and increased apoptosis in the developing eye. All of these phenotype are rescued
by overexpression of PNTP2, suggesting that overexpression of MAE inhibits PNTP2 function.
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that has been shown to bind directly to both transcription factors, plays a pivotal role in
modulating their activities (Baker et al., 2001; Tootle et al., 2003). For example, our previous
work showed that MAE contributes positively to RTK signaling output by facilitating nuclear
export and down--regulation of YAN in response to pathway activation (Tootle et al., 2003). In
this study we demonstrate that MAE also antagonizes PNT function, putting it in the unique
position of being a dual positive and negative regulator of EGFR-mediated signals. Intriguingly,
we find that mae expression is itself regulated by PNT and YAN, suggesting a whole new layer
of feedback loops that fine-tune and down-regulate signaling.
MAE negatively regulates both YAN and PNTP2
We have shown that while overexpression of MAE blocks YAN's repression capability
(Tootle et al., 2003), this occurs without altering YAN nuclear localization. Thus increased
MAE expression appears to interfere directly with YAN-mediated transcriptional repression. An
intriguing model to explain this finding originates from the observation that homotypic
interactions mediated by the PD (pointed domain) of TEL, the mammalian ortholog of YAN,
result in the formation of TEL polymer that may facilitate transcriptional repression by wrapping
around the target DNA (Kim et al., 2001). YAN is similarly capable of self-association and the
residues that are required for TEL polymerization have been conserved, suggesting YAN-YAN
polymerization might similarly be critical for repression (Jousset et al., 1997). In this context,
perhaps clusters of EBSs, similar to those we have described in mae, by recruiting multiple YAN
molecules to a common target site may provide a scaffold for nucleating and promoting YAN
polymerization.
Such a model requires a mechanism to limit the extent of polymer formation, such that
the cell can achieve efficient but reversible repression of target genes. Considering its
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multifaceted role in down-regulating YAN activity and its ability to bind the PD of YAN, MAE
is a prime candidate to fill such a role. Consistent with this prediction, recent studies have found
PD-mediated polymerization of YAN is required for transcriptional repression and that MAE
effectively "caps" YAN oligomerization by occluding the residues required for polymerization
(Jim Bowie, personal communication). Thus it is tempting to speculate that MAE's ability to
abrogate YAN-mediated repression may reflect a role in "depolymerizing" YAN at the DNA, an
intriguing model that remains to be validated in vivo.
Assuming the model holds true, then our combined results suggest that MAE antagonizes
YAN activity both in the absence and as a consequence of RTK pathway stimulation. Under
lower levels of pathway activation, MAE would play a key role in mitigating the strength of
YAN-mediated repression, essentially ensuring that the threshold barrier that blocks
inappropriate cellular responses to RTK signaling is not set too high. In response to pathway
activation, MAE would then contribute at multiple levels to the phosphorylation and nuclear
export mechanisms that ensure timely and efficient down-regulation of YAN.
In addition to antagonizing YAN activity, our work suggests that MAE also negatively
regulates PNTP2 function, thus positioning it uniquely within the RTK pathway as both a
positive and negative regulator. For example, the phenotypes associated with misexpression of
MAE in the Drosophila visual system are completely suppressed by co-expression of PNTP2,
arguing strongly that MAE can antagonize EGFR signaling in the eye by interfering with the
activity of PNTP2. While the photoreceptor loss and increased apoptosis phenotypes associated
with MAE overexpression resemble the consequences of blocking YAN nuclear export and
down-regulation (Rebay and Rubin, 1995), the reduced YAN expression observed in MAE-
expressing eye disc argues against such an explanation. Furthermore, if MAE were inducing
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premature downregulation of YAN in these cells, one would expect to observe ectopic
photoreceptors, rather than the neuronal loss that actually occurs. Thus, although we cannot rule
out a direct effect on YAN, we favor the interpretation that the primary consequence of MAE
overexpression is reduction in activity of PNTP2, and that the loss of YAN expression is a
secondary outcome. It is important to note that both our cell culture and in vivo experiments
employ overexpression strategies that are subject to the caveats inherent to such analyses. Thus
we view these experiments as an opportunity to reveal new mechanistic hypothesis that will
provide an important foundation for future studies designed to unravel the complex regulatory
circuitries that exist between MAE, YAN and PNT in vivo.
YAN and PNTP2 regulate mae expression
Induction of both positive and negative feedback loops by signal transduction pathways
plays an important role in regulating the response to pathway activation (Freeman, 2000; Rebay,
2002). Activation of PNTP2 by EGFR/RAS/MAPK results in the transcription of target genes
including Argos and Kekkonl, which have been shown to negatively regulate the pathway
(Ghiglione et al., 1999; Golembo et al., 1996). We have identified another target of the Ets
transcription factors PNT and YAN, mae, which performs the dual role of promoting and
inhibiting signaling by the EGFR/RAS/MAPK pathway. Based on the effects on mae expression
pattern observed in pnt and yan mutants and in embryos overexpressing PNT and YAN, we
propose that PNT activates while YAN represses mae transcription (Figure 3-6).
Based on MAE's ability to antagonize EGFR signaling output, activation of mae transcription by
PNTP2 provides a negative feedback loop that would prevent runaway pathway activation
(Figure 3-6). While Kekkon-1 and the secreted antagonist Argos act at the level of the receptor
to down-regulate signaling (Jin et al., 2000), the induction of mae transcription would ensure the
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clown-regulation of the pathway by inhibiting the function of the effector PNTP2. This would
result in cell autonomous inhibition of the EGFR/RAS/MAPK pathway at the level of the
transcription factor. Moreover, while the previously identified inhibitors Argos, Sprouty (Casci
et al., 1999) and Kekkonl function solely as antagonists of RTK signaling, as discussed above,
MAE is unusual in that it acts both as a positive and negative regulator of the pathway by
inhibiting both YAN and PNTP2 function. Because MAE negatively regulates both YAN and
PNTP2 function, imposing constraints on MAE protein levels becomes critical. This appears to
be achieved by regulating mae expression levels directly by YAN and PNT. For example, and as
discussed above, because excess MAE could potentially break up YAN-YAN polymer to such an
extent that YAN would no longer able to repress appropriate target genes, the negative regulation
of mae expression by YAN sets up a situation whereby excessive levels of MAE do not
accumulate. Thus in the absence of RTK signaling, repression of mae by YAN would ensure
that only low MAE levels are present in the nucleus, allowing YAN to repress transcription.
Emphasizing the importance of fine-tuning the expression levels of these three nuclear RTK
pathway regulators and further complicating the circuitry, it has been suggested that YAN and
PNT may also directly regulate each others transcription, setting up additional positive and/or
negative regulatory loops (Rohrbaugh et al., 2002). For example, our finding that overexpression
of PNTP2 leads to upregulation in YAN in the eye disc is consistent with a feedback loop
whereby the activity of PNTP2, a positive pathway effector, attenuates its own activity by
increasing expression of the YAN repressor. A great deal of future work will be needed to
unravel the precise in vivo contexts in which these complex transcriptional regulatory networks
operate.
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Figure 3-6
Model for regulation of PNT, YAN and mae. EGFR/RAS/MAPK signaling leads to
MAE-mediated phosphorylation and down-regulation of YAN, resulting in activation of targets
by PNTP2. As mae itself is a target of PNT and YAN and negatively regulates their function,
activation of PNTP2 would result in induction of mae and subsequent down-regulation of the
pathway by inhibition of PNTP2 to limit the duration of the signal (see text).
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Assuming, developmental contexts in which YAN and MAE are coexpressed, something
that at present is difficult to ascertain given the lack of antibody reagents specific to MAE, why
does endogenous MAE not inhibit YAN function in the absence of RTK signaling? One
possible answer stems from the finding by Yamada et al. (2003) that MAE binds PNTP2 with
much higher efficiency than YAN. Therefore, under conditions of moderate MAE expression,
binding to PNTP2, or some currently unidentified other binding partner, would result in MAE
being sequestered away from YAN. In this scenario, activation of the RTK/RAS/MAPK
pathway and subsequent phosphorylation of PNTP2 might result in dissociation of the PNT-
MAE complex. Free MAE could then facilitate phosphorylation and nuclear export of YAN,
thereby permitting subsequent activation of target genes by PNTP2. As mae is itself one such
target gene and as it inhibits PNTP2 function, the resulting increased MAE expression would
establish a negative feedback loop resulting in attenuation of RTK signaling. Alternatively,
MAE might require a co-factor whose expression or function is regulated by EGFR signaling to
down-regulate YAN activity. In the absence of signaling, the co-factor would be inactive/absent
and MAE would be unable to inhibit YAN function.
In conclusion, MAE joins the panoply of regulators of EGFR signaling that have been
shown to play an important role in modulating and restricting the strength, range and duration of
signaling events. By establishing negative feedback loops that act at multiple levels within a
signal transduction cascade, a robust checkpoint is established to attenuate as well as prevent
constitutive signaling by the RTK pathway.
Materials and Methods
Molecular biology
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The upstream EBS cluster (MaeEBS 1) was generated by PCR amplification using
forward EBS 1 5' TTGGGATCCTTTCCGCTTCCTGTGGCCCAGATTA3' and reverse EBS 1 5'
TTAAGATCTTTGAGCCTAGACAATTGCATTTCCT3' and ligated with BamHI/BglII
digested pBluescript-Sk+; the intronic cluster (MaeEBS2) by PCR amplification using forward
EBS2 5' TTGCTCGAGGCCAAATGACAGGAAACGC-GTCAT3' and reverse EBS2 5'
TTGGTCGACCTGCATTCACTTCCGCCCACGTTA-GAA3' and ligated with XhoI/SalI
digested pBluescript-Sk+. These constructs were subcloned into KpnI/PstI digested pBSSK-
luciferase (Silver et al., 2003) to obtain MaeEBSl-luciferase and MaeEBS2-luciferase.
Transfections
Drosophila S2 cells were transfected with various combinations of plasmids (Pascal and
Tjian, 1991) and transcription assays were done as described previously (Tootle et al., 2003).
nImmunohistochenistry and in situ hybridization
Fixation and staining of S2 cells and embryos were performed as previously described
(Fehon et al., 1991; Fehon et al., 1990; Tootle et al., 2003). Antibodies used were mouse anti-
YAN MAb 8B 12, mouse anti-myc (a gift from R. Fehon), rat anti-ELAV MAb 7E8A10 and
mouse anti-CUT MAb2B 10. All secondary antibodies were from Jackson ImmunoResearch.
Monoclonal supernatants were generated by growing hybridoma lines obtained from the
Developmental Studies Hybridoma Bank in DMEM supplemented with 10% fetal bovine serum
and 10% NCTC-109 (Gibco). Eye imaginal discs were dissected from third instar larvae in
Schneiders S2 media and fixed in 4% paraformaldehyde in PBS for 10 minutes. Discs were
washed in PBS+ 0.1% TritonX-100 (PT) for 15 minutes on ice and then incubated in antibody, in
PBS+5% normal goat serum+ 0.1% TritonX-100 (PNT) overnight. Discs were washed three
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times in PNT and then incubated in secondary antibody for 2 hours at 4° . Discs were washed
three times with PNT. If HRP secondary was used then discs were incubated in
diaminobenzidine (0.5 mg/ml diaminobenzidine, 0.1% saponin, 0.003% H20 2 in PBS) until
pattern was visible and then washed three times in PT. Discs were mounted in 50% PT and 50%
glycerol. Acridine orange staining was performed by incubating dissected discs in 1:500 lmM
acridine orange in ethanol at room temperature for 10 minutes, washing in media and mounting
in PBS.
In situ hybridizations were performed as described previously (Tautz and Pfeifle, 1989)
using a 500bp mae probe generated by PCR amplification (5' CCCAAGTGGAAT-
CGAGCTATACC 3'; 5' CTATGATAGCAGGGCCATTGCTCGG 3').
Histology
Preparation of tissue for scanning electron microscopy was performed as previously
described (Tootle et al., 2003). Fixation and tangential sections of adult eyes was performed as
previously described (Tomlinson et al., 1987).
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Chapter 4
The transcription factor Eyes absent is a protein tyrosine phosphatase.
Tina Tootle*, Serena Silver*, Erin Davies*, Victoria Newman, Robert Latek, Ishara Mills,
Jeremy Selengut, Beth Parlikar, and Ilaria Rebay.
Nature. 2003. 426:299-302.
This Letter to Nature work was a collaborative effort. Initial efforts to isolate substantial amount
of Eya protein from a variety of sources and determine whether Eya possesses phosphatase
activity were performed by Erin Davies, Victoria Newman, and myself. Successful purification
of Eya from bacteria and subsequent kinetic analysis was a joint effort by myself and Serena
Silver. The observation that Eya is tyrosine phosphorylated in Drosophila insect cultured cells
by Beth Parlikar led me to analyze the levels of tyrosine phosphorylation of wild-type versus
catalytic mutants. I found that catalytic mutants exhibit higher tyrosine phosphorylation than
wild-type, and went on to show in an in vitro assay that bacterially purified Eya can
dephosphorylate tyrosine phosphorylated Eya from cultured cells.
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Summary
Post-translational modifications provide sensitive and flexible mechanisms to
dynamically modulate protein function in response to specific signaling inputs(Hunter 2000). In
the case of transcription factors, changes in phosphorylation state can influence protein stability,
conformation, subcellular localization, interactions with cofactors, transactivation potential and
transcriptional output(Hunter 2000). Here we show that the evolutionarily conserved
transcription factor Eyes absent(Treisman 1999; Wawersik and Maas 2000) belongs to the
phosphatase subgroup of the haloacid dehalogenase superfamily(Collet et al. 1998; Thaller et al.
1998) and propose a novel function for it as a non-thiol based protein tyrosine phosphatase. In
vitro assays demonstrate that Eyes absent has intrinsic phosphatase activity that is blocked by
mutations altering the active site. Experiments performed in Drosophila cultured cells and in
vitro indicate that Eyes absent has protein tyrosine phosphatase capability and may act
autocatalytically to dephosphorylate itself. Confirming the biological significance of this
function, mutations that disrupt the phosphatase active site severely compromise Eyes absent's
ability to promote eye specification and development in Drosophila. Given the functional
importance of phosphorylation-dependent modulation of transcription factor activity, our
evidence of a nuclear transcriptional coactivator with intrinsic phosphatase activity suggests
exciting new mechanisms for fine-tuning transcriptional regulation.
Results and Discussion
The transcriptional coactivator Eyes absent (EYA) is a member of an evolutionarily
conserved set of nuclear transcription factors and cofactors collectively termed the retinal
determination (RD) gene network(Bonini et al. 1997; Treisman 1999; Wawersik and Maas
2000). While RD network members are perhaps best known for their roles in eye specification,
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redeployment of these genes, either individually or as a network, contributes to a diverse array of
essential developmental processes in all metazoans(Treisman 1999; Wawersik and Maas 2000).
EYA family members are defined by a conserved -275 amino acid motif, referred to as the EYA
domain (ED), that has been shown to bind two other RD members, Sine oculis (SO) and
Dachshund (DAC)(Bonini et al. 1997; Chen et al. 1997; Pignoni et al. 1997). Together, EYA
and SO form a potent transcriptional activator(Silver et al. 2003), while the mechanistic
implications of EYA-DAC interactions are less clear(Ikeda et al. 2002; Kim et al. 2002).
Emphasizing the functional conservation among EYA homologs, mammalian EYA transgenes
can rescue the "eyeless" phenotype of Drosophila eya mutations(Bonini et al. 1997; Bui et al.
2000).
We have explored a new function for EYA's C-terminal ED that is suggested by protein
motif searches and structural modeling studies. These investigations place EYA within the
phosphatase subgroup of the Haloacid dehalogenase (HAD) superfamily (Figure 4-la and
Supplementary Figure 4-S a). HAD family members constitute a diverse collection of enzymes
found in all organisms ranging from bacteria and archaea to humans, that includes
dehalogenases, ATPases, phosphonatases, phosphomutases, epoxy hydrolases and a growing
number of magnesium-dependent phosphatases(Collet et al. 1998; Thaller et al. 1998; Collet et
al. 1999). Understanding of the in vivo function of HAD family phosphatases remains extremely
limited, particularly in eukaryotic systems.
X-ray crystallography combined with mutagenesis studies of several HAD family
proteins has revealed a conserved c/I3-hydrolase fold that unites three non-contiguous sequence
motifs to form the catalytic core of the enzyme(Aravind et al. 1998; Collet et al. 1999; Selengut
2001). Structural modeling studies predict that the ED will form a HAD c/13-hydrolase-like fold
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(Figure 4-lb). Five conserved residues brought together by this tripartite configuration surround
the active site and are essential for catalysis(Aravind et al. 1998; Collet et al. 1999; Selengut
2001). These residues are strikingly conserved in the ED of all EYA proteins (Figure 4-la and
Supplementary Figure 4-S lb). In Motif 1 (DXDX (TV)) the invariant first aspartic acid serves
as the nucleophile in all HAD family proteins and likely forms a phospho-aspartate
intermediate(Ridder and Dijkstra 1999; Cho et al. 2001). The second aspartic acid distinguishes
the phosphatase/phosphohydrolase subgroup from other branches of the HAD superfamily
(Collet et al. 1998; Thaller et al. 1998; Selengut 2001) and is strictly conserved in all EYA
homologs. Motif 2 contains an essential Serine/Threonine at the end of the -strand and Motif 3
contributes at least three required residues, a lysine and two aspartic acids, the second of which
has undergone a conservative substitution to glutamic acid in EYA proteins. Requirement for the
two acidic residues within Motif 3 appears strictest within the phosphatase/phosphohydrolase
branch of the HAD superfamily (Thaller et al. 1998). The high degree of conservation of this
catalytic quintet (D, S/T, K, D, E) in invertebrate, vertebrate and plant EYA homologs suggests
that EYA belongs to the phosphatase subgroup of the HAD superfamily.
To investigate whether EYA has intrinsic phosphatase activity, we tested the ability of
recombinant GST-tagged ED fusions to dephosphorylate the synthetic substrate para-nitrophenyl
phosphate (pNPP). Using a murine homolog, we demonstrate that EYA can function as a
phosphatase (Figure 4-2). Mutations altering the presumptive HAD active site residues severely
compromise activity (Figure 4-2a; see Supplementary Information for details). Sensitivity to the
tyrosine phosphatase inhibitor vanadate, but not to inhibitors of serine/threonine phosphatases
(Figures 4-2a, b), and a requirement for Mg++ are consistent with EYA being a HAD family
phosphatase(Selengut and Levine 2000). We also tested recombinant Drosophila EYA in these
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Figure 4-1
EYA is a member of the phosphatase subgroup of the HAD superfamily.
a, The non-contiguous sequences comprising the HAD Motifs 1, 2, and 3. Pink residues define
the HAD motif, with those mutated in this study marked with a "*". Blue residues are most
strongly conserved among the phosphatase subgroup of the HAD superfamily. Green residues
are highly conserved in both ATPases and phosphatases(Aravind and Koonin 1998; Collet et al.
1999).
b, Structural modeling studies predict a similar active site configuration for Drosophila EYA and
other HAD proteins. The HAD template backbone is identified with a white ribbon and the EYA
model backbone is rendered with a cyan ribbon. Key active site residues are highlighted as
sticks, either white for the HAD or yellow for EYA.
c, Superimposition of mutant DmEYAHAD residues on the DmEYA model. Alignment of the
substitutions (in magenta) and their wild type counterparts (in yellow) is shown.
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Figure 4-2
EYA exhibits phosphatase activity in vitro.
a, Kinetics for mouse EYA3 GST-ED fusion proteins (GST-MmEYA). D246N, T420A, K449Q,
D474N and E478Q are mutations analogous to the D493N, S670A, K699Q, D724N and E728Q
described for Drosophila EYA. For those mutant enzymes whose activity was too low to be
measured, >>> indicates a Km significantly higher and an efficiency (kcat/Km) significantly
lower than that measured for D246N.
b, Like the HAD family phosphatase MDPl(Selengut and Levine 2000), phosphatase activity of
MmEYA is blocked by tyrosine phosphatase inhibitors (Inhibitor II and Na3VO4) but not
serine/threonine phosphatase inhibitors (Inhibitor I).
c, Phosphatase activity of Drosophila EYA (DmEYA), although significantly weaker than that
obtained with MmEYA, is also blocked by addition of the tyrosine phosphatase inhibitor
Na3VO4.
cd, Kinetics for mouse EYA3 GST-ED fusion proteins (GST-MmEYA) with respect to the
tyrosyl phosphorylated peptide substrate (pY)GEF.
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assays, and although its activity is significantly lower, it remains Mg++-dependent and vanadate
sensitive (Figure 4-2c). While the most likely explanation for the weak in vitro activity of the fly
ED is that we have not identified appropriate conditions for purifying properly folded and active
protein, we cannot rule out the possibility that Drosophila EYA, although it retains all the
conserved residues comprising the HAD motif (Figure 4-1), may have only limited ability to
function as a phosphatase. However, the fact that the mouse EYA isoform used in our in vitro
assays is able to substitute for Drosophila EYA in vivo(Bui et al. 2000), when considered
together with the results of the in vivo experiments described below, leads us to propose that
EYA proteins possess a conserved phosphatase function.
To investigate whether EYA might have protein phosphatase capability, something that
has not been definitively demonstrated for any other HAD family protein(Selengut 2001),
several phosphotyrosine or phosphothreonine containing synthetic peptides were tested as
substrates. We find that EYA exhibits robust activity toward one of the tyrosyl phosphorylated
peptides, with a Km significantly lower than that measured using pNPP as a substrate (Figure 4-
2cd). No measurable activity was detected with the phosphothreonine or other phosphotyrosine
containing peptides (data not shown; see Methods for details). These results demonstrate that
EYA has protein tyrosine phosphatase (PTP) capability, although they do not rule the possibility
that EYA could dephosphorylate other substrates as well. The fact that not all tyrosyl
phosphorylated peptides were hydrolyzed suggests EYA has specific sequence preferences with
respect to its putative protein substrates. Because HAD family phosphatases employ a catalytic
aspartate(Ridder and Dijkstra 1999; Cho et al. 2001) as the nucleophile rather than the cysteine
residue used by standard PTPs(Andersen et al. 2001), these results suggest EYA is the founding
member of a new class of non-thiol-based PTPs.
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We have used the genetically tractable Drosophila system to investigate the physiological
relevance of EYA's putative PTP activity. For these experiments, site-directed mutagenesis was
used to target the five HAD active site residues in Drosophila EYA (Figure 4-1c). Five single
and four double mutant combinations were generated and will be referred to collectively as the
EYAHAD mutants. These EYAHAD mutants were first tested in transfected Drosophila S2 cultured
cells where immunostaining and western blotting analyses revealed no apparent changes in
subcellular localization (data not shown) or expression levels (Supplementary Figure 4-S2a)
WT
relative to EYAw .
EYA, like most other RD genes, induces formation of eye tissue outside the normal eye
field when ectopically expressed(Bonini et al. 1997; Treisman 1999; Wawersik and Maas 2000;
Hsiao et al. 2001). Scoring the percentage of flies exhibiting ectopic eye formation provides a
sensitive measurement of EYA activity(Hsiao et al. 2001). To determine whether the HAD
active site mutants compromise EYA's ectopic eye induction potential, we generated transgenic
lines carrying full-length EYAHAD mutant expression constructs. All EYAHAD mutants exhibit
strikingly reduced ectopic eye induction relative to EYAWT (Figure 4-3a). Protein expression
levels from the EYAHAD transgenes were comparable to those from EYAWT lines
(Supplementary Figure 4-S2b), indicating that the reduction in ectopic eye inducing potential
reflects a change in protein activity rather than reduced expression. Comparable reductions in
EYA activity were also observed with EYAHAD transgenes in which two of the five HAD active
site residues were mutated simultaneously (data not shown).
Because the HAD motif active site mutants compromise EYA's ability to induce ectopic
eye formation, we asked whether an intact HAD motif is required for normal EYA function
during eye development. We compared the ability of EYAwT versus EYAHAD transgenes to
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Figure 4-3
EYAHAD mutants exhibit severely reduced activity relative to EYAWT in ectopic eye induction
and genetic rescue assays.
a, The frequency of ectopic eye induction associated with expression of EYA transgenes was
calculated from multiple independent transgenic lines: EYAw T, 2465 flies from 8 lines(Hsiao et
al. 2001); EYAD 49 3N , 1502 flies from 5 lines; EYA 67 A, 955 flies from 3 lines; EYAK699Q, 953
flies from 3 lines; EYAD7 2 4 N, 265 flies from a single line; EYAE72 8Q - 1239 flies from 4 lines.
b, The percentage of eyes from flies of the genotype eya2; UAS-EYA/dpp-GAL4 exhibiting rescue
of the eya2 eyeless" phenotype (black bars) and average size of the rescued tissue relative to a
wild type eye (grey bars) is plotted. Data derives from the following lines: EYAWT, 155 flies
D493N S670Afrom two independent lines; EYAD 4 9 3N , 124 flies from a single line; EYA 67 A, 281 flies from a
single line; EYAK699Q, 176 flies from a single line; EYAD493N+S67 0A , 209 flies from two
independent lines; EYAD 49 3 N+D72 4N, 151 flies from two independent lines.
1118 2 2 Ec-f, Scanning electron micrographs of adult eyes. c, wh 8. d, eya2. e, eya2; UAS-EYAWT/dpp-
GAL. f, eya2;UAS-EYAA/dpp-GAL, arrow points to a small patch of rescued eye tissue.GAL4. f, eya ,;UAS-EYA"/dpp-GAL4, arro  points to a s all patch of rescued eye tissue.
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complement the eye-specific loss-of-function eya2 allele. eya2 homozygous mutant flies exhibit a
completely penetrant "eyeless" phenotype, in which the entire eye is missing (Figure 4-3c, d).
For these experiments we define "rescue" as the ability of a given transgene to produce
recognizable eye tissue within the normal eye field of an adult fly. We also estimate the size of
the rescued eye tissue relative to that of a wild type eye in order to compare the extent of rescue.
Expression of EYAWT transgenes rescues the eya2 "eyeless" phenotype with complete
penetrance (Figure 4-3b, e) in both eyes of each individual fly (data not shown). In striking
contrast, all EYAHAD mutant transgenes exhibit a significantly reduced frequency and extent of
rescue, with rescue usually occurring in only one of the two eye fields of an individual (Figure
4-3b, f). For all EYAHAD transgenes tested, even in cases where rescue efficiency is only two to
three fold lower than that of EYA w r , the size of the rescued eye tissue is always significantly (5-
10 fold) reduced relative to that obtained with EYAWT lines (Figure 4-3b, e, f). Western blot
analyses of eye imaginal discs again ruled out the possibility that reduced protein expression
might be responsible for this result (Supplementary Figure 4-S2c). In combination with the
ectopic eye induction assay data, the results of these rescue experiments argue strongly that
EYA's activity as a putative HAD family phosphatase is required to promote normal eye
development in Drosophila.
Because the region of the ED that binds to the RD gene network protein SO(Pignoni et al.
1997; Bui et al. 2000) partially overlaps with Motif 1 of the HAD domain (Supplementary
Figure 4-S lb), we checked whether the EYAHAD missense mutations compromise EYA's ability
to interact productively with SO. EYA and SO interact to form a potent transcriptional activator
required for eye specification, in which SO contributes the DNA binding domain and EYA
provides the transactivation potential (Pignoni et al. 1997; Ikeda et al. 2002; Silver et al. 2003).
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Using a transcription assay in Drosophila S2 cultured cells(Silver et al. 2003), we find that the
ability of EYAHAD mutant proteins to synergize with SO to activate transcription of a reporter
gene is comparable to that of EYAw r (Figure 4-4 and Supplementary Figure 4-S3). Although we
cannot rule out the formal possibility that in vivo the EYAHAD mutations disrupt interactions with
other proteins rather than blocking phosphatase activity, the finding that mutational disruption of
the HAD motif active site does not abrogate EYA's ability to function as a transcriptional
coactivator in conjunction with SO leads us to propose that EYA proteins have two essential
functions: a previously described role as a transcription factor and a novel role as a protein
tyrosine phosphatase.
To investigate further EYA's intrinsic PTP capability with respect to physiologically
relevant substrate candidates, we exploited our finding that EYA can be tyrosine phosphorylated
in Drosophila S2 cells (Figure 4-5a; see Supplementary Information for discussion) by affinity
purifying full-length EYA from these cells and using it as a protein substrate in an in vitro
phosphatase reaction. Because the phosphotyrosine signal associated with the EYAHAD mutant
proteins was consistently elevated relative to EYAWT (Figure 4-5a; see Supplementary
Information for discussion), the EYAHAD protein was used as the substrate. We find that
incubation of EYAHAD protein with recombinant murine GST-ED fusion protein strongly reduces
the phosphotyrosine signal (Figure 4-Sb). HAD active site mutants that exhibit impaired activity
both in vitro and in vivo (Figures 4-2 and 4-3) also have severely reduced activity in this assay
(Figure 4-Sb). These results demonstrate that EYA has PTP capability with respect to a full-
length endogenous protein substrate and that such activity depends on an intact HAD motif.
Although we do not yet understand the physiological relevance of tyrosine phosphorylation and
dephosphorylation of EYA, the results of these experiments (Figure 4-5), together with our
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previous demonstration that EYA is able to self-associate(Silver et al. 2003), suggest that EYA
may act autocatalytically to dephosphorylate itself.
In conclusion, we propose that EYA is both the founding member of a novel class of non-
thiol based PTPs and to our knowledge, the first example of a transcription factor with intrinsic
phosphatase activity. Further work will be required to understand how tyrosine phosphorylation
and dephosphorylation regulates EYA function in vivo, and what substrates, potentially
including EYA itself, may be regulated by its PTP activity. Elucidation of the biochemical
regulatory mechanisms that coordinate EYA's dual functions as transactivator and phosphatase
during eye specification will provide new insights into the function of the RD gene network, and
more generally a new paradigm for transcriptional regulatory strategies. Although preliminary
analyses have not identified other HAD-motif containing proteins that are annotated as
transcriptional regulators (R. R. L. and I. R., unpublished observation), it seems likely that dual
function mechanisms analogous to that we propose for EYA may prove to be a general strategy
for fine-tuning transcriptional output, particularly in highly regulated developmental systems.
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Figure 4-4
EYAH A D mutations do not disrupt EYA's role as a transcriptional coactivator in conjunction with
Sine oculis. The Drosophila cell culture based transcription assays were performed as recently
described(Silver et al. 2003). Lanes: 1, Are-Luciferase; 2, WT; 3, D493N; 3, S670A; 4, K699Q;
5, D724N; 5, E728Q; 6, D493N + S670A; 7, D493N + K699Q; D493N + D724N; D493N +
E728Q. Are-Luciferase is a multimer of SIX family binding sites. See Supplementary Figure S3
for further details.
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Figure 4-5
EYA has protein tyrosine phosphatase capability.
Top panels show immunoblots probed with anti-phosphotyrosine (anti-P-Y); bottom panels
show immunoblots of the same samples probed with anti-Flag to detect EYA (anti-EYA).
a, Lanes: 1-2, independent transfections of EYAWT; 3, EYAD4 9 3N + S670A; 4, EYAD49 3N + K699Q; 5,
EYA[D 49 3 N + D724N; 6 EYAD 4 9 3 N + E728Q Fold increase in P-Y levels for the EYA mutants
relative to an average of the P-Y signal in the two EYAW T lanes, and corrected relative to the
strength of the anti-EYA signal, is indicated underneath the anti-P-Y blot.
b, Dephosphorylation of Drosophila EYA by recombinant GST-ED. Full length tyrosine
phosphorylated Drosophila EYA D493N + D724N (all lanes) was immunoprecipitated and incubated
with recombinant mouse GST-ED, either wild type (WT) or HAD mutant variants (Lanes: 1-2,
control; 3-4, WT; 5, D246N, 6, T420A; 7, K449Q; 8, D474N; 9, E478Q). The percentage of anti-
P-Y signal on EYA D 4 9 3 N + D724N relative to controls and corrected for relative protein levels is
indicated. Numbers shown are an average from two independent experiments for each GST-ED
tested; results from only one of the two experiments are shown for the GST-ED HAD mutants.
Samples were run on the same gel to allow quantitative comparisons.
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Methods
Bioinformatics
For a description of the computational analyses, see Supplementary Information.
Phosphatase assays
Phosphatase assays were performed using GST-ED fusion proteins (purification protocol
described in Supplementary Information). For enzyme kinetics with the synthetic substrate p-
Nitrophenyl Phosphate (pNPP, Sigma), assays were done in triplicate with six substrate
concentrations over six timepoints. 80ul reactions performed in microfuge tubes at 30°C in
200mM PIPES pH 7.0, 5mM EDTA and 10mM MgCl2 were quenched by addition of 40ul of
10M NaOH. PNP anion was detected at 405 nm (extinction coefficient OM= 1.78 x 104 /cm M)
using a Tecan GENios plate reader. Reactions were normalized to buffer alone controls and the
results analyzed by Lineweaver-Burk plot using Microsoft Excel. Synthetic peptide substrates
tested were: I (pY)GEF and TSTGPE (pY)EPGENL (Calbiochem); END (pY)INASL, DADE
(pY)LIPQQG and RRA (pT)VA (Promega). 50ul reactions were performed at 25°C in 200mM
HEPES pH7.0, 10mM MgCl2, 5mM EDTA and quenched with 50gl of Molybdate Dye Solution
(Promega). Malachite Green/Ammonium Molybdate-phosphate complex was detected at 595
nrim and converted to moles of free phosphate using a phosphate standard curve. Assays with I
(pY)GEF were carried out for five substrate concentrations over five timepoints and the results
were analyzed as described for pNPP.
Phosphatase Inhibitor Cocktail Sets I and Set II (Calbiochem; see Supplementary
Information for details) were used at 1:50 in pNPP phosphatase assays. Sodium Orthovanadate
was used at 4mM final concentration in pNPP phosphatase assays.
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Amino terminally flag epitope tagged EYA constructs were subcloned into the copper
inducible metallothionein promoter vector. 5 gtg of DNA for each construct was transfected into
S2 cells as previously described(Tootle et al. 2003). Following published protocols(Imbert et al.
1994; Cohen et al. 1997; Huyer et al. 1997; Ruff et al. 1997; Scanga et al. 2000), cells were
treated with 100gM NaVO 3, 200jM H 20 2 for 15 minutes prior to lysis in 100mM NaCl, 50mM
Tris, pH 7.5, 2mM EDTA, 2mM EGTA, 1% NP-40, lmM Na3VO4 , and one mini-complete
protease inhibitor tablet (Roche) per 10 ml. All subsequent solutions include lmM Na3VO4.
Clarified lysates were incubated with 25gl of anti-flag M2 agarose affinity gel (Sigma) for 1.5
hours at 4°C. Beads were washed twice in lysis buffer and twice in 10mM Tris, pH 7.5, 150mM
NaCl, resuspended in 30gl of 2x SDS sample buffer, boiled and 10gl were loaded per lane.
Westerns were performed as previously described(O'Neill et al. 1994) except that blocking and
antibody incubations were performed in 1% Casein According to Hammarsten (EM Science).
Antibodies: guinea pig anti-Eya 1: 16,000, rabbit anti-phosphotyrosine 1:400 (.21 mg/ml,
Upstate); HRP-conjugated goat anti-guinea pig and anti-rabbit 1:5000 (Jackson
ImmunoResearch). Determination of fold increase in phospho-tyrosine signal relative to EYA
protein amounts was performed using NIH Image software; samples analyzed in this way were
always run together on the same gel.
To obtain sufficient tyrosine phosphorylated Drosophila EYA to use as a substrate in the
in vitro phosphatase assay, a stable cell line expressing flag-tagged EyaD 4 9 3 N + D724N was
generated. 500gl of cells were immunoprecipitated for each reaction as described above, except
the mM Na3VO4 was omitted from the wash buffer. The washed immunoprecipitates were
incubated in phosphatase assay reaction buffer (as described above but without pNPP), either
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with GST agarose or with 100gg GST-ED proteins for 1 hour at 30°C, processed for western
blotting and analyzed as described above.
Molecular Biology and Genetics
Site-directed mutagenesis, subcloning, generation of transgenics, crosses, ectopic eye
scoring, calculation of % ectopic eye induction and scanning electron microscopy were
performed as previously described(Hsiao et al. 2001; Tootle et al. 2003). Fly crosses were at
250C with the exception of the genetic rescue assays which were performed at 20°C.
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Supplementary Information
Discussion
We have found that EYA is a novel protein tyrosine phosphatase member of the HAD
superfamily. Specific point mutations shown previously to compromise the HAD active site in
other superfamily members severely reduce EYA's phosphatase activity. The in vitro assays, one
using pNPP or a tyrosyl phosphorylated peptide as artificial substrates (Figure4-2) and the other
using tyrosine phosphorylated Drosophila EYA protein as a physiologically relevant substrate
(Figure 4-5), and the in vivo assays, ectopic eye induction and genetic rescue (Figure 4-3),
consistently reveal this trend. However there are subtle activity differences between the various
mutants tested, as well as slight variations between the same mutants tested in different assays.
The most notable example results from our analyses of the D493N mutant (D246N in
murine EYA3). This mutation alters the aspartic acid residue that serves as nucleophile and
forms a phospho-aspartate intermediate in the reaction(Ridder and Dijkstra 1999; Cho et al.
2001). Given its critical role in catalysis, the prediction is that a mutation in this residue should
severely compromise activity. In fact, in all the in vitro assays (Figure 4-2 and Figure 4-Sb) and
in the ectopic eye induction assays (Figure 4-3a), the activity of D246N is greatly compromised.
However in the genetic rescue experiment, although activity is significantly reduced relative to
EYAw'r , the residual activity is greater than that measured for any of the other HAD mutants
(Figure 4-3b). While the reason for this is unclear, it presumably reflects the complexity of
assaying function in the context of normal eye development, where both functions of EYA as a
phosphatase and as a transcriptional cofactor are required. Elucidation of the mechanisms
whereby EYA's dual functions as transcriptional coactivator and phosphatase are coordinated
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will be required to fully understand such subtle distinctions in activity between the different
HAD active site mutants in vivo and how these correlate with their relative activities in vitro.
A second example is the D724N mutant (D474N in murine EYA3), which unlike all the
other mutants tested and consistent with its previously characterized role in Mg++ binding rather
than substrate binding(Cho et al. 2001), does not increase the Km measured in the pNPP assay
(Figure 4-2). Activity in both the PTP and ectopic eye induction assays is comparable, although
perhaps slightly elevated, to that measured for the other HAD active site mutants. In general,
interpreting modest differences in activities between different mutants in the various assays must
be performed with caution because we do not yet understand the biochemical mechanisms that
coordinate and regulate EYA's dual functions as transcription factor and phosphatase.
The Drosophila EYAHAD protein used in the PTP assay (Figure 4-5b) was purified from a
stably transfected S2 cell line that had been artificially stimulated with pervanadate. Confirming
that EYA is tyrosine phosphorylated in the absence of pervanadate, we find that EYAHA D is
tyrosine phosphorylated in unstimulated cells, although the signal is reduced relative to that
observed in stimulated cells (Figure 4-S4a). We have been unable to immunoprecipitate
sufficient EYAWT protein from transient transfections to detect a signal in the absence of
pervanadate and efforts to generate a stable cell line have not yet been successful (Clark et al.
2002). Therefore, to facilitate detection of PTP activity in our assay (Figure 4-5b), we elected to
purify EYAH A D protein from pervanadate stimulated cells in order to increase the pool of
tyrosine phosphorylated protein substrate.
The most likely explanation as to why we require the use of pervanadate to detect
tyrosine phosphorylation of EYA in transiently transfected cells (Figure 4-5a) is that EYA has
autocatalytic activity and actively dephosphorylates itself. Drosophila S2 cells express
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significant levels of endogenous wild-type EYA. We have recently shown that EYA has the
ability to self-associate (Silver et al. 2003), leading us to postulate that endogenous EYA may
associate with the transfected EYA and dephosphorylate it. Addition of pervanadate presumably
greatly impairs, but does not totally knock out phosphatase activity resulting in a weak but
detectable signal for EYAWT (Figure 4-5a, Lanes 1 and 2). This interpretation is consistent with
our finding that addition of vanadate in the pNPP assay doubles the apparent Km, but does not
completely inactivate the enzyme (Figure 4-2a). EYAHAD mutants exhibit increased
phosphotyrosine signal in this assay (Figure 4-5a), likely reflecting their reduced activity as a
phosphatase (Figure 4-2). In the case of the stable cell lines expressing the catalytically inactive
EYA HAD mutants, in the absence of pervanadate, the endogenous EYA is sufficiently active to
dephosphorylate a significant portion, but not all, of the overexpressed EYAHAD mutant protein
(Figure 4-S4a). However, because these experiments were carried out in Drosophila cells rather
than in vitro, it is possible that rather than reflecting impairment of intrinsic PTP activity in the
EYAHAD mutants, the increased phosphotyrosine signal resulted from a second coprecipitating
PTP that interacts more strongly with EYA wT than with EYA HAD, or from the EYAHAD proteins
serving as better substrates for the relevant tyrosine kinase. Arguing against this interpretation,
we find that incubation with recombinant EYAWT fusion protein, but not EYAHAD fusion protein,
strongly reduces the phosphotyrosine signal associated with Drosophila EYAHAD (Figure 4-5b).
This suggests that EYA may serve as its own substrate, likely acting in trans to dephosphorylate
itself. Based on our genetic analyses indicating that EYA's phosphatase activity is required for
eye specification and development (Figure 4-3), we propose that EYA may autoactivate by
dephosphorylating itself on specific tyrosine residues.
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Methods
Bioinformatics
The phylogenetic tree of a number of different hydrolase family members (PFAM 00702.6) was
generated by the neighbor-joining method using ClustalX(Thompson et al. 1997). EYA protein
sequences from Drosophila (Dm, gi: 17737399), mouse (Mm, gi:6753794), human (Hs,
gi:3183005), zebrafish (Dr, gi:18858653), arabidopsis (At, gi:21593200) and nematode (Ce,
gi:3875091) were aligned with the Bacillus cereus phosphonoacetaldehyde hydrolase (Bc,
gi: 10835405) HAD protein using ClustalX (Thompson et al. 1997). For the structural modeling
analyses, Prospect Pro (Xu and Xu 2000) was used to thread the Drosophila EYA ED sequence
(DmEYA) against structures in the protein data bank. From these comparisons,
Phosphonoacetaldehyde hydrolase (PDB: 1FEZ) was selected as a suitable modeling template.
DmEYA and the template initially were aligned according to threading results and then modified
by anchoring several phosphonatase active site residues to their synonymous positions within
DmnEYA. The structural model of DmEYA was created with Modeler (Sali and Blundell 1993)
employing the alignment and using the coordinates of the Phosphonoacetaldehyde hydrolase
structure. The original template, FEZ, and the DmEYA model were aligned using CCP4
(Otwinowski 1993). Key active site positions within the DmEYA model were replaced with the
variants described in this study using the Builder module within InsightIl (Accelrys TM, 2001).
AMolecular Biology and Genetics
The cell culture based transcription assays were performed as recently described(Silver et al.
2003). For western blot analyses of protein expression levels, equivalent samples of either S2
cells, embryos or dissected eye-imaginal discs were lysed in SDS-sample buffer, separated by
SDS-PAGE and immunoblotted with GP anti-EYA antiserum diluted 1:10,000.
207
Protein Purification
GST-MmEYA3 ED (aa 237-510 of mouse EYA3) or GST-DmEYA ED (aa 438-760 of
I)rosophila EYA) fusion proteins were purified from BL21 E. coli cells grown to an OD6 0 0 of 1.0
and then induced with IPTG for 2.5 hours at 18°C. Cells were harvested by centrifugation,
resuspended in 50mM Tris buffer pH 8.0, lmM EDTA and 100mM NaCl plus protease inhibitor
cocktail (1 tablet per 50 mls, Roche) and lysed by three passes through a French Press at 1000
psi. Clarified lysates were rocked overnight at 4°C with glutathione-agarose beads. Beads were
washed five times with 50mM HEPES, 300mM NaCl, and left in a final 1:1 slurry. Protein
concentrations were estimated by Coomassie Blue staining of an SDS-PAGE gel run with a
dilution series of GST-ED and a BSA standard curve. Depending on the protein concentration,
appropriate amounts of beads were diluted for the phosphatase assays. To determine Km and
enzyme efficiency, GST-ED was eluted by rocking for 20 minutes at 4°C with 300mM reduced
glutathione in 50mM Tris pH 7.0, 150mM NaCl. For peptide assays, 10mM reduced glutathione
was used in the elutions. Protein concentrations were determined by Bradford Assay.
Phosphatase Inhibitor Cocktail Ingredients
Inhibitor Cocktail Set I (Calbiochem) contains p-Bromotetramisole (inhibits alkaline
phosphatase), Oxalate 2.5mM, Cantharidin 500uM (inhibits serine/threonine protein
phosphatase), Microcystin LR 500nM (inhibits serine/threonine protein phosphatase). Inhibitor
Cocktail Set II (Calbiochem) contains 200mM Imidazole (inhibits alkaline phosphatase), 100mM
Sodium Fluoride (inhibits acid phosphatase), 115 mM Sodium Molybdate (inhibits acid
phosphatase), 100mM Sodium Orthovanadate (inhibits protein tyrosine phosphatase and
alkaline phosphatase), and 400mM Sodium Tartrate Dihydrate (inhibits acid phosphatase).
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Figure 4-S1
Figure 4-S 
EYA is a member of the phosphatase subgroup of the HAD superfamily.
a, A HAD superfamily phylogenetic tree suggests EYA proteins are related to protein
phosphatases. Branches are labeled with the two letter species abbreviation and common protein
name. The EYA branch is highlighted in red.
b, Multiple Sequence Alignment reveals that the conserved EYA domain shares similarity with
the HAD hydrolase domain, particularly in those regions implicated in forming the active site
(PFAM 00702.6). Residues comprising Motifs 1-3 of the HAD domain are boxed. Labeled
arrows designate the positions of variant residues used in this study or identified in Drosophila
and human EYA mutations. Site-directed mutations generated in this study are shown in red.
Additional variants associated with specific Drosophila eya alleles(Bui et al. 2000) or derived
from human patients suffering from the EYA1-specific branchio-oto-renal syndrome (Azuma et
al. 2000) are shown in black, with the human mutations prefaced with the letter "h". While none
of these variants overlap with the five residues focused on in this study, one, the Drosophila
G723E mutation, affects a conserved glycine residue in Motif 3 of the HAD domain. The
putative Sine oculis binding site(Pignoni et al. 1997; Bui et al. 2000) is denoted with a solid
black line.
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Figure 4-S2
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Figure 4-S2
HAD active site mutations do not result in appreciable changes in protein levels relative to wild
type EYA.
a, Western blot of transfected S2 cells showing comparable expression of EYAHAD mutants
WT
relative to EYA . Equivalent samples from pools of stably transfected S2 cell lines expressing
EYANT and four different EYAHAD mutants. Lanes 1-5: EYAWT; EYAD 493N + S670A; EYAD493N +
K699Q; EAD493N + D724N EAD493N + E728QEYA D74; EYA +E78
b, Western blots of equivalent samples of embryos in which the EYA transgenes have been
expressed using a ubiquitin-GAL4 driver line reveal comparable expression levels in EYAHAD
lines relative to EYAWT . Each lane represents an independent transgenic line. Lanes: 1-4,
EYANVT; 5-9, EYAD493N; 10-13, EYA S670A; 14-17, EYAK6 9 9 Q; 18, EYAD724N; 19-22, EYAE 72 8Q;
23-24, EYAD4 9 3N + D724N
c, Western blots of equivalent samples of eye imaginal discs in which the EYA transgenes have
been expressed using a dpp-GAL4 driver line reveal comparable expression levels in EYAHAD
lines relative to EYAWT . Each lane represents an independent transgenic line used in the rescue
assay. EYA sometimes runs as a doublet (for example, lanes 1 and 2 and lanes 16-20 of panel
3c). Lanes: 1, EYAWT; 2, EYAD493N; 3, EYA S670A; 4, EYAK69 9 Q; 5&6, EYAD 49 3N + S6 7 0A ;7,
EYAD49 3 N + D724N
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Figure 4-S3
EYAHAD mutations do not disrupt EYA's role as a transcriptional coactivator in conjunction
with Sine oculis. EYAWT versus EYAHAD activity was tested at three different concentrations
of EYA DNA (1.25 ug, 2.5 ug and 5 ug) to confirm the linearity of response. A mutation (D223-
438; last sample in graph) that deletes the transactivation domain of EYA, but can still bind S04,
demonstrates that it is possible to block activity in this assay system. The reporter baseline level
in the absence of EYA and SO is shown (ARE-luciferase; first sample in graph).
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Figure 4-S4
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Figure 4-S4
Using tyrosine phosphorylated EYAHAD as a substrate in an in vitro phosphatase reaction.
a, Tyrosine phosphorylation of EYAHAD in the absence of pervanadate is reduced relative to
levels achieved in the presence of pervanadate. Quantitation was not performed because the
exposure time necessary to obtain a sufficiently strong signal in the (-) pervanadate lane placed
the signal in the (+) pervanadate range outside of the linear range of detection.
b, A titration curve of amounts of GST-ED necessary to achieve maximal activity in the PTP
assay was performed. Duplicate experiments are shown. Lanes: 1-2, lug, set at 100%; 3-4, Sug;
5,6, 10ug; 7,8, 50ug. EYAD493N+D724N was used as the substrate as in Figure 4b.
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Chapter 5
Efforts to determine where and by whom EYA is tyrosine phosphorylated.
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Abstract
Eyes absent, EYA, functions as both a transcriptional coactivator in the Retinal
Determination Network, and as a protein tyrosine phosphatase. EYA is tyrosine phosphorylated
and can dephosphorylate itself. It is unclear how tyrosine phosphorylation regulates EYA's
activities. We find that EYA is likely to be phosphorylated within the EYA domain (ED), and a
putative site of phosphorylation is tyrosine 719. Attempts to identify the kinase(s) responsible
for this phosphorylation have thus far been unsuccessful. This work, along with future efforts
discussed in Chapter 6, should clarify where EYA is tyrosine phosphorylated and the effects of
such phosphorylation.
Introduction
Eyes absent, EYA, is an evolutionarily conserved transcriptional coactivator in the
Retinal Determination (RD) Network, which encompasses a signaling cascade of transcriptional
regulators best known for their necessity during Drosophila eye development. Eye specific
mutations in RD network members exhibit eyeless phenotypes, while overexpression either alone
or in conjunction with other RD network members results in ectopic eye tissue. While one
outcome of this signaling cascade is eye formation, known null mutations within this network
exhibit lethality, indicating further roles during development.
The RD Network functions in a hierarchical manner in that Twin on Eyeless (TOY) turns
on the expression of Eyeless (EY), which in turn leads to expression of EYA and Sine oculis
(SO), who turn on Dachshund (DAC) (Chen et al. 1997; Pignoni et al. 1997; Czerny et al. 1999;
Hauck et al. 1999). TOY and EY are Pax6 homologs and contain both Paired and Homeo-
Domain DNA binding domains (Quiring et al. 1994). SO is a homeodomain transcription factor
(Cheyette et al. 1994; Serikaku and O'Tousa 1994). EYA and DAC are more novel nuclear
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factors. It has recently been suggested that DAC possesses intrinsic DNA binding ability (Kim
et al. 2002), while EYA is known to function as a transcriptional coactivator with SO (Ohto et al.
1999; Silver et al. 2003).
Structure-function analysis has yielded insight into how the various domains within EYA
function in relation to its transcriptional activity (Figure 5-1). There are two evolutionarily
conserved domains in EYA, EYA Domain 2 (ED2) and EYA Domain (ED) (Xu et al. 1997;
Zimmerman et al. 1997). The ED2 is a tyrosine rich domain contained within a larger proline,
serine, threonine (PST) rich region. The PST region is necessary for EYA's transcriptional
activity with SO (Silver et al. 2003). There are two MAPK phosphorylation sites, shown to
positively regulate EYA, at the carboxy-terminus of the PST region (Hsiao et al. 2001). The ED
has been shown to bind to SO and DAC (Pignoni et al. 1997); in addition the ED possesses
homology to a broad family of enzymes called haloacid dehalogenases (HADs) (Li et al. 2003;
Rayapureddi et al. 2003; Tootle et al. 2003).
Homology between the ED and HADs suggested that EYA, in addition to acting as a
transcriptional coactivator, could be functioning as a phosphatase. It has been shown, Chapter 4,
that EYA is a protein tyrosine phosphatase (Rayapureddi et al. 2003; Tootle et al. 2003), while
others have observed that EYA is a dual specific phosphatase (Li et al. 2003). Phosphatase
activity is necessary for EYA function, as phosphatase mutants cannot rescue eya mutant
phenotypes or induce ectopic Eyes at a comparable level to wild-type EYA (Tootle et al. 2003).
In addition EYA is tyrosine phosphorylated by an unknown kinase(s) in Drosophila insect
cultured cells (see Figure 4-5) (Tootle et al. 2003). In vitro assays have shown that the
bacterially purified EYA protein tyrosine phosphatase (PTP) domain can dephosphorylate EYA
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(Tootle et al. 2003), suggesting that EYA may regulate itself, and its two activities, by
dephosphorylation of tyrosine residues.
Tyrosine phosphorylation of nuclear factors is a poorly studied area (Chapter 1).
Therefore, it is of interest both to understand the general mechanisms of regulating nuclear
proteins by tyrosine phosphorylation and to specifically understand how EYA and its two
functions are regulated by tyrosine phosphorylation. To begin to understand how tyrosine
phosphorylation regulates EYA, I have attempted to determine where within the protein EYA is
tyrosine phosphorylated, and which kinase/s is/are responsible for this phosphorylation.
Materials and Methods
Subcloning
The deletion construct EYADD+AED2 and EYAD/D+APST were made exactly as described
DID WTpreviously, except EYA / was used as the starting construct instead of EYA T.
DIDED D/D construct was made by PCR amplifying from pRMHa3 Eya , using the
forward primer, EYA 1309-Sma (5' TGACCCGGGGTGGGTACCGCCGGCTCTGGG 3'),
which contains a SmaI site at its 5' end and the reverse primer, EYA A2676Stop-Sal (5'
TI'AAT'GTCGACTCATAAGAAGCCCATGTCGAGGGC 3'), which contains a SalI site at its 5'
end. The PCR product was first digested with SmaI and then with SalI. The digested product
was ligated into pBS flag that was SmaI/SalI digested. The resulting pBS flag-ED D/D was
digested with Sac and SalI, and subsequently ligated into pRMHa3 similarly digested.
EYAAED construct was made by ligating the SmaI and SalI digested pRMHa3 Gal4BDB
WTEYA N term and the similarly digested pRMHa3 flag-EYA T .
Protein biochemistry
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Transient transfections, 5 tg/construct, were performed as previously described in
Chapter 2 [Tootle, 2003 #622]. Immunoprecipitation and western blot analyses were performed
as described in Chapter 4 [Tootle, 2003 #883], using 3ml of transfected
cells/immunoprecipitation. Upstate rabbit anti-phosphotyrosine was used 1:400, Sigma rabbit
anti-flag was used 1:5000, and Jackson Laboratories HRP conjugated goat anti-rabbit was used
]L :5000.
Peptide analysis
Peptides were synthesized by Tuft University Core Facility, with an acetyl group at it
amino-terminus and a -NH2 group at its carboxy-terminus. Stock solutions of peptides were
made with phosphate free water. Initial phosphatase assays were performed in duplicate at two
substrate concentrations (50 and 100 iM) for one time point (10 min). Free phosphate was
measured as previously described (Chapter 4) [Tootle, 2003 #883] except the dye, BIOMOL
Green, was from Biomol Research Laboratories Inc. and used according to the product
specifications. Kinetic analysis and calculations were performed as previously describe in
Chapter 4 [Tootle, 2003 #883], using five substrate concentrations and five timepoints.
RNAi screen
RNAi primers were designed as previously described in Chapter 2 [Tootle, 2003 #622].
See primer list at end of chapter for RNAi primers used.
Approximately 1 x 106 cells of a stable S2 cell line expressing EYAD/D under the control
of the metallothionine promoter was suspended in 1 ml of serum free Gibco Schneider's Insect
Media, and 40 jig of dsRNA per kinase for 1.5 hrs. 2 ml of media +12.5% serum were then
added, and EYAD/D expression was induced on Day 4, approximately 76 hours after the dsRNA
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was added. Assays were performed on Day 5, approximately 94 hours after the dsRNA was
added.
1 ml of cells was used for phosphotyrosine western blot analysis, see above. The
remaining 2 ml of cells were used for RNA isolation, following the RNA STAT-60 protocol
(TEL-TEST "B" Inc.). The RNA pellet was resuspended in 30 gl of DEPC H2 0. 15 l was
DNase treated (15 gl DEPC H20, 4 gl DNase, 5 gl DNase Buffer) for 2 hrs at 37°c, and then 1
Stl 25 mM EDTA was added and it was heat inactivated for 10 minutes at 70°C. 2 g of RNA
were used per reverse transcriptase (RT) reaction. The RNA, dNTPs, primers and DEPC H20
were incubated for 5 minutes at 70°C (concentrations according to kit used, either Ambion
RetroScript or Promega Reverse Transcription System). The mixture was cooled on ice for 5
minutes, and then the following were added: RT PCR buffer, RNase Inhibitor, and reverse
transcriptase. The total reaction volume was 20 l. The reaction was performed according to the
kit directions, except that reactions were allowed to proceed for 1 hour. Control reactions
without the reverse transcriptase were performed to verify that the DNase treatment was
complete.
Specific PCR reactions using 3 al of the RT reaction were performed using the RNAi
primers for the kinase, and control primers for Rps 17, a ribosomal protein (Forward- 5'
CGAACCAAGAC GGTGAAGAAG 3', reverse- 5' CCTGCAACTTG ATGGAGATACC).
Conditions vary per primer set. PCR reactions were analyzed by running products on 3% gels.
Knock-down of multiple kinases at once was performed in the same manner except that 3
ml of cells were used for western analysis and 3 ml were used for RT analysis.
Results
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The ED of EYA is likely to by tyrosine phosphorylated
It has been shown that EYA is tyrosine phosphorylated in Drosophila insect cultured
cells. There are thirty-nine tyrosines within the EYA protein, eleven of these are conserved
among all mouse and human homologs, while an additional seven are conserved among some
members, three of which are tyrosine to phenylalanine substitutions in the non-conserved
members (Figure 5-2). All of the conserved tyrosine residues are within domains of EYA that
have been shown to play roles in both transcription and protein-protein interactions (Figure 5-1).
The two most conserved domains of EYA, the ED and the ED2 contain eight and five conserved
tyrosines respectively. The ED has been shown to have roles in protein-protein interactions, as it
mediates binding to SO and DAC, in addition to possessing protein phosphatase activity. The
ED2 resides within the PST region that has been shown to be required for transcriptional
activation.
Deletion analysis was performed to determine which region of the EYA protein is
tyrosine phosphorylated. Previous studies had shown that protein tyrosine phosphatase catalytic
mutants exhibit a higher level of tyrosine phosphorylation than wild-type, presumably due to
their significantly reduced phosphatase activity (Figure 4-5A). Therefore the analysis was
performed using the mutant exhibiting the highest level of tyrosine phosphorylation, EYAD/D.
The various deletion constructs (Figure 5-3A) were transiently expressed in Drosophila insect
culture cells, immunoprecipitated, and the level of tyrosine phosphorylation was analyzed by
anti-phosphotyrosine western blots. The results definitively show that EYAD/D+AED2 is tyrosine
phosphorylated (Figure 5-3B lane 2, and 5C lanes 5-6), while EYA4ED and ED only+D/D are not
phosphorylated (Figure 5-3C lanes 9-10 and 7-8, respectively). A background band of the same
size complicates the analysis of EYAD/D+aPST. Initial experiments clearly indicate that
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ClustaiX alignment of Drosophila, mouse, and human EYA proteins. Conserved
tyrosines are boxed in red. Structurally conserved, meaning Y/F, are boxed in
green, while non-conserved tyrosines are boxed in blue.
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Figure 5-3
EYA is tyrosine phosphorylated within its ED. A) Schematic of the deletion constructs
used to determine where EYA is tyrosine phosphorylated. B and C Western blot analysis, with
the top row showing the level of tyrosine phosphorylation (Upstate Rabbit anti-phosphotyrosine
1L:400) and the bottom showing the protein expression level (Sigma Rabbit anti-flag 1:5000). B)
Lane 1 is EYA D/D Lane 2 is EYA D+aED2, Lane 3 is EYA D/D+PST All three EYA constructs are
tyrosine phosphorylated. C) Lane 1-2 EYAD/D, Lane 3-4 EYAD/D+APST, Lane 5-6 EYAD/D+AED2,
Limane 7-8 ED D/D, Lane 9-10 EYA AED. As before, B, EYA DD, EYAD/D+AED2, and EYAD/D+' PST
are tyrosine phosphorylated, although the level of tyrosine phosphorylation of EYAD/D+APST
appears reduced (see text for discussion). Neither EYAAED or the ED D/D are tyrosine
phosphorylated.
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EYAD / D + P s T is tyrosine phosphorylated (Figure 5-3B lane 3), although possibly to a lesser
extent, while in later experiments it is difficult to determine (Figure 5-3C lanes 3-4). The PST
domain contains two completely and three partially conserved tyrosines outside of the ED2. All
constructs tested expressed appropriately sized proteins (Figure 5-3B,C, anti-flag).
These data suggest that EYA is likely to be tyrosine phosphorylated with the ED. While
the lack of phosphorylation of ED only+D/D appears to disagree with this, it could be due to
severe alterations in protein structure resulting in destabilization of the protein, as double the
amount of expression plasmid transfected was required to obtain similar levels of protein
expression (data not shown) and in vivo analysis of ED alone constructs reveal they are non-
functional (I. Rebay, personal communication).
One other caveat to the above deletion analysis is that the subcellular localization of these
constructs could affect tyrosine phosphorylation even if the normally phosphorylated tyrosine
residues are retained. Analysis of the localization of the deletion constructs revealed that like
[)/D D/D+AED2. D/+AP5T AEDEYA /D, EYA D+ ED2 is strictly nuclear (Figure 5-4A,B), while EYAD/D + P T, EYA ED, and ED
only+D/D are both nuclear and cytoplasmic (Figure 5-4C-E). Thus, all of the constructs
exhibiting no or reduced tyrosine phosphorylation have altered subcellular localizations.
However, a significant portion of all the deletion constructs localize properly to the nucleus,
suggesting that some tyrosine phosphorylation should be able to occur. This altered subcellular
localization might be the reason for reduced phosphotyrosine signal of EYA D/D+APST, while it
remains possible that this reduced signal is due to deletion of some of the tyrosines which are
phosphorylated. As EYA a ED localizes to the nucleus but it is not tyrosine phosphorylated, it
seems likely that EYA is indeed tyrosine phosphorylated within the ED.
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Figure 5-4
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Figure 5-4
Like EYA[ /D , EYAD/D+AED2 is strictly nuclear, while the other deletion constructs are
nuclear and cytoplasmic. The top row is EYA localization by anti-flag (1: 10000;
CY3 secondary 1:2000), and bottom row is DAPI (1:10000) overlayed on top of the
anti-flag signal. (A, A') EYADD. (B, B') EYA DD+ED2 . (C, C') EYAD/D+ PsT (D,
D') EYAAED. (E, E') ED D/D. (A-B') EYAD'D and EYA DD+±D2 are strictly nuclear.
(C-E') EYAD /D+APST, EYAAED, and ED D/D are nuclear and cytoplasmic.
EYAAED EDDD
MmnEYA3 is tyrosine phosphorylated
There are eighteen tyrosines that are at least partially conserved among the mouse and
human homologs, specifically eight out of ten tyrosines within the ED of EYA are conserved.
To verify that the phosphorylated tyrosine(s) is/are likely to be conserved, Murine EYA3
(MmEYA3) was expressed in Drosophila S2 insect cultured cells and analyzed by
phosphotyrosine western blot analysis. Indeed MmEYA3 is tyrosine phosphorylated (Figure 5-
5A) and thus it is likely that a conserved tyrosine(s) is phosphorylated. Tyrosine
phosphorylation and dephosphorylation could be a conserved mechanism of regulating the
functions of EYA.
Determining which tyrosines are phosphorylated: Initial Phosphopeptide analysis
The sites of tyrosine phosphorylation within EYA are also likely to be sites of
dephosphorylation by EYA, as EYA can dephosphorylate itself (Chapter 4) (Tootle et al. 2003).
Therefore, we reasoned that a quick way to assess which tyrosine residues are likely to be
phosphorylated was to synthesize phosphotyrosine peptides and analyze which are the best
substrates for EYA by in vitro phosphatase assays.
We initially focused on tyrosines within the ED, as the above deletion analysis suggests
EYA is tyrosine phosphorylated within the ED. Three phosphopeptides were synthesized and
tested. Peptides and 3 are conserved tyrosines, while Peptide 2 is a nonconserved tyrosine
whose sequence resembles the known EYA substrate Src Substrate II (Figure 5-SB). Structural
modeling predicts that these three tyrosines are surface exposed, and thus could be targets of
phosphorylation (R. Latek, personal communication). An initial in vitro phosphatase trial assay
was performed using one substrate concentration. From this analysis it was apparent that Peptide
3 could serve as a substrate for GST-MmEYA3. Kinetics were then performed with Peptide 3,
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HETC ERIV
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KESC ERIM
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KES FERIM
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RKS9 ~ IG
RKV LLIG
RKA\ IVIG
KKV9 .VVIG
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Figure 5-5
Mouse EYA3 is tyrosine phosphorylated and Peptide 3 (Y719) is an excellent substrate
for GST-mEYA3. (A) Western blot analysis, with the top row showing the level of tyrosine
phosphorylation (Upstate Rabbit anti-phosphotyrosine 1:400) and the bottom showing the
protein expression level (Sigma Rabbit anti-flag 1:5000). MmEYA3 is tyrosine phosphorylated
in Drosophila cultured cells. (B) Alignment of the three Drosophila EYA phosphopeptides
synthesized with the corresponding mouse and human homolog sequences. (C) Graph of the Km
of Peptide 3 in comparison to the known Km with Src Substrate II phosphopeptide. Peptide 3
with a Km of 65 [tM is the best substrate for EYA identified thus far.
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revealing the Km=65RM (Figure 5-5C). The Km with Src Substrate II was 99 gM (Figure 4-2D)
(Tootle et al. 2003). Therefore, Peptide 3, a conserved tyrosine from the EYA Domain, is the
best substrate for EYA identified thus far.
Y719, the phosphotyrosine in Peptide 3, is an excellent candidate for a site of
phosphorylation within EYA. For discussion on how further peptide analysis, and subsequent
experiments can be utilized to determine where EYA is tyrosine phosphorylated see Chapter 6.
RNAi screen to determine the tyrosine kinase which phosphorylates EYA
EYA is tyrosine phosphorylated in Drosophila insect cultured cells. There are forty-one
tyrosine kinases in Drosophila, eighteen of which are non-membrane bound kinases. To
elucidate which kinase or kinases are responsible for tyrosine phosphorylating EYA an RNAi
screen was initiated utilizing a stable cell line expressing EYAD/D, a catalytically inactive mutant
exhibiting a high level of tyrosine phosphorylation. These cells are soaked in dsRNA to a
particular kinase, and then assayed by RT-PCR to verify knock-down of the kinase and anti-
phosphotyrosine western blot analysis to determine whether loss of the kinase reduces the level
of tyrosine phosphorylation of EYA (Figure 5-6).
During the first attempt at the screen cells were soaked in dsRNA to one kinase at a time,
four days were allowed for knock-down and then cells were assayed. No repeatable difference in
the level of tyrosine phosphorylation of EYA was seen (data not shown). However, RT-PCR
technical difficulties occurred early in the screening process, and it is likely that expression of
the majority of the kinases screened was not knocked-down. It is also possible that loss of one
kinase alone is not sufficient to reduce the tyrosine phosphorylation of EYA enough to visualize
the difference.
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Another caveat to the screen is that the cells were treated with pervanadate to increase the
level of tyrosine phosphorylation and there is some thought that such a treatment also stimulates
kinases, possibly leading to aberrant phosphorylation. By utilizing more cells per
immunoprecipitation it is possible to visualize a phosphotyrosine signal for EYA in the absence
of pervanadate (Figure 5-7).
The plan for the second attempt at the screen was to knock down multiple kinases at once
and to not treat the cells with pervanadate. To narrow the number of kinases to test, I first
determined which tyrosine kinases are expressed in Drosophila insect cultured cells via RT-
PCR. I found that only twenty-two of the forty-one kinases are definitely expressed in the cells,
while an additional five may be expressed (Table 5-1). At attempt was made to knock-down the
expression of four kinases at once in the absence of pervanadate treatment, while extending the
incubation time. However, the RNAi was not successful as all the kinases were still expressed.
The experiment was useful in that it showed that the phosphotyrosine signal of EYA in the
absence of pervanadate is not robust enough to perform the screen with (data not shown).
Although this experimental approach has not been successful to date I believe that once the
technical difficulties are overcome it should elucidate the kinase(s) responsible. The steps that
should be taken to get the system working are as follows: 1) the stable cell line should be
maintained at a particular density, 2-3x106; 2) particular care should be taken to perform RNAi
on lx106 cells suspended in 1 ml of serum free media for 1.5 hrs; 3) the experiment should be
done as a time course, with the cells being grown for 3, 4, 5, and 6 days after addition of dsRNA
before analysis. Additionally, it is probably best to perform that screen by treating the cells with
pervanadate and knocking down the expression of one kinase at a time. By using a time course
one can make sure enough time is allowed for knock-down of a specific kinase, while lethality
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Figure 5-6
Schematic of the cultured cell based RNAi screen to identify the kinase(s)
responsible for the phosphorylation of EYA.
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Figure 5-7
EYA is tyrosine phosphorylated in Drosophila insect cultured cells in the absence of
pervanadate treatment. Western blot analysis, with the top row showing the level of
tyrosine phosphorylation (Upstate Rabbit anti-phosphotyrosine 1:400) and the
bottom showing the protein expression level (Sigma Rabbit anti-flag 1:5000).
Table 5-1
Non-membrane
Abl
Ack
CG 10673
CG3277
Csk
Doa
Fak56D
Fps85D
Hop
Mnb
Myti
Pr2
Shark
Slpr
Src42A
Src64B
Twf
WVee
Expressed
Yes
Yes
Yes
No
Yes
Yes
Yes
Maybe
Maybe
No
Yes
Yes
Yes
No
No
Maybe
Yes
Yes
Membrane associated
Alk
Btk29A
Btl
Cad96Ca
CG 10743
CG31640
Ddr
Dnt
Drl
Drl-2
Egfr
Eph
Htl
InR
Nrk
Otk
Pvr
Ret
Ror
Sev
Stam
Tie
Tor
Tyrosine kinases in Drosophila. Table shows whether kinases are expressed in Drosophila S2
cultured cells.
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Expressed
No
No
Yes
Maybe
No
Maybe
Maybe
Yes
No
No
Yes
Yes
No
Yes
Yes
Yes
Yes
No
Maybe
No
Yes
Maybe
No
due to knock-down can be avoided. Performing the screen in this manner should determine
which kinase(s) tyrosine phosphorylates/phosphorylate EYA.
Concluding remarks
The above experiments suggest that EYA is likely to be tyrosine phosphorylated within
the ED, and a putative site of phosphorylation is Y719. Further work in this area, as discussed in
Chapter 6, should definitively determine the tyrosine residues within EYA that are tyrosine
phosphorylated. From there we can begin to study how phosphorylation regulates the two
functions of EYA, as a transcriptional activator and as a protein tyrosine phosphatase.
Successful completion of the RNAi screen we have begun will determine which kinase or
kinases tyrosine phosphorylate EYA. This too, will be a jumping off point from which one can
begin to understand how tyrosine phosphorylation regulates EYA.
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RNAi primers for kinase screen
Gene:CG3277
CG3277 F
5' GAATTAATACGACTCACTATAGGGAGAagtgctggcttgaggagccc 3'
CG3277 REV
5' GAATTAATACGACTCACTATAGGGAGACGTTTAAATCTCACAGCACA 3'
Gene:Abl tyrosine kinase
Ab] F
5' GAATTAATACGACTCACTATAGGGAGAGTGATAGCCGCTCCGGTCAC 3'
Abl Rev
.'5' GAATTAATACGACTCACTATAGGGAGAGAGTTGCTCCTGATCATTTG 3'
Gene: C-ter Src kinase (CSK)
Csk F
5' GAATTAATACGACTCACTATAGGGAGAATGAACAGCCACGCGACTGC 3'
Csk Rev
5'' GAATTAATACGACTCACTATAGGGAGATGCTGGTTCGTCGTCTGTTG 3'
Gene: Hopscotch
Hop F
5' GAATTAATACGACTCACTATAGGGAGACTGTTGACAACTGAATGAAA 3'
Hop Rev
5' GAATTAATACGACTCACTATAGGGAGAGTTCAGTGTTTATGCGTGGT 3'
Gene: Minibrain
Mnb F
5' GAATTAATACGACTCACTATAGGGAGATGTACTCCTTGAATCCCCAC 3'
Mnb Rev
5' GAATTAATACGACTCACTATAGGGAGAGTCTTGGGGTCAAAGTCGAG 3'
Gene:Wee
Wee F
5' GAATTAATACGACTCACTATAGGGAGAGTGGTCAGCTGGACAGCTACA 3'
Wee Rev
5' GAATTAATACGACTCACTATAGGGAGAGTGTCCTGGGTGGGCAGTTT 3'
Gene: Src42a
Src42a F
5' GAATTAATACGACTCACTATAGGGAGAATGGGTAACTGCCTCACCAC 3'
Src42a Rev
5' GAATTAATACGACTCACTATAGGGAGACGTGTCATTCAGTATCTCCA 3'
Gene: FAK-like tyrosine kinase/PR2
Pr2 F
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5'GAATTAATACGACTCACTATAGGGAGAGGTGAAATCTATGACCAACT 3'
Pr2 Rev
5'GAATTAATACGACTCACTATAGGGAGAGTCTGAAGAGAGTCAGGACT 3'
Gene: Shark
Shark F
5'GAATTAATACGACTCACTATAGGGAGACGGTTCCGCCACAGCCCAAG
Shark Rev
:5'GAATTAATACGACTCACTATAGGGAGATGTTCCTGGGCACGTTGTAC
Gene: Fak56d
Fak56d F
5'GAATTAATACGACTCACTATAGGGAGATGCTCGGTGTAAAGCCTTTCC 3'
Fak56d Rev
5' GAATTAATACGACTCACTATAGGGAGACCGCGGGATTTTGTGCAATA 3'
Gene: Ack
Ack F
5'GAATTAATACGACTCACTATAGGGAGACGACACAATCGCCATTATCG 3'
Ack Rev
5' 'GAATTAATACGACTCACTATAGGGAGAAGGAACTATCGCCTGCTCCC 3'
Gene: Src64b
NewSrc64b For
5'GAATTAATACGACTCACTATAGGGAGACAATGTGCAGACGGTCGGTG 3'
NewSrc64b Rev
5' GAATTAATACGACTCACTATAGGGAGAGAGCTTTTCGTGGCGGTTTT 3'
Gene: Mytl
Mytl F
5' GAATTAATACGACTCACTATAGGGAGACGCGCCGTTTGGGGAAGAAT 3'
MytI Rev
5'GAATTAATACGACTCACTATAGGGAGAGCGGAAGATAGGGCGGAACA 3'
Gene: Slpr
Slpr F
5'GAATTAATACGACTCACTATAGGGAGACAACAACAGCATCTCCGCCAA 3'
Slpr Rev
5'GAATTAATACGACTCACTATAGGGAGATAACTGGTTGGGCAGTGCAA 3'
Gene: Fps85D
Fps85D F
5'GAATTAATACGACTCACTATAGGGAGAGCCTGGACAACAGCCACTAA 3'
Fps85D Rev
5'GAATTAATACGACTCACTATAGGGAGAGACAAACGTAGGGATTGCAT 3'
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Gene: Twinfilin- Twf
Twf F
15'GAATTAATACGACTCACTATAGGGAGACTATCGCCGGCACAAGCAGGAT 3'
Trwf Rev
5' GAATTAATACGACTCACTATAGGGAGACGCGAGCTCGTCGAGAAAAG 3'
Gene: Darkener of apricot -Doa
Doa F
'5' GAATTAATACGACTCACTATAGGGAGATGTGAGCTCTTCAGTCTGAT 3'
Doa Rev
5' GAATTAATACGACTCACTATAGGGAGAGCAACATGTGCTCGAAGTAT 3'
Gene: CG10673
CG10673 F
5'GAATTAATACGACTCACTATAGGGAGAGAAATCCTGAAACAAGGCGC
CG10673 Rev
5' GAATTAATACGACTCACTATAGGGAGAAGATCCACACCCTTGTCCTC
Gene: Eph
Eph F
5' GAATTAATACGACTCACTATAGGGAGACTTGTCATGCAAGGAAAC ATTTAG 3
Eph Rev
5'GAATTAATACGACTCACTATAGGGAGATGTAATTCGGCTCATAGCCA 3'
Gene: CG31640
CG31640 F
5'GAATTAATACGACTCACTATAGGGAGAATGTGCCGGAAGGTGGTTAC 3'
CG31640 Rev
5'GAATTAATACGACTCACTATAGGGAGAAAGTTGTAGGTCCTGGCGCG 3'
Gene: Ddr
[)dr F
5'GA.ATTAATACGACTCACTATAGGGAGAAGGACTATGCGGTGCCTCAC 3'
Ddr Rev
5'GAATTAATACGACTCACTATAGGGAGACGCTCCTCGTTAATGTCGGC 3'
Gene: Pvr
Pvr F
5'GAATTAATACGACTCACTATAGGGAGATTCTAACCAGAACGTACAAC
Pvr Rev
5'GAATTAATACGACTCACTATAGGGAGAATAGGAGCGTACTGTGCACT
Gene: Btk29a
Btk20a F
5' GAATTAATACGACTCACTATAGGGAGACCGCTTTCCGTGTGCTCATG 3'
Btk29a Rev
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5'GAATTAATACGACTCACTATAGGGAGATGTCAGTTGTTGCGCTTCGT 3'
Gene: Ror
Ror F
5'GAATTAATACGACTCACTATAGGGAGAGGATATGAACGCAAATTGCC 3'
Ror Rev
:5'GAATTAATACGACTCACTATAGGGAGACGTTGGCCACTCCTCTATAT 3'
Gene: Stam
Stam F
5' GAATTAATACGACTCACTATAGGGAGAAGTGCTGAAGAACTGGGCTG 3'
Stam Rev
5' GAATTAATACGACTCACTATAGGGAGACACATGAATGATCTCGCCGG 3'
Gene: Drl
D)rl F
5'GAATTAATACGACTCACTATAGGGAGAGACAGTGCGCACGAGGAGTA 3'
Drl Rev
5'GAATTAATACGACTCACTATAGGGAGAATATGGTGGGCAGTCTCTGG 3'
Gene: Dnt
I)nt F
5' GAATTAATACGACTCACTATAGGGAGAGAAGATCTGTCTTATGAATGAC 3'
D)nt Rev
5' GAATTAATACGACTCACTATAGGGAGAATAAACTCGTCCAAACGTTC 3'
Gene: Ret
NewRet For
5' GAATTAATACGACTCACTATAGGGAGATAGTGTTTCCCAGAGTTCTA 3'
NewRet Rev
5' GAATTAATACGACTCACTATAGGGAGAGTTTAGCTTATGGCGTAAAT 3'
Gene: Torso
Torso F
5'GAATTAATACGACTCACTATAGGGAGAATGCTTATTTTCTACGCGAAG 3'
Torso Rev
5'GAATTAATACGACTCACTATAGGGAGAACAGCATCCACCCGGATTAT 3'
Gene:Off track-Otk
Otk F
5'GAATTAATACGACTCACTATAGGGAGAGCTATGTCTACCAGTCCAGT 3'
Otk Rev
5'GAATTAATACGACTCACTATAGGGAGAATAATGCTGGCAAAGCTTAG 3'
Gene:Drl-2
Drl-2 F
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5' GAATTAATACGACTCACTATAGGGAGAATGGCCAGTCACGGGGAGAA 3'
Drl-2 Rev
5' GAATTAATACGACTCACTATAGGGAGATGGTGATGTGCAGCCCAAAC 3'
Gene: Nrk
Nrk F
5' GAATTAATACGACTCACTATAGGGAGAGTGGACCCCAATGCTGTCGA 3'
Nrk Rev
5' GAATTAATACGACTCACTATAGGGAGAACTTCTCCAGGCGTGCATTC 3'
Gene: Alk
Alk F
5' GAATTAATACGACTCACTATAGGGAGATGGTGGTGGTGCTGGCCA TCCTAT 3'
Alk Rev
5' GAATTAATACGACTCACTATAGGGAGAATCCGCAGATCCTAGGCCCTGA 3'
Gene: EGFR
EGFR F
5' GAATTAATACGACTCACTATAGGGAGAAGCACCTGGTCCTAGTCACA 3'
EGFR Rev
5' GAATTAATACGACTCACTATAGGGAGAACTCGTGATCGGAGCTCGTT 3'
Gene: Tie
Tie F
5' GAATTAATACGACTCACTATAGGGAGAATGTGTGTGTCGGTCTGTGC 3'
Tie Rev
5' GAATTAATACGACTCACTATAGGGAGAGGCTGAAAATTTCCGCTGAA 3'
Gene: CG10743
CG10743 F
5' GAATTAATACGACTCACTATAGGGAGAAACATTAATCAGAAGGCCTT 3'
CG10743 Rev
5' GAATTAATACGACTCACTATAGGGAGATTTCATTCTCACCGAACAAC 3'
Gene: Btl
Btl F
5' GAATTAATACGACTCACTATAGGGAGAGGCAAAAGTGCCGATCACGCTG 3'
Btl Rev
5' GAATTAATACGACTCACTATAGGGAGACGACTCTCATTCAGGGGCTG 3'
Gene: Htl
Htl F
5' GAATTAATACGACTCACTATAGGGAGATGGAGTTGGCGAGCCAGTCA 3'
Htl Rev
5' GAATTAATACGACTCACTATAGGGAGAGCCATTGCGATACCATGTGA 3'
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Gene: InR
InR F
5'GAATTAATACGACTCACTATAGGGAGAATGTTCAATATGCCACGGGG 3'
InR Rev
5'GAATTAATACGACTCACTATAGGGAGAAGCAGCGATTGCAATGTTCG 3'
Gene: Cad96Ca
Cad96Ca F
5' GAATTAATACGACTCACTATAGGGAGATATCCACCGGTGCCCCAGAA 3'
Cad96Ca Rev
5'GAATTAATACGACTCACTATAGGGAGATTAGCGTCCTGCTGATGGCG 3'
Gene: Sev
Sev F
5' GAATTAATACGACTCACTATAGGGAGAGTTTTGGCAACAAAATGTAGA CCAC 3'
Sev Rev
5'GAATTAATACGACTCACTATAGGGAGATTGGTCTTTGGAGACGGGTT
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Eyes absent, EYA, is one of a small but growing number of transcription factors
possessing enzymatic activity, functioning as both a transcriptional coactivator with Sine oculis
(SO) (Ohto et al. 1999; Silver et al. 2003) and a protein phosphatase (Figure 6-1) (Chapter 4) (Li
et al. 2003; Rayapureddi et al. 2003; Tootle et al. 2003). Both of EYA's activities are required
for Drosophila eye development, although the exact roles of and the interplay between these two
activities are unknown. As post-translation modifications are commonly used to regulate the
activities of both transcription factors and enzymes, such modifications may be used to
differentially regulate the two activities of EYA.
During eye development, EYA is positively regulated by MAPK-mediated
serine/threonine phosphorylation, as EYA's ability to induce ectopic eyes when overexpressed is
inhibited by either mutating the phosphoacceptor site to alanine or decreasing the amount of
MAPK, while mimicking phosphorylation by mutation to aspartic/glutamic acid or increasing the
amount of activated MAPK results in increased induction of ectopic eyes (Hsiao et al., 2001).
Serine/threonine phosphorylation of EYA also enhances EYA's ability to function as a
transcriptional coactivator with SO (Silver et al., 2003). This suggests that the role of
serine/threonine phosphorylation of EYA in the eye may be to regulate EYA's transcriptional
activity, although it does not rule out the possibility that other facets of EYA function could also
be modulated.
In addition to MAPK-mediated serine/threonine phosphorylation, EYA is tyrosine
phosphorylated in Drosophila cultured cells and can dephosphorylate itself on tyrosine residues
(Tootle et al., 2003). The sites and functional consequences of EYA's tyrosine phosphorylation
are likely to be conserved as Murine EYA3 (MmEYA3) is also tyrosine phosphorylated (Chapter
5). EYA phosphatase mutants, EYA HAD, exhibit increased levels of tyrosine phosphorylation,
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Figure 6-1
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Figure 6-1
Schematic representation of EYA's two known functions. EYA possess two functions,
one as a transcriptional coactivator, and one as a protein phosphatase.
and reduced ability to induce ectopic eyes or rescue the eyeless phenotype of the eya2 mutationt
(Tootle et al., 2003). The observed increase in tyrosine phosphorylation of EYAHAD mutants
may contribute to their loss of activity in vivo, indicating the tyrosine phosphorylation may
negatively regulate EYA. It is equally probable that EYAHAD phenotypes do not result directly
from increased tyrosine phosphorylation of EYA but rather are due to loss of dephosphorylation
of other substrates. Thus, it is unclear how tyrosine phosphorylation and dephosphorylation of
EYA are regulated or how such modifications regulate the two functions of EYA, as a
transcriptional coactivator and a protein phosphatase.
As a scientific community our understanding of tyrosine phosphorylation and
clephosphorylation of nuclear proteins is extremely limited. Analyses on EYA, how it is
regulated by tyrosine phosphorylation and how it regulates the tyrosine phosphorylation of other
transcriptional regulators, may yield insight into the roles which tyrosine phosphorylation and
dephosphorylation generally play in regulating transcription.
The first step toward understanding the roles of tyrosine phosphorylation in regulating the
two distinct functions of EYA is to determine the sites of phosphorylation. Figure 6-2A lists the
conserved tyrosines and the sequences surrounding them in Drosophila EYA (DmEYA), and the
corresponding sequences in MmEYA3. Utilizing the phosphorylation prediction program
NetPhos, only four of the conserved tyrosines are likely to be phosphorylated, scoring >0.5
(Figure 6-2B). Three of these four tyrosines, two of which are Peptides 1 and 3 from Chapter 5,
are within the ED, the domain predicted to be tyrosine phosphorylated by deletion analysis in
Chapter 5. Thus both deletion analysis (Chapter 5) and NetPhos precidtions indicate EYA is
likely to be tyrosine phosphorylated within the ED.
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Figure 6-2
A
I)DrnEYA-b
227 GSNLpYGCSS
265 DYYYpYNSMQ
2 84 YGIPpYAAAT
326 YSSPpYAGYN
329 PYAGpYNNIFG
3 45 YNEQpYGNYY
348 QYGNpYYSPA
349 YGNYpYS PAN
354 SPANpYSPYA
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Peptide 3
Conserved tyrosines between Drosophila and mammalian EYA homologs. A. List of the
phosphotyrosine peptides of conserved tyrosine in DmEYA and MmEYA3. B. Four of
conserved tyrosines between Drosophila and mammalian EYA homologs are predicted by
NetPhos to be phosphorylated. Scores 0.5 indicate a high probability of being phosphorylated.
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Figure 6-2
Intriguingly Peptide 3, which is the best substrate for EYA thus far, has the highest
NetPhos scores overall. One caveat to these analyses is that NetPhos predictions are founded on
a database of known phosphorylated sequences, and thus novel phosphorylation sequences
would not be predicted (Blom et al. 1999). As EYA is the defining member of a novel class of
protein phosphatases it is difficult to predict whether the sequences recognized by EYA will be
similar to known sites or identify new motifs.
As the sites of phosphorylation within EYA are also likely to be sites of
dephosphorylation by EYA (Chapter 4, Figure 4-5B), one method that can be utilized to
determine which tyrosines are phosphorylated it to synthesize EYA phosphopeptides and use
these peptides as substrates for EYA's phosphatase activity. The tyrosine residues within the
phosphopeptides that are the best substrates for EYA are good candidates for sites of
phosphorylation within EYA. In addition to yielding insight into which tyrosines are
phosphorylated within EYA, the phosphopeptide analysis may be able to determine a consensus
sequence that is dephosphorylated by EYA, and this consensus could be used to identify other
putative substrates of EYA. One caveat to the phosphopeptide analysis is that although these
peptides are sequences from EYA, the residues within a particular peptide might not be adjacent
to one another in the three dimensional protein, and therefore, the peptide results may not have
any relevance to the actual sites of phosphorylation within EYA.
A more direct approach to identify the sites of tyrosine phosphorylation is to digest EYA
into small fragments and analyze these fragments by mass spectrometry. The success of this
analysis will depend on the homogeneity of the sample, on what percentage of the protein sample
is tyrosine phosphorylated, and the number and complexity of the sites that are phosphorylated.
By utilizing a stable S2 cell line expressing an affinity tagged phosphatase mutant (EYAHAD) a
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highly tyrosine phosphorylated sample of EYA can be obtained. Therefore, mass spectrometry
analysis of EYAHAD should identify the sites of tyrosine phosphorylation, along with the sites of
other post-translational modifications.
Both the phosphopeptide analysis and mass spectrometry should indicate which tyrosines
within EYA are likely to be phosphorylated. To address the relevance of these findings, these
tyrosines can be mutated, to phenylalanine to block phosphorylation and aspartic acid to mimic
the negative charge of phosphorylation (Figure 6-3), and analyzed to see whether loss of the
tyrosine residue affects the level of tyrosine phosphorylation. If no loss of phosphotyrosine
signal can be detected by individual mutations, multiple tyrosines can be mutagenized at a time
and analyzed in the same manner. By utilizing mutations that result in a decrease or complete
loss of the phosphotyrosine signal, the effects of tyrosine phosphorylation on both of EYA's
functions, as a transcriptional coactivator and a protein phosphatase, may be elucidated by the
full spectrum of in vivo and in vitro assays that have been developed (Figure 6-4).
Post-translational modifications like tyrosine phosphorylation often affect protein-protein
interactions. EYA is known to homodimerize and interact with SO, and may interact with DAC.
By co-immunoprecipitation experiments one can determine whether loss of or mimicking
tyrosine phosphorylation has any effect on EYA's protein-protein interactions. It is unlikely that
tyrosine phosphorylation affects EYA's abilities to interact with itself or SO, as EYAHAD
mutants, which exhibit a high level of tyrosine phosphorylation, are still capable of
homodimerizing and binding to SO. As EYA interacts with SO and DAC in yeast-two hybrid
assays, it is also unlikely that tyrosine phosphorylation is required for these protein-protein
interactions. These analyses should determine whether tyrosine phosphorylation of EYA affects
its known protein-protein interactions.
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Figure 6-3
EYA phosphopeptide analysis Mass spectrometry analysis
V/0
Mutagenesis
Y-F and Y-E
Phosphotyrosine western blot analysis
Protein-protein
interactions:
EYA-EYA
EYA-SO
EYA-DAC
Transcriptional
reporter assays
In vivo
analysis
Protein,
phosphatase
In vitro
phosphatase
assays
K%
How does loss of or mimicking
phosphorylation affects EYA's
two functions?
Figure 6-3
General schematic of how putative sites of tyrosine phosphorylation will be analyzed by
mutagenesis. Tyrosines identified as potential sites of phosphorylation by either phosphopeptide
analysis or mass spectrometry will be mutagenized to F to analyze the effects of loss of
phosphorylation and E to analyze the effects of mimicking phosphorylation. These mutants will
be analyzed for how they affect EYA known protein-protein interactions. In addition, by using
multiple experimental avenues, including transcription assays, in vivo function analyses, and in
vitro phosphatase assays, the mutants will be used to attempt to determine whether tyrosine
phosphorylation affects/regulates one or both of EYA's activities.
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Figure 6-4
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Methods and tools
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Schematic representation of the methods and tools we and others have developed to
analyze EYA's two known functions.
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The effects of both loss of and mimicking tyrosine phosphorylation on both EYA's
ability to function as a transcriptional co-activator with SO and as a protein phosphatase can be
examined by transcriptional reporter assays. Two distinct EYA-SO transcriptional reporter
assays have been developed. The first reporter is a multimer of the known SIX family binding
site termed ARE (Silver et al. 2003), while the second transcriptional reporter is a native response
element from the lozenge promoter and is termed LMEE (S. Silver, personal communication;
Yan et al. 2003). Utilizing the ARE reporter it has been shown that EYA functions as a
transcriptional coactivator with SO (Silver et al. 2003). EYA's phosphatase function does not
appear to be important for transcriptional activation as EYA HADmutants can still function as
coactivators with SO in this context (Chapter 4, Figure 4-4) (Tootle et al., 2003). In addition,
cc)expression of the other RD network member DAC has no effect on EYA-SO mediated
transcription using the ARE-reporter (Silver et al. 2003). Utilizing the LMEE-reporter, wild-type
EYA functions as a transcriptional coactivator with SO, while EYAHAD mutants exhibit varying
degrees of coactivation (S. Silver, personal communication), indicating that phosphatase function
has some role in mediating transactivation of this reporter. Intriguingly on the LMEE-reporter,
DAC can function as a coactivator with both the EYAWT-SO transcription factor and the
EYA HIAD-SO transcription factors (S. Silver, personal communication). Therefore, coactivation
of the LMEE-reporter by DAC is independent of EYA's phosphatase activity.
By using both of these reporter systems one can gain insight into whether loss of or
mimicking tyrosine phosphorylation of EYA affects one or both of EYA's activities. Analysis
with the ARE-reporter should provide information as to whether these mutations affect EYA's
ability to act as a transcriptional coactivator with SO, as loss of phosphatase function has no
affect on this read-out of transcriptional activity (Figure 6-5A). Conversely, studies using the
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LMEE-reporter may indicate whether these mutations affect one or both of these activities, as
EYAHAD mutants function distinctly from EYAWT (Figure 6-5B). If mutating the tyrosine
residues within EYA solely inhibits transcriptional coactivator function then there will be
decreased transcriptional activation with SO and loss of coactivation by DAC, while if the
mutations only affect phosphatase function there will be normal coactivation with DAC and
there may or may not be a decrease in transcriptional activation with SO (Figure 6-SC). If the
mutations inhibit both activities of EYA there will be both a loss of coactivation with DAC and
decreased transcriptional activation with SO. Analyses with these two transcriptional reporter
systems will provide information on how loss of or mimicking tyrosine phosphorylation of EYA
affect EYA's two functions, as a transcriptional coactivator with SO and as a protein
phosphatase (Figure 6-SC).
To determine whether tyrosine phosphorylation of EYA is important for Drosophila eye
development transgenic fly lines can be established to express both loss of and mimicking
tyrosine phosphorylation EYA mutations under the control of the UAS/GAL4 system. These
transgenic lines can be used to analyze how such mutations affect EYA's ability to induce
ectopic eyes, as overexpression of wild-type EYA results in 50% of the flies exhibiting ectopic
eyes (Hsiao et al. 2001). Additionally, it will be important to determine whether these mutations
can rescue the eyeless phenotype of the eya2 mutation. These experiments will show whether
tyrosine phosphorylation is important for EYA function in the developing Drosophila
eye, but as both of EYA's activities, as a transcriptional coactivator and a protein phosphatase,
are required in vivo, they will not provide information as to which function is affected.
If the tyrosine phosphomimetic EYA mutations give any indication that they actually
mimic phosphorylation, i.e. by behaving differently than loss of phosphorylation mutations, they
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Figure 6-5
Two transcriptional reporter systems can be used to determine how tyrosine
phosphorylation affects both EYA's function as a transcriptional coactivator and as a protein
phosphatase. A. Schematic illustrating the known outcomes of transcription assays utilizing the
ARE-reporter. The EYA-SO transcription factor activates transcription, this activation is not
affected by addition of DAC, or loss of EYA's phosphatase ability. B. Schematic illustrating the
known outcomes of transcription assays utilizing the LMEE-reporter. The EYA-SO transcription
factor activates transcription, this activation is enhanced by addition of DAC, inhibited to various
degrees by loss of EYA's phosphatase ability. Interestingly, EYA's phosphatase activity is not
required for DAC mediated enhancement of transcription. C. Schematic illustrating the
predicted outcomes of transcription assays with both reporters in response to Y mutations. If
mutating the tyrosines inhibits only coactivator activity then I would expect loss of or decrease in
transcriptional activation with both reporters, and loss of DAC mediated enhancement of
transcription from the LMEE-reporter. If mutating the tyrosine inhibits only phosphatase activity
then I expect that there will be no affect of transcriptional response from the ARE-reporter, a
decrease or loss of transcription and retention of DAC mediated enhancement of transcription
from the LMEE-reporter. If mutating tyrosine inhibits both activities I would expect to find that
transcription from both reporters is lost or reduced, and there will be no enhancement of
transcription by addition of DAC using the LMEE-reporter.
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can be used to directly look at how tyrosine phosphorylation affects EYA's protein phosphatase
activity. The tyrosine to aspartic acid mutations can be made in MmEYA3, and the effect of
such mutations on the enzyme's ability to dephosphorylate substrates can be analyzed. As a
control it will be important to also test the tyrosine to phenylalanine mutations. It will be
important to determine whether the mutations can dephosphorylate both the phosphopeptide
substrates and immunoprecipitated tyrosine phosphorylated EYA, as tyrosine phosphorylation
could only affect the dephosphorylation of one of the substrates and not the other.
By utilizing the variety of in vivo and in vitro assays described above (Figure 6-4), one
may begin to understand how tyrosine phosphorylation of EYA regulates EYA's two activities,
as a transcriptional coactivator and protein phosphatase. In addition, once the tyrosines that are
phosphorylated have been identified, phosphotyrosine specific EYA antibodies can be generated.
Such antibodies can be used to determine when and where EYA is tyrosine phosphorylated
during development, yielding insight into why such modifications occur. The antibodies can
also be used to identify proteins that interact with tyrosine phosphorylated EYA. These
interactors are likely to have phosphotyrosine binding domains and play roles in mediating the
effects of tyrosine phosphorylation of EYA.
In addition to determining the sites of tyrosine phosphorylation within EYA it is also
important to identify the kinase(s) which tyrosine phosphorylate EYA. A variety of methods, in
addition to the RNAi based screen discussed in Chapter 5, can be utilized to determine which
kinase(s) is (are) responsible for tyrosine phosphorylating EYA (Figure 6-6). One method is to
use EYA as a substrate for in vitro kinase assays with the kinases known to be expressed in
Drosophila S2 insect cell culture, as EYA is tyrosine phosphorylated in these cells (Chapter 4).
By utilizing the EYA phosphorylation mutants one should be able to determine which kinase
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Figure 6-6
Which kinase tyrosine phosphorylates EYA?
RNAi screen
(Chapter 5)
Can kinases
dephosphorylate full-
length EYA?
Does tyrosine phosphorylation
affect phosphatase EYA's
function?
Genetic screen:
How do various kinase
alleles affect EYA's
ability to induce ectopic
eyes?
Kinases that regulate Kinases that directly
EYA but do not phosphorylate EYA.
directly phosphorylate
EYA.
How does tyrosine
phosphorylation mediated by the
kinase(s) identified affect the
outcome of transcription assays?
See Figure 6-4
Figure 6-6
Schematic illustrating the planned experiments to elucidate which kinase or kinases
tyrosine phosphorylate EYA. If a kinase or kinases are found to phosphorylate EYA, the effect
of phosphorylation on EYA's ability to function as a protein phosphatase can be analyzed.
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phosphorylates which tyrosine within EYA. In addition a genetic modifier screen of ectopic eye
induction by overexpression of EYA can be used to identify the kinase(s) which tyrosine
phosphorylate EYA. As similar genetic interactions have successfully established the in vivo
relevance of ERK MAPK-mediated phosphorylation of EYA (Hsiao et al. 2001), loss of function
or activated tyrosine kinase alleles which alter EYA-mediated ectopic eye induction will indicate
the kinases involved in regulating EYA. This screen may identify the kinase or kinases that
directly tyrosine phosphorylate EYA. In addition, it will identify tyrosine kinases involved in
indirectly regulating the functions of EYA during Drosophila eye development, yielding more
insight into how RD network members are regulated by various signaling events. Kinases for
which alleles exhibit a modification of the EYA overexpression phenotype can be tested by in
vitro kinase assays with full-length EYA to determine whether the effect is due to direct
phosphorylation.
The kinases that can phosphorylate EYA in vitro can then be analyzed to determine
whether they possess such functions Drosophila cultured cells. Knocking down the expression
of the kinase or kinases by RNAi, or utilizing dominant negative allele(s) of the kinase(s)
responsible for tyrosine phosphorylating EYA, should result in a loss or decrease in the level
tyrosine phosphorylation of EYA. Conversely, expression of an activated form of the kinase(s)
should increase in the level of tyrosine phosphorylation of EYA. These effects should not be
seen with EYA phosphorylation site mutations. Using this method one can identify which kinase
or kinases tyrosine phosphorylate EYA in vivo.
The functional consequences of tyrosine phosphorylation by specific kinases can be
analyzed using the same series of assays utilized to look at EYA phosphorylation mutants. How
loss of the kinase(s) or expression of activated kinase(s) affects EYA's two activities, as a
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transcription coactivator and a protein phosphatase, can be analyzed by the transcriptional
reporter assays as described above. The results of the loss of phosphorylation mutants of EYA
and the loss of kinase experiments should exhibit the same effect, while expression of activated
kinase and the phosphomimetic EYA mutants may give the same results. The in vivo effects of
kinase alleles, including loss of function, dominant negative, and activated alleles, can also be
analyzed by ectopic eyes assays, and rescue of the eya2 eyeless phenotype. One can even
determine the effect of specific tyrosine phosphorylation events on EYA's protein phosphatase
activity by in vitro phosphorylating EYA with a particular kinase, and using this phosphorylated
EYA in phosphatase assays. The above analyses on the kinase(s) which tyrosine phosphorylate
EYA, in addition to assays on EYA phosphorylation site mutations, will yield insight into how
tyrosine phosphorylation affects EYA's activities.
Having identified the kinase or kinases involved in mediating the tyrosine
phosphorylation of EYA one can address the regulatory mechanisms that affect this
phosphorylation. By analyzing where and when the kinase or kinases are coexpressed with
EYA, one can determine the spatial and temporal regulation of tyrosine phosphorylation of EYA.
In addition, it will be important to understand what upstream signaling events regulate the
activity of the kinase(s) and thus regulate the tyrosine phosphorylation of EYA. This may
provide insight into how the many signaling pathways implicated in regulating RD network
members affect their activities.
As different post-translational modifications can affect other modifications, it is
important to determine whether/how serine/threonine phosphorylation affects tyrosine
phosphorylation of EYA. The phosphotyrosine specific EYA antibodies can be used in
conjunction with the already existing phosphoserine specific EYA antibodies (I. Rebay, personal
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communication) for immunofluorescence, western blot, and co-immunoprecipitation analyses to
determine whether both modified forms of EYA colocalize or are co-expressed throughout
development, and whether both modifications can occur on EYA at the same time. Also
RAS/MAPK signaling can be stimulated by a variety of means, and the effects of this on the
tyrosine phosphorylation of EYA can be analyzed by phosphotyrosine western blot analysis.
In addition, both the transcriptional reporters, the ARE-reporter and the LMEE-reporter,
can be used to analyze whether there is interplay between these phosphorylation events (Figure
6-7). Analysis with the ARE-reporter has shown that serine phosphomimetic EYA mutants
exhibit increased transcriptional coactivator ability (Silver et al. 2003), while both addition of
activated RAS and serine phosphomimetic EYA mutants exhibit increased activity with the
LMEE-reporter (S. Silver, personal communication). Double mutants of loss of or mimicking
tyrosine phosphorylation and loss of or mimicking serine phosphorylation can be analyzed with
both transcriptional reporters. If both phosphorylation events function in the same direction than
further transcriptional activation will be seen with the double phosphomimetic mutant (Figure 6-
3). By using the LMEE-reporter one can look at the effects of activated RAS on the ability of
EYA tyrosine phosphorylation mutants to coactivate transcription. These experimental
approaches can be used to begin to understand whether/how serine/threonine phosphorylation
affects the tyrosine phosphorylation of EYA.
It is debated as to whether EYA is a dual specific phosphatase and can dephosphorylate
both serine/threonine and tyrosine residues (Li et al. 2003), or whether EYA is solely a protein
tyrosine phosphatase (Chapter 4) (Rayapureddi et al. 2003; Tootle et al. 2003). To truly
understand EYA's functions, the interplay of the separate functions, and how tyrosine
phosphorylation regulates these functions, it must be clear what type of phosphatase EYA is.
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Figure 6-7
Schematic illustrating how S/T phosphorylation is known to affect transcription by the
EYA-SO transcription factor on both reporters. Mimicking serine phosphorylation of EYA
results in increased transcription from both reporters, while addition of activated RAS only
increases transcription from the LMEE-reporter. If serine and tyrosine phosphorylation of EYA
both positively regulate its activities I would expect to find that double phosphomimetic mutants
will exhibit an even higher level of transcription.
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Full length Arabidopsis Eya, which only contains an ED, is a protein tyrosine phosphatase
(Rayapureddi et al. 2003), indicating that evolutionarily EYA is a protein tyrosine phosphatase
and not a dual specific phosphatase. It is possible that the different conditions used for the in
vitro phosphatase assays between the various groups result in the different activities detected. It
is also possible that EYA evolved from a tyrosine specific phosphatase into a dual specific
phosphatase, similar to its gain of transcriptional coactivator function. To verify which type of
phosphatase EYA is, the conditions utilized by the group seeing dual specific phosphatase
activity need to recapitulated to determine if EYA can indeed dephosphorylate both phospho-
serine/threonine and -tyrosine peptides.
If EYA is a dual specific phosphatase it will be important to determine whether EYA can
clephosphorylated itself and SO on serine/threonine residues. To determine if EYA can
dephosphorylates itself at phospho-serine/threonine residues one can use the phosphoserine
specific EYA antibodies and analyze whether bacterially purified EYA can dephosphorylated
itself at phosphoserine residues. Knowing whether EYA can regulate itself in this manner will
help us to interpret the effects of EYA phosphatase mutants.
The activity of SIX1, one of the human orthologs of SO, is regulated by S/T
phosphorylation, and phosphorylated SIX1 runs as three distinct bands on western blots (Ford et
al. 2000). Interestingly, immunoprecipitated SO also runs as a triplet on western blots (S. Silver,
personal communication) and metabolic labeling has revealed that SO is phosphorylated in
cultured cells (E. Davies, personal communication), indicating that SO is likely to be
phosphorylated in a similar manner to SIX1. As EYA is known to interact with SO, and EYA
may be a dual specific phosphatase, SO may be a substrate for EYA. It is important to first
verify that the three SO bands seen on western blots are indeed due to differential
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phosphorylation. After which, one can analyze whether incubation of serine/threonine
phosphorylated SO with the phosphatase EYA results in the loss of any of the three bands. By
this analysis I should be able to determine whether EYA can dephosphorylate SO.
EYA is a dual function protein, possessing both transcription coactivator and protein
phosphatase activity, that is regulated by both serine/threonine and tyrosine phosphorylation.
While there is some understanding of how serine/threonine phosphorylation regulates EYA,
there is no information on how tyrosine phosphorylation affects EYA's functions. The above
experimental avenues should help to determine which tyrosines are phosphorylated by which
kinases, how individual phosphorylation events affect EYA's known functions by
transcriptional, in vivo, and in vitro readouts of activity, the interplay of serine/threonine
phosphorylation and tyrosine phosphorylation, and whether EYA is a dual specific phosphatase.
Understanding the mechanistic details of how post-translation modifications, like tyrosine
phosphorylation, affect EYA's functions will give us a better handle on how cells can
differentially regulate the two functions of EYA.
Additionally as a community, our understanding of how tyrosine phosphorylation affects
transcription factor function is severely limited. Analyses on how tyrosine phosphorylation
individually affects specific transcription factors will yield insight into possible general
mechanisms of tyrosine phosphorylation function and encourage others to analyze whether
similar regulation is occurring with other transcription factors.
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Appendix I
Deficiency kit screen for mislocalizers of YAN
Tina Tootle, Xiao Tan, Karolina Fraczkowska and Ilaria Rebay
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Results
In conjunction with the work presented in Chapter 2, a screen was undertaken to further
pursue the mechanisms regulating the export of YAN. The deficiency kit, -200 fly lines which
sequentially delete small genomic regions, was screened for embryonic mislocalization of YAN
by myself and two undergraduates, Xiao Tan and Karolina Fraczkowska. The dynamic
embryonic expression pattern of YAN (Figure A-1) has been well characterized. Embryos were
collected from individual lines and analyzed by immunofluorescence. We chose to focus on
YAN expression in the ventral midline during embryonic stages 10-12 due to YAN's
clownregulation and presumed degradation in this tissue (Figure AI-1 C), but observed all stages
of development.
If a deficiency line resulted in the deletion of a protein involved in the nuclear export of
YAN, the expected phenotype would be nuclear YAN expression in the ventral midline, while
loss of a protein involved in the degradation of YAN could result in cytoplasmic YAN
expression. Twenty-five deficiencies were identified as mislocalizers (Figure AI-2). One class
of mislocalizers exhibited the expected cytoplasmic staining (Figure AI-3A), while the other
main class was unexpected and showed unusual clumping of YAN protein (Figure AI-3B). Only
two deficiencies exhibited some nuclear retention of YAN in the ventral midline (Figure AI-3C).
The largest class of mislocalizers is made up of a variety of phenotypes that exhibit aberrant
YAN expression (Figure AI-3D).
Each deficiency deleted a large number of genes, making isolation of the gene or genes
causing the mislocalization phenotype rather labor intensive. Due to the success of other
experimental avenues, I did not pursue further the deficiencies exhibiting mislocalization of
YAN.
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Figure AI-1
Figure AI- 
YAN expression pattern during embryogenesis. (A-D) Immunofluorescence, as described
in Chapter 2, of Drosophila embryos collected for 6 hours at 25° and stained with mouse
monoclonal YAN antibody (1:500) and CY3 secondary (1:2000). (A) Stage 5 embryo
exhibiting ubiquitous nuclear YAN staining. (B) Ventral view of stage 10 embryo; nuclear
YAN staining in mesoderm and ectoderm, while no YAN is present in the ventral midline
or developing CNS. (C) Dorsal-lateral view of stage 11 embryo, expression is equivalent
to Stage 10. (D) Dorsal-lateral view of stage 13 embryo; YAN expression is restricted to
the peripheral nervous system.
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Figure AI-3
Figure AI-3
Examples of mislocalization of YAN. (A) Cytoplasmic YAN localization.
(B) Retention of nuclear YAN in the ventral midline. (C) Clumping YAN
expression. (D) An example of general defects in YAN localization, no
nuclear YAN expression.
Appendix II
YAN regulation by JNK and p38 MAPKs
Tina Tootle and Ilaria Rebay
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Results
Others had shown that the MAPK JNK phosphorylates and inactivates YAN during
embryonic dorsal closure (Riesgo-Escovar and Hafen 1997). In addition it had previously been
shown by in vitro kinase assays that ERK, JNK, and p38a/p38b MAPKs phosphorylate YAN (F.
Hsiao, personal communication). As ERK-mediated phosphorylation results in export of YAN
from the nucleus to the cytoplasm (Tootle et al. 2003), we wanted to determine whether
phosphorylation by JNK and p38 had similar effects. JNK and p38 MAPKs are stress-activated
kinases.
To determine how phosphorylation of YAN by JNK and p38 MAPKs affects YAN
localization we transiently transfected various constructs of YAN, including wild-type and
phosphorylation mutants, along with the respective kinase. We activated JNK and p38 MAPKs
by heat shock. This analysis showed that like ERK, JNK-mediated phosphorylation of YAN,
particularly at the first phosphorylation site results in cytoplasmic localization of YAN (Figure
AII-1A). Phosphorylation by p38a or p38b does not affect YAN localization, as YAN remains
nuclear (Figure AII-1B). Therefore, it seems like regulation of YAN by ERK and JNK MAPKs
occurs by the same mechanism, while regulation of YAN by p38 MAPKs is happening by a
different method.
References
Riesgo-Escovar, J.R. and E. Hafen. 1997. Drosophila Jun kinase regulates expression of
decapentaplegic via the ETS-domain protein Aop and the AP-1 transcription factor DJun
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Figure AII- 
JNK but not p38 mediated phosphorylation of YAN leads to cytoplasmic localization of
YAN. Transient transfections of the YAN construct listed along with the MAPK, JNK in A and
p38b in B. Kinases were activated by 10 minutes of heat shock at 30°C. Results were analyzed
by immunohistochemistry with anti-YAN MAb 8B12 at 1:250 with CY3 conjugated goat anti-
mouse secondary (1:10000). A) Activated JNK leads to cytoplasmic localization of YANWT and
YAN2- 8 -A, while YANis-A remains nuclear in the presence of activated JNK. B) Activated p38b
and activated p38a (same as with p38b, data not shown) has no effect on YAN localization, as
YAN remains nuclear.
284
Appendix III
More insights into the roles of MAE in regulating YAN and PNT.
Tina Tootle and Ilaria Rebay
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Introduction
One pathway used reiteratively throughout development is the receptor tyrosine kinase
(RTK) signaling network. RTKs signal through the evolutionarily conserved GTPase RAS and
the mitogen activated protein kinase (MAPK) cascade. Among the best characterized
downstream targets of activated MAPK are the Drosophila ETS-domain transcription factors
encoded by pointed (pnt) and yan. In response to RTK activation, MAPK-mediated
phosphorylation abrogates YAN repressor activity, allowing PNT to prevail in the competition
for promoter access and turn on genes formerly repressed by YAN. Thus the coordinate
regulation of these two antagonistic transcription factors plays a key role in determining specific
clifferentiative and proliferative responses to RTK signaling.
We have shown, Chapter 2, that nuclear export of YAN is a necessary step in its
downregulation, is mediated by CRM1, and is dependent on both YAN's nuclear export
sequences (NESs) and pointed domain (PD) (Tootle et al. 2003). MAPK-mediated
phosphorylation of YAN and PNT, and the ensuing abrogation of YAN's repressor activity and
activation of transcription by PNT, is thought to be facilitated by a protein called Modulator of
the Activity of ETS (MAE). Mechanistically, MAE binds to YAN or PNT via their respective
PDs (Baker et al. 2001). A PD is protein-protein interaction motif found at the N-terminus of
YAN or PNT and the C-terminus of MAE. We have demonstrated that MAE has a separate role
in mediating export, independent of its role in mediating phosphorylation (Tootle et al. 2003). In
addition, overexpression of MAE inhibits YAN mediated transcription repression (Tootle et al.
2003) and completely inhibits PNT mediated activation of transcription (Tootle et al. 2003;
Yamada et al. 2003). Therefore, it has been proposed that MAE plays multiple roles in
downregulation of both YAN and PNT.
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Further work, Chapter 3, has shown that overexpression of MAE in Drosophila cultured
cells inhibits nuclear export of YAN. However, overexpression in the eye does not result in
YAN being aberrantly retained in the nuclei, but instead it results in an array of phenotypes that
can be rescued by overexpression of PNT. Thus MAE appears to play a role in downregulation
of PNT in vivo. Interesting, we find that mae transcription is regulated by YAN and PNT,
adding further complexity to the signaling cascade. Many questions remain about MAE's roles
in regulating YAN and PNT.
Results and Discussion
Overexpression of MAE blocks YAN downregulation
Based on our previous finding that overexpression of MAE inhibits YAN's ability to
repress transcription (Tootle et al. 2003), we decided to investigate further the underlying
mechanisms. One possibility was that overexpression of MAE might disrupt YAN's subcellular
localization. In Drosophila S2 cultured cells YAN localizes to the nucleus (Figure AII-1A), and
upon activation of the RAS/MAPK cascade is exported to the cytoplasm (Figure AIII-IB)
(Rebay and Rubin 1995). Previous analyses studying mae loss-of-function revealed that MAE is
necessary for nuclear export of YAN, as YAN remains restricted to the nucleus in the absence of
mae in both cultured cells and in vivo (Tootle et al. 2003). Therefore, we expected that
overexpression of MAE would either not disrupt Yan localization or perhaps lead to premature
export and down-regulation of YAN in the absence of signaling. As predicted, no effect on
nuclear YAN localization in the absence of pathway activation was observed (Figure AIII-1C)
but surprisingly, overexpression of MAE prevented RASvI2 induced nuclear export of YAN
(Figure AIII-1D). In order to rule out the possibility that the MYC epitope tag on MAE was
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interfering with normal MAE function to produce a misleading phenotype, we confirmed the
results using a non-tagged MAE construct (Figure AIII-1E,F). Addition of dsRNA (RNAi)
against mae restored export (Figure AIII-1G, H), suggesting that precisely regulated levels of
MAE are critical for proper YAN regulation. Thus both loss and overexpression of mae result in
aberrant nuclear restriction of YAN in Drosophila cultured cells.
Why might overexpression of MAE restrict YAN to the nucleus? One possibility is that
MAE overexpression results in a YAN-MAE complex that is somehow different from the YAN-
MAE complex formed under lower levels of endogenous MAE expression, and that is therefore
inefficiently phosphorylated by activated ERK. Because phosphorylation is necessary for
nuclear export (Rebay and Rubin 1995), such a complex would be retained in the nucleus. To
test this hypothesis, we overexpressed activated ERK (ERKSEM), in the presence of RASv12 and
MAE, reasoning that an excess of activated ERK might more efficiently phosphorylate YAN.
Overexpression of ERKSEM partially restored YAN export (Figure AIII-1K), consistent with the
hypothesis that excess MAE results in a YAN-MAE complex that is refractory to ERK-mediated
phosphorylation.
To test this hypothesis further, we asked whether co-overexpression of PNT-P2 could
also overcome the MAE-mediated restriction of YAN to the nucleus. The rationale is that if
MAE overexpression results in aberrant YAN-MAE complexes that are no longer efficiently
phosphorylated by ERK and therefore cannot be exported, then by introducing a second MAE
binding partner, PNT-P2 (Baker et al. 2001; Tootle et al. 2003), we should be able to titrate out
sufficient MAE to restore a "normal" RAS/MAPK-responsive YAN-MAE complex. As
predicted we found that cotransfecting PNT-P2, YAN and MAE partially restored YAN export
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Figure AIII-1
MAE-YAN complex in insect cell culture is refractory to normal YAN downregulation. (A-K)
Transient transfections of Drosophila S2 insect cultured cells expressing YAN and the indicated
constructs stained with anti-YAN MAb 8B12 at 1:250 with CY3 conjugated goat anti-mouse
secondary (1:10000). (A'-K') DAPI (1:10000) staining overlaying YAN antibody staining of the
same cells. The percentage of transfected cells exhibiting nuclear localization (A, C-G, I) or
exclusively cytoplasmic localization (B, H, J, K) is indicated, n>250. (A, C, E, G, I) YAN
localization in the absence of RASV 2. (B, D, F, H, J, K) YAN localization in the presence of
RAS 12. (C, E, G, I) Coexpression of Myc-MAE, MAE, MAE+dsRNA mae, and MAE+PNT-P2
has no effect on the nuclear localization of YAN in the absence of signaling. (D, E)
Coexpression of Myc-MAE or untagged MAE along with RASV12 results in nuclear retention of
YAN. (H, J) Coexpression of either PNT-P2 or ERKS EM along with RASV12 restores nuclear
export of YAN. Overexpression of MAE results in a MAE-YAN complex that cannot be
downregulated by the endogenous machinery, and thus it requires overexpression of other EGFR
signaling components to restore proper downregulation of YAN.
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in the presence of RASV12 (Figure AIII-1J). Therefore, MAE-mediated restriction of YAN to the
nucleus can be overcome by either overexpression of ERKSEM or PNT-P2, suggesting that
precise regulation of the amount of MAE available to complex with YAN is critical in ensuring
RAS/MAPK mediated phosphorylation and export of YAN.
To confirm the in vivo relevance of MAE overexpression restricting YAN to the nucleus,
we generated UAS MYC-MAE transgenic lines and used ELAV GAL4 to drive expression in the
developing embryonic CNS. In wild-type germband extended embryos, nuclear YAN
expression is rapidly cleared from the cells of the developing brain and ventral nerve cord, but
remains expressed at high levels in the epidermis and mesoderm (Figure AIII-2A, A'). If
downregulation of YAN is blocked, for example by expressing a constitutively "active" form,
ACTYAN c , which is refractory to RAS/MAPK signaling, Yan remains nuclear and normal
induction of neuronal markers is inhibited (Figure AIII-2A") (Rebay and Rubin 1995). As
predicted from the cell culture results, MAE expressing embryos exhibit a YANACT-like
phenotype, with strong nuclear YAN expression (Figure AIII-2B, B") and inhibition of neuronal
markers (Figure AIII-2B") in the developing brain and ventral nerve cord. Thus both in cell
culture and in Drosophila, overexpression of mae inhibits YAN downregulation. However, in
ACT
contrast to YAN c , whose expression results in fully penetrant lethality, the effects of MAE
overexpression appear to be partially overcome with time, as some ELAV GAL4; UAS Myc-
MAE flies eclose, and exhibit a rough eye phenotype (data not shown). This led us to look at
germband retracted embryos (stage 15/16, Figure AIII-2C, C'). While most of the embryos
examined appeared dead, exhibiting no staining pattern, there were properly developing,
although YAN expression was weaker, germband retracted embryos (Figure AIII-2D, D').
Analysis of embryonic viability revealed that 22.5% of ELAV GAL4; UAS Myc-MAE embryos
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Figure AIII-2
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Figure AIII-2
Overexpression of MAE initially restricts YAN to the nucleus in the embryonic CNS.
(A-D") Confocal images of Drosophila embryos double labeled with anti-YAN MAb8B 12
(1:750), CY3 goat anti-mouse (1:1000) (A-D, A'-B') and rat anti-ELAV MAb 7E8A10 (1:500),
and CY2 conjugated goat anti-rat (1:2000) (A"-B". C'-D'). (A', B') (A-B") Germband extended
Drosophila embryos. Higher magnification views of regions boxed in A-B with normal or failed
YAN downregulation highlighted by bracket. ELAV GAL4 was used to drive expression of (B,
D) UAS Myc-MAE. Overexpression of MAE restricts YAN to the nucleus and delays neuronal
differentiation (B-B") in germband retracted embryos. However, this appears to be a
developmental delay as later stages reveal normal YAN localization and proper neuronal
differentiation (D-D').
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develop to larvae compared to 45.5% of ELAV GAL4 embryos. Of the 22.5% of the ELAV
GAL4; UAS Myc-MAE larvae only 43.4% mature to adults. One explanation for why the
restriction of YAN to the nucleus by MAE is overcome with time is that enough activated ERK
builds up to disrupt the complex, resulting in export and presumably degradation of YAN.
Neither in cultured cells nor in the embryonic developing CNS is YAN aberrantly
downregulated by ectopic MAE expression. This could be due formation of a MAE-YAN
complex that is refractory to signaling, as suggested by the cell culture experiments. Such a
complex could occur naturally at sites of high levels of MAE expression, although there is no
evidence for this, or it could be an unnatural phenomena caused by overexpression. However,
both loss of function mutations and overexpression of transcriptional regulators are associated
with the development of various human diseases including cancer. Thus it is possible that the
MAE-YAN complex formed during overexpression of MAE could have implications for human
diseases, as loss of function and chromosomal translocations fusing the PD of the human
homolog of YAN, TEL, are associated with leukemia and solid tumor development, and the
likely homolog of MAE, TEL2b, is known to interact with TEL.
YAN phosphorylation mutants
In an attempt to further understand the roles of MAE in regulating YAN's activity, we
analyzed how overexpression of MAE affects the localization of YAN phosphorylation mutants
in insect cultured cells. YAN has nine MAPK phosphorylation consensus sequences, P-X-S/T-P.
The first consensus site has been shown to be the critical phosphorylation site for YAN
regulation (Rebay and Rubin 1995). We found that like wild-type YAN, YAN2- 8 -A, which is
nuclear in the absence of high levels of RAS/MAPK signaling and is exported upon signaling, is
restricted to the nucleus by MAE in the presence RAS/MAPK signaling (Figure AIII-3).
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YAN -A always localizes to the nucleus and is unresponsive to RAS/MAPK signaling;
overexpression of MAE has no effect on YANls -A localization (Figure AIII-3). These data are in
agreement with the work of others (Baker et al. 2001) suggesting that MAE plays an integral role
in mediating phosphorylation of YAN at the first phosphorylation site.
We next examined the effects of MAE overexpression on the YAN phosphorylation
mutants' abilities to repress transcription (Figure AIII-4). We have previously shown that PNT-
P1 drives transcription of an EBS-luciferase reporter and co-expression of YAN results in
transcriptional repression; this repression is relieved by addition of RASV2 , MAE, or both.
ACTWhen we express YAN c , which can not be phosphorylated and thus can not be downregulated
v12 v12by RASv 2 , we see that neither RASv or MAE, alone or together, significantly relieves the
transcriptional repression. This result with MAE is in disagreement with previously published
work (Baker et al. 2001) and with repeats of this experiment in the Rebay lab by Pavithra
Vivekanand. Both phosphorylation mutants YAN Is -A and YAN2-8S-A exhibit reduced response to
v12RAS , most likely due to reduced levels of phosphorylation. These mutants exhibit the same
extent of removal of repression by addition of MAE as they do in response to RASv2, but
interestingly addition of both MAE and RASv restores the level of response to wild-type levels.
This indicates that MAE and RASv2 play independent and additive roles in downregulating
S-DYAN. YAN -, which mimics the negative charges of phosphorylation and can not be
phosphorylated, is also unresponsive to RASV12, but is almost completely wild-type in its
response to addition of MAE. Addition of both RASv l 2 and MAE do not synergize to remove
YANS-D mediated repression even further. Again, these results further support the idea that
MAE is playing a phosphorylation independent role in mediating the downregulation of YAN.
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Figure AIII-3
MAE restricts YAN2S-A to the nucleus. Drosophila S2 insect cultured cells were
transiently transfected with the constructs as labeled and analyzed by
immunohistochemistry with anti-YAN MAb 8B 12 at 1:250 with CY3 conjugated goat
anti-mouse secondary (1:10000) and DAPI (100 gg/ml at 1:5000).
1 1-11,4 1 I-VI I
. . . I -
C04 C 0 
(X/
'7Y
6
1V1
IV
lxzI7X
()e
f
vt
IT
0-0-4
0-0
w
mmI
U
wo
1:11 N C) 00T- T- T-
Figure AIII-4
MAE plays a phosphorylation independent role in regulating YAN's transcriptional
activity. Transcription assays were performed in Drosophila S2 insect cultured cells as
described in Chapter 2 (Tootle et al. 2003). As previously shown YAN represses transcription
V12 1
and this repression is relieved by addition of RASv, or MAE; addition of both RASVl2 and
S-AMAE synergizes to remove repression even further. YAN s -a , which knocks out the key
phosphorylation site for regulating YAN, and YAN2-8S-A, which knocks out seven
phosphorylation sites but leaves the first, key site intact, are only partially responsive to the
addition of RASv 12 or MAE, yet addition of both still synergizes to remove repression further.
YANS-D, which mimics the negative charge of phosphorylation at eight of the phosphorylation
sites, represses transcription but is not RASV2 responsive. It is however responsive to MAE.
The synergism upon addition of both RASv l2 and MAE, along with YANs -D being only
responsive to MAE, indicates that MAE has a role or roles in regulating YAN activity separate
from its previously identified role in mediating the phosphorylation of YAN.
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Together these data indicate that the synergism seen with wild-type, and the S-A mutants of
YAN upon addition of MAE and RASv l2 is due to separate effects on YAN.
This analysis on the effects of MAE on YAN phosphorylation mutants, supports the
previous results (Chapter 2; Tootle et al. 2003), and suggest that MAE plays phosphorylation
independent roles in mediating the downregulation of YAN.
The effects of MAE on PNT
As we have shown in Chapter 3, the overexpression of MAE phenotypes in the
developing Drosophila eye are rescued by overexpression of PNT-P2. This suggests that the
phenotype of MAE overexpression is due to loss of PNT function. The most intriguing
phenotype of MAE overexpression is the loss of basal YAN expression in third instar larval eye
discs. As null pnt mutations are embryonic lethal, we utilized an allelic combination of pnt
mutants that results in viable escapers and analyzed YAN expression in third instar larval eye
imaginal discs, revealing wild-type YAN expression (Figure AIII-5). This result suggests that
loss of pnt function does not result in decreased YAN expression, however this result could
simply be due to the hypomorphic nature of these alleles. To really determine the role of PNT in
regulating basal YAN expression will require clonal analysis of pnt null alleles. Overexpression
of PNT-P2 by itself results in increased basal YAN expression (Figure AIII-6), but does not
inhibit photoreceptor or cone cell differentiation. This suggests the PNT does play a role in
regulation of YAN expression, but as with all overexpression results this could be due to
unnatural affects of excess PNT. As discussed in Chapter 3, these data support the model that a
complex regulatory network with multiple feedback loops regulates YAN, PNT, and MAE
expression and activity.
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Figure AIII-5
Wild-type pnt3680A21/pnt78d5A82
Figure AIII-5
Hypomorphic pnt-/- flies exhibit normal YAN expression in third instar eye imaginal
discs. pnt3680A12/pnt 7 8d5A82 allelic combination results in viable escaper flies. Eye discs
were dissected and stained as described in Chapter 3.
Figure AIII-6
WILD-TYPE GMR GAL4;UAS PNT-P2
,
, ,
, ..I> i,
V ' ''':~~" , ',.,
Figure A11-6
Overexpression of PNT-P2 results in increased basal YAN expression in third
instar larval eye imaginal discs with no loss in photoreceptor (anti-ELAV) or
cone cell recruitment (anti-cut). Eye discs were dissected and stained as
described in Chapter 3.
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pnt mutants result in aberrant changes in midline glia, resulting in the loss of separation
of the anterior and posterior commissures (Klambt 1993). As overexpression of MAE inhibits
PNT-P2 function, both in transcriptional reporter assays (Chapter 2, Tootle et al, 2003; Yamada
et al. 2003) and in the developing Drosophila eye (Chapter 3), we asked whether overexpression
of MAE in the midline glia would exhibit a pnt-l- phenotype. Overexpression of MAE in the
midline glia exhibited a wild-type phenotype (data not shown). This indicates that in midline
glia overexpression of MAE does not inhibit PNT function. A possible reason for this could be
that MAE is not normally expressed in this cell type and other regulatory proteins prevent MAE-
PNT interactions.
Concluding remarks
While these data do not currently add to our understanding of the roles of MAE in
regulating YAN and PNT, in conjunction with future experiments in this area these data may
help to further elucidate the activities of MAE.
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